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In the field of chemical biology, chemical probes are widely used for live imaging, 
target identification, inhibitor screenings and so on. This thesis mainly involved three 
projects. In the first project, a small molecule-assisted protein labeling strategy based 
on a mutant SNAP-Tag (mSNAP) and its FRET substrate pairs has been developed. 
Based on this general protein imaging approach, both one- and two-photon 
fluorescence microscopic experiments were successfully demonstrated in living cells. 
In theory, this approach can probe and image any interested protein in a real-time time 
manner.  However, this approach does not permit a specific visualization of selected 
endogenous proteins in living cells. Activity-based probes (ABPs) can address this 
limitation. Thus, in the second project, two different ABPs were designed and 
synthesized for imaging of caspase-1 in living systems. One was designed with a 
acyloxylmethylketone (AOMK) group and hence might form a covalent bond with 
caspase-1. But our experimental results didn’t support this assumption. On the 
contrary, the other ABP probe, which was substrate based, showed remarkable 
reactivity with caspase-1 and thereby can be used as a good tool to detect and image 
caspase-1. Moreover, the results also indicated this substrate based probe could 
greatly improve efficiency and accuracy of the inhibitor screening for Caspase-1. 
Finally, in the third project, bioorthogonal chemistry between tetrazine and 
trans-cyclooctene (TCO) was used to generate a small molecule microarray (SMM). 
The immobilization through this method was so fast the printing compounds on glass 
slide could be finished in several minutes, which was to our knowledge, so far, the 
fastest immobilization method. Additionally, screening this SMM identified potent 
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1.1 Protein imaging 
It is reported that humans receive approximately 80% of all the information from 
the external world through vision. As the proverb “seeing is believing” suggests, an 
access to the eyes would be most effective and informative in the world of science. 
Proteins perform a vast array of functions within living organisms. One of the great 
challenges in the post-genome era is to visualize and clarify the biological 
significance of intracellular proteins directly in living cells. In this post-genomic era, a 
lot of proteins are identified. But there are still many questions needed to answer: to 
name just a few, when does a protein started to be translated and synthesized? what’s 
the amount of protein in living systems? what kind of post-translation modification 
does occur to a protein? We will have clear picture if we can see the proteins with our 
naked eyes. Unfortunately, however, proteins are made of amino acids and do not 
supply enough visual information to let us see the protein’s activity. Under these 
circumstances, fluorescence imaging is an ideal tool as it is sensitive enough to 
provide sufficient spatial and temporal resolution. But to make the protein fluorescent 
is not that simple as the native proteins in the living system are seldom can emit 
fluorescence except a few auto fluorescent proteins. With the development of 
chemistry, biology and others scientific fields, there are now a large number of 
approaches to fluorescently visualize proteins in living system. Owing to the space 
limit, the following four methods will be discussed: 1) protein imaging with auto 
fluorescent proteins (AFPs); 2) protein imaging by specific labeling of fusion proteins 
with synthetic fluorophores; 3) protein imaging with fluorescent -amino acid 
analogues (FlAAs); 4) protein imaging with small molecule chemical probes.  
Imaging proteins with positron emission tomography (PET) and magnetic resonance 
imaging (MRI) are out of scope of this section. 
 
1.1.1 Auto Fluorescent proteins (AFPs) 
 





 More than 30 years later, Prof. Chalfie firstly delivered the gene of 
GFP and subsequently observed fluorescent product in E.coli and elegans without 
applying exogenous substrates and cofactors, which indicated GFP expression can be 
used to monitor gene expression and protein localization in living organisms if GFP 
was fused with the proteins of targets.
[2]
 But at that time, the mechanism that the 
chromophore formed within GFP was unknown. In 1994, Prof.Tsien’s group found 
out this mechanism (Figure 1) and then did mutation to the original GFP to generate 
enhanced GFP (eGFP) and other fluorescent proteins with different colors.
[3]
 Since 
then, GFP has quickly become an indispensable tool in almost every cell biology 
laboratory. And given GFP’s importance, the Nobel Prize for chemistry in 2008 was 




Scheme1.1 Initial mechanism of formation of the GFP chromophore. Recently it has 




Although AFPs play an important role in tracking the localization, lifetime and 
function of proteins in living cells, AFPs have obvious limitations: 
[5]
 1): the big size 
(more than 200 amino acids) was too large and occasionally perturbative when fused 
to the protein of interests; 2) requirement O2 for chromophore formation prevents 
applications in organisms that cannot tolerate even transient exposure to any O2; 3) 
they are restricted to a genetically encoded fluorophore and thereby there are much 
smaller diversity of AFPs compared to the synthetic fluorescent molecules; 4) AFPs 
are no or very limited value in human patients, because human gene therapy would 





1.1.2 Imaging of target proteins by specific labeling of fusion proteins with 
synthetic fluorophores 
An approach that can, to some extent, address these limitations is based on the 
specific labeling of fusion proteins with synthetic fluorophores (Figure 1.2).
[6,7] 
Generally, the proteins of interest are firstly fused with a tag which is usually smaller 
the AFPs through DNA cloning. After the fused proteins are expressed in the living 
systems, the chemical probes that can specifically label the fused tag through covalent 
or non-covalent manner will be added. By this indirect labeling can the proteins of 
interest be tracked and studied.  
   
 
Figure 1.1 Representitive of tags fused with target proteins and their corresponding 
chemical probes 
 
  One example of this strategy developed by Prof.Tsien’s group[8]used a tetracysteine 
tag, FlAsH tag, which specifically chelated biarsenical compounds. This small tag 
5 
 
(CCXXCC) contained four cysteines at the i, i + 1, i + 4, and i + 5 positions of an 
-helix. Four years later, the same group reported the improved version of this tag, 
CCPGCC, with optimized affinity and detection limit, which also suggested that the 
preferred peptide conformation was a hairpin rather than the previously proposed 
-helix.[9] Though the FlAsH tag is much smaller than GFP, poor labeling specificity, 
cellular toxicity, and undesired palmitoylation and oxidation of the 4-Cys  
recognition motif limit its utility.
[10]
 
  In an alternative method, the SNAP-tag is a protein tag that can be covalently and 
specifically labeled with a large variety of different chemical probes inside living cells 
and on cell surfaces.
[11] 
This SNAP tag was based on human DNA repair protein 
O
6
-alkylguanine-DNA alkyltransferase (hAGT), which irreversibly transfers the alkyl 
group from its substrate, O
6
-alkylguanine-DNA, to one of its cysteine residues. The 
mutant version of hAGT, 
w160
hAGT (G160W), possessed an increased activity against 
O
6
-benzylguanine based chemical probes(Figure 1.2). A lot of BG based chemical 
probes, such as BGAF, BGFL and so on, were synthesized and used in visualizing the 
proteins of interest in vivo. In 2008, the same group developed another tag proten 
(CLIP tag) which can specifically O
2
-benzylcytosine (BC) based chemical probes.
[12]
 
By combination of these two tags can two fusion proteins be simultaneously and 
specifically labeled and imaged.    
  Another similar approach is PRIME (Probe Incorporation Mediated by 
Enzymes).
[10] 
The fused tag here was 13-amino acid LplA acceptor peptide (LAP) and 
the probe usually contains a lipoic acid motif. The major difference with the 
abovementioned two approaches is that, in PRIME, the labeling between the tag and 
its chemical probe need a mutant of the Escherichia coli enzyme lipoic acid ligase 
(LplA). This strategy is with suitable sensitivity and labeling speeds, but the usage of 
an additional enzyme to finish the labeling between the tag and it substrate chemical 
probe, to some extent, confounded its use in the field of chemical biology.  
   Many other similar methods were also reported by different groups. Here, these 
approaches are just briefly mentioned owing to the word limit of thesis. In 2004, 
Prof.Johnsson’s group reported labeling of fusion proteins through post-translational 
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modifications on the carrier proteins (CPs) by phosphopantetheine transferases 
(PPTases) and chemically diverse compounds.
[13]
 In 2005, Prof.Cornish’s group 
published labeling of Escherichia coli dihydrofolate reductase (eDHFR) fusion 
protein with trimethoprim chemical probes in wild-type mammalian cells with 
minimal background and kinetics.
[14]
 In 2006, Prof.Hamachi’s group labeled 
oligo-aspartate sequence (D4 tag) fused proteins with Zn(II) complex probe.
[15]
 In 
2008, Prof Wood’s group developed the so-called Halo tag modified from haloalkane 
dehalogenase, which could specifically react with its synthetic ligands comprise a 
chloroalkane linker attached to a variety of useful molecules, such as fluorescent dyes, 
affinity handles, or solid surfaces.
[16]
 
   It should be noted that some of the abovementioned approaches are now 
developed with new features. For example, a Föster Resonance Energy Transfer 
(FRET) based chemical probes for the SNAP technique have been developed, which 
will be discussed in detail in chapter 2.  
 
1.1.3 Protein imaging with fluorescent -amino acid analogues 
(FlAAs) 
A complementary approach to these mentioned above is the application of 
fluorescent -amino acid analogues.[17] Its advantages include: 1) being relatively 
nonperturbing replacements for the native residues, thereby maintains the overall 
native structure of a target peptide or protein; 2) modularity of amino acid building 
blocks makes them versatile components in the protein assembly toolbox; 3) targeted 
protein can be labeled at any position. Incorporation of FlAAs into proteins can be 
achieved by expressed protein ligation (EPL), unnatural amino acid mutagenesis (by 
using modified translation systems, and other methods (Figure 1.2) in a direct manner 







Figure 1.2. Approaches for incorporating unnatural amino acids into proteins and peptides. Reprinted from Ref. [17] with permission. 
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1.1.3.1 Direct Incorporation of FlAAs into Targeted Proteins 
Direct incorporation means that the used unnatural amino acid contains a 
fluorophore. A large number of fluorophores have been incorporated, such as aladan, 
coumarin and so on (Scheme 1.2), to interrogate protein-protein interaction and reflect 
local protein conformational changes.
[18]
 FlAAs were also used to visualize some 





Scheme 1.2 Selected unnatural amino acids used in fluorescent incorporation for 
targeted proteins. 
 
Although this direct incorporation of FlAAs into targeted protein have been 
successful, those non-incorporated free FlAAs could produce big background.
[21] 
Additionally, some FlAAs with bulky size may have a low incorporation rate. One 
approach that can greatly address these drawbacks is to involve the bioorthogonal 
chemistry by a two-step manner.  
 
1.1.3.2 Indirect Incorporation of FlAAs into Targeted Proteins 
   Indirect incorporation means that he used unnatural amino acid does not contain a 
fluorophore but contain a proper handle which can be selectively and specifically 
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applied to introduce the fluorophores. This indirect incorporation is usually done by 
virtue of bioorthogonal chemistry. 
 
1.1.3.2.1 Bioorthogonal Chemistry 
Bioorthogonal chemistry has been widely used in the field of chemical 
biology.
[22] 
Bioorthogonal chemistry typically possesses the following properties
[23]
: 1) 
the reaction involved would have to proceed rapidly in aqueous media at 
biocompatible pH and temperature; 2) the reagents used should be nontoxic as 
applications involving live cells or organisms; 3) the participating functional groups 
could not engage endogenous biological functionalities in competing side reactions, in 
other words, abiotic; 4) in terms of chemistry, the second reaction constant (k2) 




. Notably, the properties of bioorthogonal 
chemistry relate closely to the concept of click chemistry (like, high selectivity and 
functional group tolerance) and any reaction that meets the demands of the former 
probably would classify as an example of the latter.
[24]
  
Bioorthogonal chemistry has been observed great development during the last 
decade. Examples (Scheme 1.3) of this kind of reactions include Staudinger-bertozzi 
ligation, copper catalyzed cycloadditon between azide and alkyne (CUAAC), strain 
promoted cyloaddtion between cyclooctyne and zide (SPAAC), strain-promoted 







Scheme 1.3 Representatives of bioorthogona chemistry 
 
1.1.3.2.2 Indirect Incorporation of FlAAs through bioorthogonal chemistry  
    Using this approach, Prof. Tirrell’s group successfully imaged those cells that 
metabolically incorporated the unnatural amino acid (azidonorleucine) followed by 
incubation with alkyne containing coumarin dye.
[25]
 It should be noted that those 
participants of the bioorthogonal reactions that can make the used fluorophore less 
fluorescent before reaction with their partners are very favorable because of the low 
background. For example, coumarin azide was non-fluorescent (quantum yield was 0) 
at 478 nm. But the triazole product was highly fluorescent (quantum yield was 0.3) at 
478 nm after reaction with the alkyne.
[26]
 Lemke et al. utilized this coumarin azide to 
specifically image cyclooctyne AA incorporated mCherry protein.
[27]
 Recently, Prof. 
Bertozzi’s group reported fluorogenic florescein azide which showed more than 30 
fold fluorescence intensity enhancement upon reaction with cyclooctyne.
[28]
 This new 
fluorogenic compound can further enrich the tools used for incorporation of FlAA into 
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targeted proteins.  
 
 
Scheme 1.4 Structures of cyclooctyne containing unnatural acid and its fluorogenic 
substrates. 
    
 Another less fluorescent substrate used in this indirect incorporation of FlAAs by 
bioorthogonal chemistry was the tetrazine containing dyes. Tetrazine had the 
quenching effect on many dyes including BODIPYL and fluorescein. And this effect 
disappeared after conjugation with tetrazine’s partner such as trans-cyclooctene, 
norbornene and so on.
[29]
 In 2012, Prof. Chin’s group applied this bioorthogonal 
chemistry to selectively member-localized fusion protein EGFR-GFP by first 
encoding norbornene AA into this fusion protein followed by treatment with tetrazine 
TAMR X (Scheme 1.5).
[21]
 An advantage of this approach over the abovementioned 
azide based one is the faster reaction speed.  
 
Scheme 1.5 Structures of norbornene containing unnatural acid and its quenched 
substrates. 
 
Recently, Prof. Weissleder’s group reported a new tetrazine based derivatives, 
BODIPYL-tetrazines (Figure 1.3).
[30]
 These probes showed extraordinarily efficient 
turn-on of fluorescence intensity upon reaction with the trans-cyclooctyne (TCO). 
Extremely low background and no washing requirement would make these probes 





Figure 1.3. Recently published superbright bioorthogonal turn-on probes. Reprinted 
from Ref [30] with permission.  
 
1.1.4 Protein imaging with small molecule fluorescent probe 
   A common limitation shared among the above mentioned imaging methods is that 
neither of them can target the endogenous proteins in the living systems. And it is also 
quite challenging to translate those methods to be applied in human patients. Small 
molecule fluorescent probes possess the potential capability to address these problems. 
The number as well as the scope of small molecule fluorescent probes for proteins is 
now pretty expanding. Generally speaking, if the targeted proteins have enzymatic 
activities, these proteins could be targeted by activatable fluorescent probes.
[31]
 For 
those proteins who do not possess an enzymatic activities, other activity based probes 
are good choices, such as the affinity based probes and bioorthogonal approaches. 
 
1.1.4.1 Protein imaging with activatable fluorescent probes 
Two strategies are often used to design activatable fluorescent probes (Figure 
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1.4).  One is based on Föster Resonance Energy Transfer (FRET). FRET is a 
nonradiative transfer of energy between two fluorescent molecules, one being the 
donor and the other being the acceptor. If FRET happens, fluorescence of the donor 
molecule is weakened while the fluorescence from the acceptor molecule is observed. 
And if the acceptor molecule is a quencher, the whole probe will be weakly 
fluorescent because of the FRET. To achieve efficient FRET, the spectral overlap, 
together with the distance between the acceptor and the donor is important.[32]  
 
 
Figure 1.4. Two strategies used for development of small molecule activatable 
fluorescent probes targeting proteins. 
 
FRET based probes have wide usage in the field of chemical biology because of 
their low background and easy design. In 2005, Bogyo and coworkers
 [33]
 developed a 
quenched probe (Scheme 1.6a) by using BODIPYL as the fluorophore and QSY7 as 
the quencher. This probe also contained an acyloxyl methyl ketone (AOMK) reactive 
group, which can form a covalent bond with the targeted proteins, papain-family 
cysteine proteases. The fluorescence didn’t show up until the AOMK formed a 
covalent bond with the proteins and then released the quencher. And the dye part 
would be irreversibly attached to the targets, which rendered the dye difficult to 
diffuse. Kikuchi and co-workers
[34]
 used the similar approach to FRET-based probe to 
probe mutated TEM-1 -lactamase(E166N). This probe (Schem 1.6c) was shown to 
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undergo 30 fold fluorescent activation upon incubation with 
E166N
TEM-1 in vitro.  In 
2006, Nagano and coworkers
[35]
 also reported a FRET probe for -galactosidase 
(Schem 1.6b). Being different from the previous two cases, the FRET in this study 
occurred between two different fluorophores whose emission and absorption spectrum 
were overlapped. After -galactosidase removed the sugar part, a quinone methide 
intermediate formed and further covalently attached to -galactosidase. In 2011, Yao 
and coworkers
[36]
 used the same strategy to target different enzymes with multicolor, 
one- and two-photon imaging. A general property shared with FRET based probes is 
that the molecule weight of the probes is high according to introduction of the FRET 
partner (a different dye or quencher). This property may reduce their utility for 
whole-body methods.  
  
 
Schem 1.6. Selected FRET based probe for protein imaging 
15 
 
Another activatable fluorescent probes are based on fluorogenic design. Some 
fluorophores can be rendered non-fluorescent by chemical modification of their 
electronic properties. Besides the previous mentioned azide coumarin fluorogenic 
substrate, Rao and coworkers reported alkylation of the 7-hydroxyl of coumarin 
severely diminishes the quantum yield of the molecule. But fluorescence would be 
restored when -lactamase cleaved the alkyl group.[37] It is also reported conjugation 
of a ketone to a coumarin type dye diminishes fluorescence, but reduction of the 
ketone to a hydroxyl group restores it.
[38]
 Recently, Yao and coworkers reported a 
fluorogenic two photon dye to probe endogenous phosphatase activities in both live 
mammalian cells and Drosophila brains. This probe worked well based on the fact 
that removal of phosphate group from the probe could make the probe’s fluorescent 
intensity increased.
[39]
 Alternatively, an alteration in excitation wavelength can also be 
used to differentiate activated and unactivated probes,
[40]
 where the cleavage substrate 
observed a 50-nm red shift. More fluorogenic substrates and their targeting proteins 
are listed in Scheme 1.7.  
 
Scheme 1.7 Representative fluorogenic probe for different proteins. Numbers below 




1.1.4.2 Protein imaging with activity based probes (ABPs) 
In the original sense, activity based probes(ABPs) are compounds that have been 
engineered to covalently modify enzyme targets in an activity based manner. ABPs 
typically contain three parts: 1) a reactive functional group (warhead); 2) a tag for 
visualization or affinity purification; 3) a linker between the previous two parts. 
Besides ABPs, there is another term, affinity based probes (AfBPs), frequently 
appeared in literature. AfBPs are probes based on non-covalent protein-binding 
compounds and need additional group to form covalent bond with their targets.
[41]  
But both ABPs and AfBPs are dependent on the target protein’s activity because their 
labeling efficiency would dramatically decrease if the target protein becomes 
denatured. Hence, in a broad sense, AfBPs belong to ABPs. And they are discussed 
under same section in this chapter. Following this rational, activatable fluorescent 
probes talked in the previous section also could be pertaining to ABPs. Thereby, those 
presented above will not be included in this section. 
ABPs are frequently used to image and interrogate cellular functional proteins. 
Recently, Bogyo and coworkers 
[42]
 reported an ABP (AWP28, Scheme 1.8) to 
monitor caspase-1 activation in response to proinflammatory stimuli. This probe was 
designed and based on the well-known caspase-1 inhibitor VX-765 which was 
developed by Vertex pharmaceuticals and it is now in phase II clinic study. AWP28 
showed remarkably reduced nonspecific background labeling compared to the 
commercially available caspase-1 probe FLICA. In conclusion, using AWP28, the 
authors claimed that upon salmonella infection, caspase-1 activity was required to 
bypass apoptosis in favor of proinflammatory pyroptotic cell death. Although it had 
low background and played an important role in interrogate caspase-1 activity, this 
probe had limitation in the real time imaging of caspase-1 because of its general 







Scheme 1.8. Selected activity based probe for caspase-1 
 
Cell permeable probes are important to image the presence and localization of 
kinases and further to study their function and as diagnostic tools. There are 
remarkably few probes available though kinases are now widely recognized as 
therapeutic targets. Winssinger and cowokers
 [43]
 very recently reported an activity 
based probe to image kinase EGFR and ERBB2. This probe was developed from a 
potent kinase inhibitor RA1 which was identified from a small molecule library based 
on a scaffold derived from the resorcyclic acid lactones. RA1 was found to form a 
covalent adduct by reacting specifically with an unconserved cysteine in the 
nucleotide-binding site of the kinases. Introduction of Cy3 fluorophore from the 
position that pointed towards the solvent converted RA1 to an imaging probe 
Cy3-RA1.   
 
Scheme 1.9 An activity based probe for EGFR and ERBB2 
 
Affinity based probes (AfBPs) was also used for protein imaging. In 2012, Yao and 
coworkers 
[44]
 reported a kinase inhibitor (Dasatinib) based AfBP (DA-2). This probe 
consisted of main scaffold of Dasatinib, a diazirine photo-reactive group to form 
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covalent bond with its target proteins under UV irradiation and an alkyne handle to 
introduce the fluorophore using click chemistry. The authors demonstrated that DA-2 
was suitable tool to suitable imaging probe to detect endogenous cellular activities of 
c-Src (membrane-bound) and other “Dasatinib-responsive” proteins. Needless to say, 
AfBPs are useful to image those proteins without covalent inhibitors or substrates. But 




Scheme 1.10 An affinity based probe developed by Dasatinib 
 
Non-covalent inhibitor can also be directly used for imaging without introduction 
of photo-reactive groups. Recently, Weissleder and coworkers
[45]
 reported a 
bioorthogonal approach to image polo-like kinase 1 (PLK1) by virtue of a PLK1’s 
reversible inhibitor (BI 2536). The probe’s design was that a handle group, 
transcyclooctene (TCO), was attached to replace the N-methylpiperazine which was 
oriented towards the solvents. It was found that the probe retained the original 
inhibitor’s affinity to PLK1. Moreover, imaging obtained by this two step labeling 
strong colocalization with that by GFP marker and PLK1’s antibody. In theory, this 
strategy can be applied to proteins beyond kinases as long as there is a specific potent 
binder available to the target proteins. Furthermore, with the advent of superbright 
bioorthogonal turn-on probe described above,
[30] 
This two step imaging approach will 




Scheme 1.11 Structures of probes used in bioorthogonal approach 
 
In conclusion, the recent progress in aspect of protein imaging with small molecule 
fluorescent probe is exciting. With the development of chemistry, more fluorophore 
will be refined. At the same time, the progress in the biology will promote design and 
development of more small-molecule probes to image various proteins. These probes 
are going to provide mechanistic insight into basic biology and diseases, and therefore 








1.2 Inhibitor screening for targeted protein  
Protein imaging doubtlessly can shed light on the molecule mechanism of 
biological process and disease detections. Owing to the development of disease 
detection, numbers of diseases can now be detected in the early stages. But to image 
and detect the diseases is one thing; to cure them is another thing. Drugs are normally 
needed to treat the diseases. In general, the drug discovery process contains the 
following steps: 1) target identification and validation; 2) lead identification and 
optimization; 3) preclinical development; 4) clinical trials; 5) launch and marketing. 
Among the overall process, lead identification and optimization plays a critical role 
and usually generates great impact on both academic field and industrial field. As for 
lead identification, it is inevitable to set up an appropriate assay to perform inhibitor 
screening for targeted protein. A good assay should provide rapid and accurate 
evaluation for the compound library. Generally, there are various assays for different 
target proteins. Owing to the space limit, only assays for caspases and bromodomains 
will be discussed in this section. 
 
1.2.1 Inhibitor screening for caspases 
Caspases are an evolutionarily conserved family of cysteine endopeptidases. 
Common features shared among all the member of caspase family include the 
catalytic cysteine residue in the active site, and the ability to cleave their substrates on 
the carboxyl side of aspartate residues.
[46]
 There are a total of 12 human caspases 
reported.
[47]
 Among them, caspase-1 was the first human caspase to be identified and 
isolated. And caspase 12 orthologue in the human genome does not encode an active 
enzyme product.
[48]
 Human caspases can be divided into two groups according to their 
functions serving apoptosis and inflammation. Caspases 2, 3, 6, 7, 8, 9, 10 and 14 
exert functions in apoptosis. These capased can be further subdivided into “initiator” 
(caspase 2, 8, 9, 10) and “executioner” caspases (caspase 3, 6, 7, 14). The other 
function served by caspases is inflammation which involves three caspases (caspase 1, 
4, 5).  
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Extensive studies of caspases in apoptosis and inflammation validated the 
enzymes as attractive drug targets, and the inhibition of which could be a potential 
therapeutic strategy. Inhibition of caspases have been shown beneficial to a variety of 
disease model, such as neurodegenerative disease, ischaemia, inflammatory disease, 
and so on.
[49]
 Hence, the drug development for caspases is a hot area in medicinal 
chemistry. And there are lots of efforts dedicated to inhibitor screening methods for 
caspases.   
 
1.2.1.1 Inhibitor screening for caspases with peptide-conjugated 
fluorophores 
Traditional protease assays use peptide-conjugated fluorophores to provide easy, 
single-step assays. Generally, the screened compounds were firstly incubated with 
studied caspase, followed by addition of the peptide-conjugated fluorophores. So the 
inhibition can be measured from the detection of fluorescence intensity. The stronger 
inhibition one compound has the less fluorescent signal it can produce. Lots of  
peptide-conjugated fluorophores have been developed (Scheme 1.12). 
 
Scheme 1.12 Peptide based fluorogenic probes for caspases 
 
    Although rhodamine based probes seem more sensitive than coumarin based 
probes.
[50, 51]
 Coumarin based peptidic fluorogenic probes are mostly used and can 
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still find its use in recent inhibitor screening for caspases.
[52, 53]
 A potential problem of 
fluorescent probe is that the screened synthetic compounds frequently exhibit 
fluorescence, which thereby causes interference. Under this consideration, inhibitor 
screening using bioluminescent probes seems a good choice. 
 
1.2.1.2 Inhibitor screening for caspases with bioluminescent probes 
Inhibitor screening for caspases can also carried out using bioluminescent probes. 
In this assay, proluminescent caspase substrate, for example, Z-DEVD-aminoluciferin 
for caspase 3 will be used to measure the remaining enzymatic activity of caspase 
after incubation of which with the screened compounds. Active caspase 3 can remove 
the DEVD part and generate the free aminoluciferin that can recognized by luciferase. 
This reorganization can emit bioluminescence which reflected the inhibition of 
screened compounds. In 2005, Wood and coworkers
[54]
 used Z-DEVD-aminoluciferin 
to perform a high-through put screening for caspase-3. As shown in Figure 1.X, 
Z-DEVD-aminoluciferin expressed 20 fold and 1000 fold more sensitive than 
Z-DEVD-Rho and Z-DEVD-AMC respectively in the 3 h-assay.   
 
 
Figure 1.5 A comparison between bioluminescent and fluorescent caspase assays. 
Reprinted from Ref.[54] with permission. 
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Although bioluminescent probes appear much more sensitive, the usage of 
luciferase makes the results complicated. A study carried out in 2012 showed that, a 
total of 43,885 compounds inhibited luciferase.
[55]
 And a significant fraction of this 
activity associated with potent and efficacious concentration response curves (Scheme 
1.13). Thereby, the accuracy of screening with bioluminescent probes would be 
discounted if the screened compounds themselves exert inhibition towards lucifearse. 
In other words, interaction of small molecules with lucifearse has, to some extent, 
confounded its use in chemical biology and drug discovery. 
 
 




In conclusion, both fluorescent probes and bioluminescent probes have their own 
limitations. Despite bioluminescent probes are more sensitive, fluorescent probes are 
more favorable in practice. So, new fluorescent probes with higher sensitivity will 
find wide use in the journey of drug discovery.   
 
1.2.2 Inhibitor screening for bromodomains 
Epigenetics refers to the study of heritable changes in gene expression or cellular 
phenotype caused by mechanisms other than changes in the underlying DNA 
sequence. -N-acetylation of lysine residues (KAc) is one of the most frequently 
occurring posttranslational modifications (PTMs) in proteins associated with 
epigenetics.
[56,57]
 Lysine acetylation is abundant in large macromolecular complexes 
that function in chromatin remodeling, DNA damage, and cell-cycle control. 
Acetylation affects the physiochemical properties of modified lysine residues by 
neutralizing their positively charged side-chains. In histones, acetylated lysines have 
reduced electrostatic interactions with the negatively charged DNA phosphates, 
providing a more relaxed chromatin structure that is associated with transcriptionally 
active genes. The cellular histone acetylation levels are stringently controlled by two 
enzyme families: the histone acetyltransferases (HATs, or the so-called epigenetic 
“writers”) and histone deacetylases (HDACs, or the so-called epigenetic “erasers”). In 
addition, acetylated lysine residues affect gene transcription through interaction with 
bromodomain (BRD)-containing proteins (BCPs, the so-called epigenetic “readers”). 
Many BCPs, including a variety of nuclear proteins comprising HATs, ATP-dependent 
chromatin-remodeling complexes, helicases, methyltransferases, transcriptional 
coactivators, transcriptional mediators, nuclear-scaffolding proteins, and the 
bromodomain and extra-terminal (BET) family proteins, are present in cells.
[58-60]
 
There is growing evidence linking the dysfunction of BCPs with human diseases, 




The development of protein-protein interaction (PPI) inhibitors that target the 
25 
 
epigenetic “readers” (e.g. BRDs in BCPs) are considered rather challenging. It is a 
generally accepted notion that, small molecules, due to their limited sizes and 
functional groups, are normally insufficient enthalpically to bind to the much larger 
surface present in the protein-protein interface.
[61, 62]
 This simplistic view, however, 
has recently been challenged by two ground-breaking studies, published 
independently in 2010 by James Bradner’s group at Harvard Medical School and a 
group of medicinal chemists at GSK.
[63,64]
 The serendipitous discovery of two small 
molecule inhibitors, JQ-1 and IBET (Figure 1A), both of which are potent, nanomolar 
inhibitors of BET bromodomains (e.g. BRD4), has spurred enormous interests in both 
academia and the pharmaceutical industry in pursuit of other small molecule 
inhibitors that might possess similar biological activities against other BRDs. 
 
 
Scheme 1.14 Representative inhibitors of bromodomains 
 
But there are great challenges to set up assays to perform inhibitor screening for 
Bromodomains. BRDs possess no enzyme activity; their function is mediated solely 
via protein–protein interactions. This scenario is quite different from the previous one 
involving caspases. Moreover, for the majority of bromodomains, there is little 
definitive knowledge about their cognate sequences. There are limited screening data 
published to date. In vitro screening options attempted thus far can be conveniently 
divided into two distinct approaches: those that monitor binding directly using a 
labelfree (LF) methodology (e.g., NMR, surface plasmon resonance, differential 
scanning fluorimetry, etc.) and those that detect the displacement of a partner protein, 
peptide, or small molecule (e.g., enzyme-linked immunosorbent assay [ELISA]–based 
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formats, fluorescence polarization, time-resolved fluorescence resonance energy 
transfer [TR-FRET], AlphaScreen, etc.).
[65]
 Owing to the space limit, three screening 
assay (NMR, fluorescence anisotropy, AlphaScreen) will be discussed. 
 
1.2.2.1 Inhibitor screening for bromodomains with NMR 
  So far, the most successfully applied LF approach to identify and characterize 
small-molecule bromodomain inhibitors is protein NMR, using 2D 
15
N-heteronuclear 
correlation spectroscopy (e.g., 
1
H–15N HSQC). This method principally involves 
running 
1
H–15N correlation experiments in the presence and absence of a ligand or 
pool of ligands and monitoring the differences within the spectrums. In 2005, Zhou 
and coworkers
[66]
 conducted NMR-based chemical screening for the BRD (PCAF) by 
monitoring ligand-induced protein signal changes in 2D 
15
N HSQC spectra. After 
screening a few thousands of small-molecules from commercial libraries, two 
compounds (Scheme 1.15) was found to possess moderate affinity with PCAF. In 
2006, the same group
[67]
 reported 8 molecules could bind CREB binding protein and 
therefore block its association with human p53. Being different from the above 
screening method, a mixture of 8 compounds was screened at same time. Positive 
mixtures were then deconvoluted to identify individual binding ligand. Although this 
method certainly cannot be considered highthroughput, it has many attributes that 
make it both an attractive and viable option for screening thousands of compounds 
against bromodomains. 
 





1.2.2.2 Inhibitor screening for bromodomains with FP 
Fluorescence polarization (FP) was based on the phenomenon that the 
fluorescence of a FP probe will be polarized when the probe binds the target proteins 
and then has slower rotation. FP usually was designed and synthesized based on the 
known inhibitor or substrate of studied proteins. Some examples are shown in 
(scheme 1.16). A potent FA probe based on the nanomolar benzodiazepene 
compounds reported as BET inhibitors has also been demonstrated (scheme 1.16).
[68]
 
The profiling of 150 benzodiazepene compounds using this assay showed an excellent 
correlation between in vitro binding to BRD4 and upregulation of Apo-A1 in a 
luciferase reporter readout. 
 
 
Scheme 1.16 Structures of selected FP probes for bromodomains 
 
1.2.2.3 Inhibitor screening for bromodomains with AlphaScreen 
Alpha screening is one of the alpha technology. The Alpha Technology (Amplified 
Luminescence Proximity Homogeneous Assay) is a homogeneous proximity-based 
reporting system. The schematic of AlphaScreen was shown in Figure 1.6. Briefly, in 
this assay, the basic components are two beads. One is donor bead containing 
phthalocyanine photosensitizer. Under laser irradiation, donor bead excites ambient 
oxygen to give molecular oxygen with a single excited electron, known as singlet 
oxygen. This is captured by acceptor beads (incorporating thioxene, anthracene, and 
rubene or Europium derivatives) in close proximity (˂ 200 nm) to generate a 
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chemiluminescent signal in the 520- to 620-nm range. No signal is produced in the 
absence of an acceptor bead. Under the assay condition, the close proximity of the 
two beads is sustained by studied bromodomain containing a poly-histidine tag and it 
acylated and biotinylated peptide substrate. Hence, less signal will produce if the 
screened inhibitor can bind and occupy the binding site belong to acylated lysine. This 






Figure 1.6. Schematic of AlphaScreen for bromodomain. Reprinted from Ref.[65] 
with permission. 
 
1.2.2.4 Inhibitor screening for bromodomains with small molecule 
microarray (SMM) 
Despite availability of various screening methods for bromodomain, there are still 
many challenges. Current methods have difficulties to carry out screening in a 
high-throughput manner, i.e., screening thousands of compounds simultaneously in 
the same assay. In addition, these methods cannot compare one compound’s inhibition 
towards two different bromodomains in a mixture-manner at the same time. Small 
molecule microarray (SMM) can potentially address these challenges.
[69] 
 
   The basic workflow of SMM are showed in Figure 1.7. Briefly, synthesized small 
molecule library are immobilized onto the surface of glass slide. Then the printed 
slides were incubated different fluorescently labeled proteins. Binding affinity of each 
29 
 
small molecule will be observed and obtained simultaneously after washing and 
imaging. Among the overall screening process, the immobilization step is rather 
critical and there is detailed discussion of this step in chapter 4. 
 
Figure 1.7 SMM-based screenings.  
 
1.3 Objectives 
   This thesis consists of two part, protein imaging and inhibitor screening for 
targeted proteins (caspase-1 and bromodomains). In the first part, a general protein 
imaging approach based on mutant SNAP and its FRET substrate was firstly 
presented in chapter 2. It is the FRET based substrate that allows this approach to be 
used in live imaging because no washing is needed during the imaging. Then in 
chapter 3, we move forward to put our efforts to develop small molecule chemical 
probes to touch and image proteins in the native conditions, which is a drawback of 
previous mentioned general imaging approach. To this end, two kinds of chemical 
probes were designed and synthesized. One is designed to form a covalent bond with 
the targeting protein (caspase-1) but it actually did not show labeling with caspase-1. 
The other one is substrate based probe designed from a specific caspase-1 inhibitor. 
This probe showed great reactivity with caspase-1 and significantly improved 
accuracy of inhibitor screening. Finally, in chapter 4, small molecule microarray 
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(SMM) was applied to perform inhibitor screening for bromodomains. It was found 
that the immobilization step of SMM was remarkably improved by bioothogonal 
chemistry between tetrazine and trans-cyclooctene. Screening of this SMM leads to 
discovery of potent inhibitors of bet family bromodomains and other bromodomains, 













One- and Two-Photon Live Cell Imaging Using a Mutant  
















Portions of the work presented here are reprinted with permission from: 
Zhang, C. -J.; Li, L.; Chen, G. Y. J.; Xu, Q. -H.; Yao, S. Q. Org. Lett. 2011, 13, 








As a complementary approach for AFPs, SNAP-tag approach greatly enriched the 
diversity of the fluorescence by introduction of synthetic organic fluorophores. But 
the requirement of washing-out free dyes before imaging hindered its use in the live 
imaging. In this chapter, a small molecule-assisted protein labeling strategy based on 
a mutant SNAP-Tag (mSNAP) and its FRET substrate pairs has been developed. Both 
one- and two-photon fluorescence microscopic experiments were successfully 
demonstrated in living cells.  
 
2.2 Introduction 
Fluorescence imaging provides an indispensable way to locate and monitor 
biological targets within complex and dynamic intracellular environments.
[70]
 The 
revolutionary discovery of genetically encoded fluorescent proteins (FPs) has made it 
possible to directly visualize proteins and various biochemical activities, with 
unprecedented resolutions, in the living system.
[5]
 The invention of two-photon 
microscopy (TPM), which employs two near-infrared photons as the excitation source, 
provides additional advantages of increased penetration depth (∼500 μm), localized 
excitation, and prolonged observation time, thereby allowing examination of 
fluorophores present even in deep living samples.
[71,72]
 Unfortunately, due to various 
undesirable photophysical properties of most FPs, they have not been widely adopted 
in TPM applications. 
[72]
 
Chemistry-based protein labeling approaches complementary to FPs have 
emerged in recent years, most of which make use of a highly specific, chemical or 
enzymatic, reaction between a fusion protein and a chemically tractable organic 
fluorophore/small molecule probe.
[7,8,73]
 They aim to address two intrinsic 
shortcomings of FP-based imaging techniques, the size of FPs (> 27 kDa) and their 
strict confinement to only genetically encoded fluorophores.
[74]
 For example, the 
FlAsH approach, developed by Tsien et al, uses a small molecule capable of binding 
to a six-amino acid tetracysteine tag fused to the target protein,
[8]
 and the SNAP-tag 
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technology, developed by Johnsson et al., makes use of a highly efficient enzymatic 
reaction between O
6














 are also available. 
Few of these methods, with the exception of FlAsH, make use of fluorogenic probes 
for protein labeling (that is, the probe is rendered fluorescent only upon protein 
labeling), which is an important feature for real-time bioimaging in live cells.
[8]
 In fact, 
this issue is already being addressed in several recent reports.
[33-35]
 Herein, we report a 
small molecule-assisted protein labeling strategy, based on a mutant SNAP-tag 
(mSNAP) and its Föster Resonance Energy Transfer (FRET) substrate pairs (Figure 
2.1). Our design principle was based on the well-known fact that, in the SNAP-tag 
technology, in which the SNAP-tag forms a covalent bond with BG derivatives by 
nucleophilic attack at the active site cysteine (Figure 2.1a), a guanine moiety is 
released. Furthermore, this reaction is independent of the dye attached to the BG 
derivative. An elegant study by Johnsson et al. provided further evidence that, 
SNAP-tag (an extensively mutated form of hAGT) and its suitable mutants may also 
accept N
9
-substituded BG derivatives (Figure 2.1b).
[76]
 In our strategy, quenched 
probes such as BGQFL-7/9 and BGQNP-7/9 (a two-photon probe; Figure 2.1c), due 
to introduction of a fluorescence quencher, Disperse Red 1 (DR1), would be 
effectively non-fluorescent. Upon covalent labeling with mSNAP, the 
quencher-containing guanine is released, resulting in transfer of the dye onto the tag 
protein (and fluorescence release). Similar concepts had been proposed 
previously,
[77,78]
 but successful and general implementation had not yet been realized 
in the literature. It should be noted that while our manuscript was in preparation, 
Urano et al. introduced what they call a fluorescence activation-coupled protein 
labeling (FAPL) method, in which BG derivatives modified with a quencher at the 
C-8 position were used together with a SNAP-tag.
[79]
 Our present study offers a 
complementary method while providing the first expansion of the SNAP-tag 





Figure 2.1. Overall strategy (a) SNAP-tag protein labeling with BG derivatives. (b) A 





-substituted BG derivatives) used. 
 
2.3 Results and Discussion 
2.3.1 Synthesis of Chemical Probes 
 The various probes were synthesized according to Scheme 2.1. Commercial 
quencher DR1 reacted firstly with 4-toluenesulfonyl chloride to give the activated 
form compound 2-1. Azide containing compound 2-2 was prepared from the 
corresponding amine starting material with good yield. The two-photon dye 
8-oxoacenaphthopyrrole (NP) was equipped with an alkyne handle by alkylation to 
give compound 2-3.
[80]
 Protected fluorescein was firstly coupled with propargylamine 
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and then de-protected under basic condition to give the compound 2-5. The key 
intermediate (compound 2-7) was obtained under strongly basic condition by reaction 
between compound 2-2 and compound 2-6 which was generated by activation of 
6-position of 6-chloro-9H-purin-2-amine with 1-methylpyrrolidine. Incubation 
compound 2-7 with compound 2-3/2-4/2-5 under the click condition, CuI (1 eq), 
DIEA (1 eq), DMSO and DCE (1:2), gave the probe BGNP, BGAF and BGFL 
respectively.      
 
 
Scheme 2.1 Synthesis of various probes used in this study 
 
  Reaction between compound 2-7 and 2-1 produced the two isomers, BGQ-9 and 
BGQ-7, at the same time. BGQ-9 was the more favored product with higher yield 
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than BGQ-7. The same phenomenon was observed during the preparation of 
BGQNP-9 and BGQNP-7 by incubation of BGNP and compound 9. BGQFL-9 and 
BGQAF-9, with the quencher at N
9
 position, were obtained by clicking with the 
corresponding dyes. And BGQFL-9 ,with the quencher at N
7
 position was gained with 
the same manner.  
 
2.3.2 Optical properties of the final Probes 
 
Table 2.1. Photophysical properties of compound 5, BGFL, compound 3, BGNP and 
DR1 in PBS buffer. 
 
UV-Vis absorption and fluorescence spectra were measured by using a Shimadzu 
UV-vis spectrophotometer and a Perkin Elmer LS50 spectrofluorometer, respectively. 
The two-photon excitation fluorescence measurements were performed by using a 
Spectra Physics femtosecond Ti: sapphire oscillator (Tsunami) as the excitation source. 
The output laser pulses have a tunable center wavelength from 760 nm to 850 nm 
with pulse duration of 40 fs and a repetition rate of 76 MHz. The laser beam was 
focused onto the samples that were contained in a cuvette with path length of 1 cm. 












Compound 2-5 493 55380 515 0.88 32 
BGFL 493 55200 515 0.86 30 
Compound 2-3 350 13770 507 0.22 102 
BGNP 350 13700 507 0.21 99 
DR1 502 15870 --
[e]
 -- -- 
 
[a] Peak position of the longest absorption band. [b] Peak position of emission, exited at the absorption 
maximum. [c] Quantum yields determined by using fluorescein aqueous NaOH (pH = 13) as standard, 
respectively. [d] The maxima two-photon action cross section values upon excitation from 750 to 860 




optical fiber that was connected to a monochromator (Acton, Spectra Pro 2300i) 
coupled with CCD (Princeton Instruments, Pixis 100B) system. A short pass filter 
with cut-off wavelength at 700 nm was placed before the spectrometer to minimize 
the scattering from the pump beam. All the measurements were performed at room 
temperature. As shown in Table 2.1 and Figure 2.2, both BGFL and BGNP 
(quencher-free versions of BGQFL-9 and BGQNP-9, respectively) exhibited excellent 
one- and two-photon fluorescence properties as expected. BGQFL-9/-7 and 
BGQNP-9/-7, on the other hand, showed almost no fluorescence, demonstrating high 
intramolecular FRETefficiency upon the addition of DR1Thereby, the BGQNP-7/9 
and BGQFL-7/9 could only generate little fluorescent signal. 
 
 
Figure 2.2 Absorption and emission of various probes. (A) Steady-state absorption of 
DR1 in PBS buffer; (B) Two-photon action spectra of compounds 2-3 and 2-5 in 




; (C) Steady-state 
fluorescence spectra (left) and two-photon excited fluorescence spectra (right) of 
BGFL and its corresponding quenching probes, BGQFL-7 and BGQFL-9 (top), 
BGNP and its corresponding quenching probes, BGQNP-7 and BGQNP-9 (bottom). 









2.3.3 Labeling efficiency of probes toward SNAP-tag and its mutants 
We next assessed the labeling efficiency of these probes towards SNAP-tag and 
its mutants. SNAP-tag is a significantly improved and truncated version of wildtype 
hAGT with key mutations of G
131→K131 and G132→T132.[76] Previous structural and 





SNAP-tag) favor BG derivatives, structurally less demanding residues (such as Gly at 
positions 131 and 132) prefer N
9





Figure 2.3. The crystal structure of human DNA repair protein O
6
-alkylguanine-DNA 





 are shown as orange sticks. As can be seen, these two residues locate in the 
entrance of a big cavity, where a N
9
-subsitituents of BG is located. 
 
We therefore generated the corresponding protein mutants of SNAP-tag (mSNAP) 
– G132-SNAP (T132 in SNAP-tag was replaced by G132) and GG-SNAP (K131 and T132 




). The bacterial expression construct 
G132-SNAP was obtained from the corresponding SNAP-tag template (His-SNAP)
[81] 
using a Quick Change site-directed mutagenesis kit (Stratagene). The GG-SNAP 
construct was generated by Gateway cloning (Invitrogen). Themammalian expression 
constructs Flag-GG-SNAP and Flag-H2B-GGSNAP, in which a nuclear localization 
sequence H2B was fused to the SNAP-tag fusion, were obtained from the 
corresponding Flag-SNAP and Flag-H2B-SNAP vectors, respectively.
[81]
 All plasmid 
DNAs were sequence verified. The recombinant proteins (His-SNAP, G132-SNAP, 
and GG-SNAP) were expressed in BL21(Ai) cells and purified to homogeneity with 
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Ni-NTA beads (Figure2.4). 
 
Figure 2.4. Purification of His-SNAP under native conditions. Lane 1: total cell lysate; 
lane 2: clear cell lysate; lane 3: flow-through; lane 4: first wash; lane 5: second wash; 
lane 6: third wash; lane 7: first elution; lane 8: second elution; lane 9: third elution.  
 
 
Figure 2.5 Fluorescence gel showing different SNAP mutants (1 M each) labeled 
with each of the three probes. (1 M each) for 4 hours. A part of the gel was  
reproduced as Figure 2.6.  
 
Because of the difference in the vector’s backbone (i.e., Gateway destination 
vector rated by Gateway® cloning (Invitrogen). pDEST17 introduces several extra 
linker residues in GGSNAP), His-SNAP/G132-SNAP and GG-SNAP migrated 
slightly differently on the SDS-PAGE gel (Figure 2.5). As expected, BGFL labeled all 
three proteins with reasonable efficiency. BGQFL-7, on the other hand, could not 
label any of the proteins (Figure 2.5).  
To our delight, BGQFL-9 was shown to successfully label all three proteins, with 









 mutations in SNAP-tag, giving GG-SNAP, have indeed 
improved this protein’s reactivity toward our quenched probe BGQFL-9. The labeling 
efficiency of SNAP-tag by BGQFL-9 decreased significantly when compared to the 
original BGFL/SNAPlabeling (Figure 2.5), indicating the steric bulk of the quencher 
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group in BGQFL-9 had predictably hindered its enzymatic attachment to SNAP-tag. 
To test whether the two-photon quenched probe, BGQNP-9, could also label 
GG-SNAP efficiently, we used an indirect competition assay since NP could not be 
detected with our fluorescence gel scanner. As shown in Figure 2.6b, preincubation of 
GG-SNAP with BGQNP-9 effectively blocked the subsequent fluorescence labeling 
of BGFL in a time-dependent manner, indicative of successful labeling between 
GG-SNAP and BGQNP-9.  
 
 
Figure 2.6 Labeling efficiency of probes toward SNAP-tag and its mutants. (a) In-gel 
fluorescence scanning of labeling reaction between different SNAP proteins (1 μM) 
and BGQFL-9 (1 μM) after 4-h incubation at room temperature. Fluorescent bands 
were quantified and plotted (bottom). (b) Indirect competition assay of 
BGQNP-9/GG-SNAP labeling reactions (for 0, 1, 4, and 9 h), followed by subsequent 
addition ofBGFL(1 μL, 100 μM; 15 min), SDS-PAGE and in-gel fluorescence 
scanning. Fluorescent bands were quantified and plotted (bottom). (c) Timedependent 
emission spectra (λex = 470 nm) of BGQFL-9 (20 μM) in the presence of GG-SNAP 
(10 μM) in PBS (pH 7.4) at 25 oC. (d) Time-dependent fluorescence intensity of 
BGQFL-9 in the presence of different SNAP mutants (λex = 490 nm, λem = 522 nm). 
Assay conditions were the same as in (c). The fitted cuves and corresponding rate 
constants were obtained by fitting the data to a first-order reaction model,[9] giving 
rise to the resulting second-order rate constants. 
 
We next evaluated whether the enhancement of BGQFL-9 fluorescence upon 
labeling by GG-SNAP could be monitored spectroscopically (Figure 2.6c,d); a 
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progressive increase in fluorescence (with max λem=522 nm) over time was observed, 
indicating successful release of the quencher (Figure 2.6c). In comparison, both 
SNAP-tag and G132-SNAP produced significantly lower fluorescence increases 
under identical conditions (Figure 2.6d). Kinetic data of the labeling reaction between 
BGQFL-9 and various SNAP mutants were obtained, indicating GG-SNAP was 
indeed the most efficient partner of our N
9
-substituted quenched probe; with a 
second-order rate constant of 8.16 ± 1.10 M-1s-1, our labeling system is not as 
efficient as the original BGFL/SNAP combination (k = ∼2 × 104 M-1 s-1)[17] or the 
newly reported C
8
-substituted quenched probe/SNAP pair (k = ∼4 × 102 M-1 s-1)[20] 




Finally, the labeled product of the BGQFL-9/GG-SNAP reaction was further 
analyzed by MALDI-TOF MS (Figure 2.7); an expected molecular weight increase of 
558 Da was observed, further confirming the success of the labeling reaction. 
 
 
Figure 2.7. MALDI-TOF MS of pure GG-SNAP protein (left) and the labeling 
reaction (GG-SNAP + BGQFL-9) (right). Major MS peaks from the MALDI-TOF 







2.3.4 Bioimaging applications of BGQFL-9/GG-SNAP protein 
labeling system in live cell 
After successful validation that our mSNAP and its FRET-based probes could 
work efficiently in vitro, we moved forward and we examined whether the 
BGQFL-9/GG-SNAP protein labeling system can be used for bioimaging applications 
in live cells. We first applied BGQFL-9 to mammalian cell lysates (Figure 2.8a); a 
single fluorescent band was detected only inmammalian cell lysates obtained from 
CHO-9 cells transiently transfected with the Flag-GGSNAP plasmid, thus 
demonstrating the successful and highly specific labeling reaction of our newly 
developed system even in complex biological systems.  
 
 
Figure 2.8 Labeling of mSNAP in live cell. (a) Coomassie brilliant blue 
(CBB)-stained (left), Western blot (center; with anti-Flag antibody), and fluorescence 
(right) gels of Flag-GG-SNAP transfected CHO-9 cell lysates incubated with 
BGQFL-9. (b) Live CHO-9 cells transfected with Flag-H2B-GG-SNAP and then 
labeled with either BGQFL-9 or BGQNP-9 (20 μM). Key: (i) nontransfected cells 
labeled with BGQNP-9; (ii) transfected cells labeled with BGQFL-9, then imaged by 
one-photon microscope (λex = 488 nm; λem = 522 nm); (iii) Transfected cells labeled 
with BGQNP-9, then imaged by one-photon microscope (λex =405 nm; λem = 470 nm); 
(iv) same as iii, except the image was acquired by a two-photon microscope (λex=800 
nm; λem=470 nm). Scale bar=10 μm. 
 
To label proteins in live cells, we had initially intended to use the cell permeable 
BGQAF-9, but it was subsequently discovered that, to our pleasant surprise, both 
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BGQFL-9 and BGQNP-9 were equally permeant in CHO-9 cells, probably due to 
their overall enhanced hydrophobicity. These two probes were therefore used to carry 
out all live cell labeling/imaging experiments. The plasmid Flag-H2B-GG-SNAP, 
which expresses GG-SNAP in the nuclei, was transfected into CHO-9 cells. After 3 h, 
to the growth media was directly added either BGQFL-9 or BGQNP-9. Following 
further incubation, cells were imaged, using one- and two-photon fluorescence 
microscopes, respectively (Figure 3b); only transfected cells exhibited strong 




In conclusion, by modifying the existing SNAP-tag protein labeling approach, 
we have successfully developed both one-and two-photon quenched probes, 
BGQFL-9 and BGQNP-9, respectively, that could covalently label a SNAP-tag 
mutant protein (mSNAP) with moderate efficiency. We showed that, in addition to 
C-8,
[79]
 the N-9 position in BG is also suitable for quencher attachment. Our results 
indicate real-time detection of both the labelling reaction and live cell imaging could 
be achieved using this system. To our knowledge, the only other small molecule based 
protein labeling approach for two-photon microscopic applications was done using the 
DHFR/Mtx noncovalent strategy.
[82]
 Our current system thus represents the first 
covalent protein labeling approach using small molecule probes for TPM applications. 
This, togeher with other recenlty developed enzyme-detecting TPM probes,
[36]
 will 
open up new opportunities for bioimaging of important enzymes and their activities in 
deep tissues, where conventional fluorescence microscopy has very limited 
utilities.
[71,72]
 Nevertheless, a potential drawback of this approach is that it is difficult 
to probe the endogenous proteins because of requirement of fused tag. A promising 
method to address this drawback is to utilize the small molecule chemical probes, 
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In this chapter, our efforts were shifted to develop small molecule chemical probes 
to touch and image proteins in the native conditions, which is a drawback of previous 
mentioned general imaging approach. To this end, two kinds of FRET based chemical 
probes were designed and synthesized. One (NPA) is designed with a 
acyloxylmethylkentone (AOMK) warhead so as to form a covalent bond with the 
targeting protein (caspase-1), but NPA actually did not show labeling with caspase-1.  
The other one (NP) is substrate based probe designed from a specific caspase-1 
inhibitor, Pralnacasan. NP’s reactivity with caspase-1 showed more than 30 fold more 
sensitivity than Ac-YVAD-AMC. Under inhibitor screening conditions for caspase-1, 
NP’s dynamic range was 3 fold higher than that of Ac-YVAD-AMC. At the same time, 
bioorthogonal chemistry between cyclooctyne and azide was used to set up a 
52-member library where each member was with an aldehyde warhead. By virtue of 
this bioorthogonal reaction, the final step to set up library proceeded clean and 
smoothly in DMSO. No followed work up will be needed, which thereby saved a 
large amount of time and resources. Screening this compound library against 
caspase-1 discovered a potent inhibitor for caspase-1 and an initial structure-activity 
relationship was figured out.  
 
3.2 Introduction 
Caspases are cysteine aspartate specific proteinases with two common features: 1) 
all members of the caspase family include the catalytic cysteine residue in the active 
site; 2) they cleave their substrates on the carboxyl side of aspartate residues.
[83]
 
Among the 12 reported human caspases, Caspase-1, also called 
interleukin-1-converting enzyme (ICE) was the first human caspase to be identified 
and isolated.
[84,85]
 Active caspase-1 is involved in the cleavage and activation of 
interleukin 1, interleukin18  and interleukin-33.[49] Interleukin 1 and interleukin 
18 are crucial mediators of innate immunity and inflammation. Inhibition of caspase-1 
has been shown to be beneficial in many experimental animal models of human 
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disease, including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, 
asthma, and sepsis, which suggests targeting caspase-1 be novel approach for these 
problems.
[46, 86]
 Hence, caspase-1 targeted small molecule fluorescent probes for 
imaging and inhibitor screening will greatly facilitate caspase-1 centered research.  
There are lots of probes developed for caspase-1 imaging. In 2004, Tung and 
coworkers
[87]
 reported a novel method for imaging caspase-1 near-infrared fluorescent 
probe. This probe was synthesized by conjugation of NIR fluorophore attached 
caspase-1 cleavable peptide (WEHD) into a biocompatible, partially pegylated 
poly-L-lysine delivery vehicle. The high local density of fluorochromes cause 
substantial fluorescence quenching. Thereby, the fluorescence did not come up until 
caspase-1 cleaved the peptide and released free fluorophores. Although it worked well 
in vitro, more than 130 fold of intensity increase was observed upon caspase-1’s 
cleavage, this probe may have limited application in vivo due to large molecule 
weight. 
 
Figure 3.1 Schematic diagram of the ICE-NIRF probe. 
Recently, Bogyo and coworkers
 [42]
 reported a new activity based probe (AWP28) 
to monitor caspase-1 activation in response to proinflammatory stimuli. This probe 
was designed based on the well-known caspase-1 inhibitor VX-765 which was 
developed by Vertex pharmaceuticals and it is now in phase II clinic study. AWP28 
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showed remarkably reduced nonspecific background labeling compared to the 
commercially available caspase-1 probe FLICA. But its general fluorescence both 
when bound to the enzyme target and when free in solution potentially hindered its 
application for in vivo real time imaging. So, small molecule activitable probe will be 
highly favored under these circumstances.  
Besides imaging, targeting Caspase-1 via small-molecule therapeutics is also an 
active area of research. A prominent example is VX-765 with a peptidic scaffold 
developed by Vertex pharmaceuticals for the treatment of epilepsy, especially for 
people who do not respond to standard medicines for epilepsy.
[88]
 In 2011, Vertex 
announced Phase II study of VX-765 in people indicated that the drug was safe and 
well tolerated. Phase IIb study of VX-765 in people with treatment-resistant epilepsy 
is being in progress. Inhibitor screening to find lead compounds is a pivotal step 
during the drug development. A large number of approaches have been used for 
inhibitor screening against Caspase-1 in vitro. One frequently applied approach 
involved the coumarin based fluorogenic substrate (like, Ac-YVAD-AMC).
[52] 
Generally, the screened compounds were firstly incubated with Caspase-1, followed 
by addition of the fluorogenic sub-strate. So the inhibition can be measured from the 
detection of fluorescence intensity. This assay usually contains two controls. One is a 
background control by omitting the Caspase-1 from the reaction mixture, which will 
give the lowest fluorescence intensity in the screening assay. The other one is a 
control where no inhibitor is added, which will give the highest fluorescence intensity. 
We termed the difference between the minimum and maximum intensity value 
dynamic range. Thus, fluorescence intensity for all the screened compounds should be 
in this dynamic range. However, based on our measurement, the dynamic range using 
Ac-YVAD-AMC in the screening assay was about 80. This small dynamic range will 
have two major limitations when screening the compound library. Firstly, all 
fluorescent readout of screened compounds will be crowded in this small range and 
their differences would be marginal in some cases. Secondly, following the first 
limitation, this trivial fluorescence intensity difference between different inhibitors 
will be easily affected by other factors, like temperature, experimental techniques and 
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so on. In other words, the accuracy of screening results might be discounted. Under 
these con-siderations, bioluminescent assay is a promising alterative owing to the 
exceptional sensitivity, dynamic range, and rapid measurement that bioluminescence 
affords.
[54, 89]
 However, a recent study found that a total of 43,885 compounds 
inhibited firefly luciferase and 30% of these compounds were associated with potent 
and efficacious concentration response curves.
[55]
 This interaction of small molecule 
with luciferase, to some extent, confounded its use in chemical biology and drug 
discovery. 
In this chapter, a lot of efforts were also going to development an efficient means 
to set up a small molecule library for caspase-1. Bioorthogonal chemistry between 
azide and cyclooctyne was used to build the library in the final step in the solvent of 
DMSO. This reaction proceeded clean and smoothly in DMSO. No followed work up 
will be needed, which thereby saved a large amount of time and resources.       
 
3.3 Results and Discussion 
3.3.1 Synthesis of Chemical Probes 
Synthesis of NPA was according to scheme 3.1. Briefly, DR1-OTs was treated 
with NH2-Gly-OMe to give 3-1, which coupled with acetic acid to give 3-2. 3-2 
underwent hydrlization and then reacted with (S)-tert-butyl 
3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-bromo-4-oxopenta-noate to give 
compound 3-4, which was de-protected to give 3-5. Then 6-amino-2-naphthoic acid  
firstly underwent methyl esterification under strong acid in methanol. Then a mono 
methyl group was introduced to amino of compound 3-6 to give 3-7. Alkyl handle 
was attached to the same amino group followed by hydrolyzation, to give the key 
intermediate compound 3-9. Meanwhile, acid of 3-10 was protected with tert-butyl 
group under optimized condition. Compound 3-11 was firstly treated with hydrazine 
hydrate and then coupled with 3-9 to give compound 3-12. 3-12 was firstly incubated 
with TFA to remove the tert-butyl group. The desired free acid intermediate was 




Scheme 3.1 Synthesis of probe NPA  
   
Scheme 3.2 Synthesis of probe NP 
  
Synthesis of NP was according to scheme 3.2. Briefly, commercial Disperse 




Compound 3-14 was coupled with protected Aspartic amino acid to give 3-15, which 
was deprotected under basic condition and then coupled with the acid (prepared 
according to published procedure
[91]
) to give 3-16. Finally, de-protection of the amine 
groups, coupling with the dye part, followed by treatment with TFA gave the probe 
NP.  
 
3.3.2 Reactivity of NPA towards Caspase-1 in vitro 
We next tested NPA’s activity towards caspase-1 in vitro. As shown in Figure 3.2, 
incubation of NPA with pure caspase-1 did not observe much difference from the 
control where no caspase-1 was added. The observed intensity increase in both 
incubation with or without enzymes was because of the slow hydrolyzation of AOMK 
group in probe NPA. We then carried out in-gel fluorescence scanning of labeling 
reactions between NPA with caspase-1 (Figure 3.2b, 3.2c) by virtue of the alkyne 
handle in NPA. No observed labeling band belong to caspase-1 was observed as the 
incubation went by. Taken together, NPA seemed little labeling with caspase-1. Thus, 
no more experiments were done for this probe. 
 
 
Figure 3.2 Measurement of NPA’s reactivity with caspase-1 in intro (A) 
Time-dependent fluorescence intensity of NPA (final conc, 12 M) incubated with 
pure caspase-1 (1 L, 2.5 U/L) in Heps buffer (100 mM NaCl, 50 mM HEPES, 10 
mM DTT, 1 mM EDTA, 10% Glycerol, 0.1% CHAPS, pH=7.4). (B) In-gel 
fluorescence scanning of labeling reactions between NPA (2 L, 1mM) and caspase-1 
(10 L, 6 mg/mL) in Heps buffer (20 L) at different incubation time 2 hours (line 1), 
4 hours (line 2), 7 hours (line 3). (C) Coomassie brilliant blue (CBB)-stain of the gel 
in (B).  
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3.3.3 Reactivity of NP towards Caspase-1 in vitro 
Km of the reaction between Caspase-1 and NP probe was firstly measured 
according the standard protocol. Briefly, 44 L of assay buffer (100 mM NaCl, 50 
mM HEPES, 10 mM DTT, 1 mM EDTA, 10% Glycerol, 0.1% CHAPS, pH = 7.4) 
was added to wells of 384-plate, which was followed by addition of Caspase-1 (2.0 
L, 2.5 U/ L) and different concentrations of NP probe (2 L, final concentration, 
6.0 M, 5.0 M, 4.0 M, 3.0 M, 2.5 M, 2.0 M, 1.5 M, 1.0 M). Then 
fluorescence intensity was monitored (ex = 350 nm, em = 460 nm) continuously 
for 30 minutes at room temperature using a BioTek Synergy 4 plate reader. The 
values of the kinetic parameter (Km) were determined from the double reciprocal plot 
of the reaction rate versus the substrate concentration (Lineweaver–Burk plot). After 
plotting, measured Km = 3.96 M.  
 
Figure 3.3 Lineweaver–Burk plot between 1/V and 1/[s] 
 
Next, more experiments were carried out to validate the reactivity of NP towards 
caspase-1. As shown in figure 3.4a, fluorescent intensity of NP increased about 130 
fold in presence of caspase-1. However, the widely used and commercial available 
fluorogenic probe YVAD-AMC only rendered 4.2 fold increase under the same 
condition. To achieve a good detection of caspase-1 (S/N > 2), NP only needed less 
than 3.2 U/mL of caspase-1 while YVAD-AMC needed more than 100 U/mL, which 
indicated that NP was about 30 fold more sensitive to caspase-1 than YVAD-ADMC 
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(Figure 3.3d). NP’s activity towards other caspases were also examined. Incubation 
with NP with caspase-3 and caspase-7 did not show up obvious fluorescent increase. 
Taken together, these data indicated probe NP can be efficiently and selectively 




Figure 3.4 Reactivity of NP with caspase-1 and other caspases. (A) Time-dependent 
fluorescence intensity of NP (12 M) in the presence of caspase-1 (1.2 U/L) in Heps 
buffer (pH = 7.4) at 25 
o
C  (λex = 350 nm, λem = 460 nm). (B) Time-dependent 
fluorescence intensity of Ac-YVAD-AMC (12 M) in the presence of caspase-1 (1.2 
U/L) in Heps buffer (pH = 7.4) at 25 oC  (λex = 350 nm, λem = 460 nm). (C) 
Time-dependent fluorescence intensity of NP in presence of different caspases. 
Concentrations of Caspase-3/7 were titrated before use (SI); (D) Fluorescence 
intensity of NP (8 M) and Ac-YVAD-AMC (8 M) incubated with different 
concentrations of caspase-1 for 1 hour. Numbers on top of column were calculated 
from ration of S/N. 
 
3.3.4 Set-up of small molecule library with bioorthogonal chemistry 
between azide and cyclooctyne 
After successful development the new caspase-1 sub-strate NP, we shifted our 
efforts to identify a new and efficient approach to discover potent small molecule 
inhibitor of caspase-1. Inhibitors of caspases usually contained two part: 1) a binding 
motif that can specifically bind the targeted caspases; 2) a warhead that can covalently 
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modify the active-site cysteine through reaction with highly nucleophilic thiolate.
[92]
 
Suitable electrophilic warheads include aldehyde, -halo ketone, acyloxymethyl 
ketone (AOMK) and so on.
[46]
 Recently, Yao and coworkers applied Cu(I)-catalyzed 
cycloaddition between azide and alkyne to efficiently set up a 198-member small 
molecule library for caspase-3.
[93]
 The resulted triazole heterocycle served a neutral 
alternative to the P2-P3 residues and also a linker to connect binding motifs and the 
warhead (aldehyde and vinyl sulfone). Although this ap proach was efficient, the 
usage of catalysts and other additives, to some extent, affected the following 
screening results. Staring from this concern, we turned to the copper free cycloadditon 
between cyclooctyne and azide. This strain-promoted cycloaddtion is now widely 
used to image small molecules and also proteins in living systems.
[23]
 But it has never 
been used to set up small molecule library to serve the inhibitor development of 
interested targets. There are unique advantages to utilize this bioorthogonal chemistry 
to set up the library for caspase-1. From the perspective of chemistry, the reaction can 
proceed well in aqueous solution and other organic solvent (like DMSO),
[94]
 which 
means no work up will be needed and therefore save large amount of time and 
resources. Moreover, the resulting motif, triazole heterocycle fused with 8-member 
ring, may be a mimic of central part of Pralnacasan16 and can be well positioned in 
the catalytic groove of caspase-1. 
 
3.3.4.1 Synthesis of key intermediates cyclooctyne-1/2 
With the above mentioned rationales in mind, we synthesized the key intermediate, 
cyclooctyne-1/2, according to the published procedure (Scheme 3.3).
[94]
 Coupling of 
compound 3-17 prepared following published procedures with NH2-Asp(OtBu)-H 
dimethyl acetal to give the two epimers. Treatment of these two epimers with TFA 





Scheme 3.3 Synthesis of cyclooctyne-1/2 
 
It should be noted that the relative stero chemistry of the two epimers (3-23-1/2) 
were achieved by J-resolving experiments. The coupling constants of H-1 provide the 
key information to assign the relative stereo chemistry in this study. H-1 is coupled 
with not only 4 protons from C-1’ and C-8 but also two F on C-2. To extract coupling 
constants of protons, we employed J-resolving experiment in the research.  
As shown in Figre 3.5, when H-1 of 3-23-2 is along the axis direction in the 
strained 8-member ring, there are two coupling constants which are larger than 10 Hz. 
As revealed in 
1
H, the H-1’ had one 10 Hz coupling with H-1. Another coupling 
comes from H-8. In the meantime, the splitting of correlations showed coupling from 




Figure 3.5 J-resolving experiment of 3-23-2. This is part of spectrum showed distinct 
difference. For full spectrm, please refer to appendix in CD. Ha means axis direction.  
 
When H-1 of 3-23-1 is along the equatorial direction (Figure 3.6), the coupling 
constants are very small between H-1 and H-8. To extract the coupling constants, we 
have to extend evolution time to acquire the small coupling constants, which lead to 
the loss of signal intensity; and the splitting from F on C-2 made the case even worse. 
There are two small couplings (2.7Hz and 1.0Hz) are exposed, which supported the 





Figure 3.6 J-resolving experiment of 3-23-1. This is part of spectrum showed extinct 
difference. For full spectrm, please refer to appendix CD. He means equatorial 
direction. 
3.3.4.2 Set-up of small molecule library by reaction between azides 
and cyclooctyne-1/2 
   With the two key intermediates containing the warhead in hands, we then used 
them to set up the small molecule library. Before all the azides were treated with 
cyclooctyne-1/2, one azide (19) was firstly cyclooctyne-1 to get a ideal incubation 
time to finish the reactions. As shown in Figure 3.7, the reaction can be finished 
within 9 hours. Moreover, the reaction proceeded smoothly and clean.  
   Then all the azides blocks (1.1 eq.) were incubated with cyclooctyne-1 (1.0 eq.) 
and cyclooctyne-2 (1.0 eq.) respectively to give a 52-membe library. After a 
24-hour-inbubation, all the reactions were clean and contained desired products 
without detection of the warhead. So, the products were directly used in the screening 




Figure 3.7 LC-MS profile of reaction between cyclooctyne-2 and azide (19) at 
different indicated time 
 




3.3.4.3 Caspase-1 inhibitor screening using probe NP 
After it was successfully synthesized, the aldehyde library was then screened 
against caspase-1 using probe NP. Briefly, 44.5 L of screening buffer (100 mM NaCl, 
50 mM HEPES, 10 mM DTT, 1 mM EDTA, 10% Glycerol, 0.1% CHAPS, pH=7.4) 
was added to wells of 384-plate, which was followed by addition of Caspase-1 (1.5 
L, 2.5 U/L) and different compounds (2 L, final concentration, 20 M). After 
incubation for 10 minutes at R.T., NP probe (2 L, final concentration, 8 M) was 
added to each well. One control well without inhibitor and one control well without 
Caspase-1 were included. The reactions were incubated for 45 minutes at R.T. and 
then fluorescence intensity was measured (ex = 350 nM, em = 460 nM).  
 
 
Figure 3.8 Caspase-1 inhibitor screening using probe NP. b1-b26 were compounds 
generated from reaction between cyclooctyne-1 and 26 different azides; s1-s26 are 
compounds generated from reaction between cyclooctyne-2 and 26 different azides; 
wh-b was cyclooctyne-1; wh-s is cyclooctyne-2; c1 was the control experiment where 
no inhibitor was added; c2 was the control experiment where no casapse-1 was added. 
 
As indicated in figure 3.8, compound b7 showed the strongest inhibition and b8 
was slightly weaker than b7 but still potent. While the rest showed much weaker 
inhibition, only slightly better than warhead 1 and 2. So, it seemed that there was a 
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special requirement on the motif connected to the triazole. Among all the different 
motifs in this position, the amino ketone methyl motif was most favorable because the 
only two compounds (b7 and b8) in the subfamily-1 with this special motif showed 
potent inhibition. Furthermore, it should be noted that compound s7 showed much 
weaker inhibition than its epimer b7, which means the chiral center on C-1 played a 
vital role on the inhibition. 
We then repeat to screen the top 5 most potent inhibitors in the sub-library 1 using 
NP together with Ac-YVAD-AMC. As shown in figure 1B, screening results using NP 
was well repeatable as the 5 compounds remained the same order to the previous 
screening. However, screening results showed small differences among the 5 
compounds when using Ac-YVAD-AMC as the dynamic range of this probe was 
small. And compound b8 appeared less potent than compound b20, which proved the 
abovementioned limitation of small dynamic range that can make the screening 














































Figure 3.9 Inhibition screening of selected compounds with NP probe (left 7 
columns) and YVAD-AMC (right 7 columns) respectively. c1/y1 were the control 
experiments where no inhibitor was added; c2/y2 were the control experiments where 
no Casapse-1 was added. 
    
We next carried out quantitative determination of IC50 of compound b7 and s7 
against different caspases. b7 showed IC50 value of 1.49 M against caspase-1 while 
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its epimer s7 showed IC50 value of 9.67 M against caspase-1 (Figure 3.10). On the 
contrary, compound Ald-D4 which was identified in previous study by Yao and 
coworkers and was structurally similar to b7 in this study except the 8-member ring 
showed moderated inhibition (IC50 = 12.7 M).[93] This indicated that the fused 
8-member ring made b7 more selective to caspase-1. 
 




1.5 b7 (IC50 = 1.496  ± 0.001 M)









Figure 3.10 IC50s of compound b7/s7 against caspase-1 measured by probe NP. 
3.3.4.4 Caspase-1 inhibitor screening using probe NP 
It should be noted that reaction between cyclooctyne and azide generated two 
regioisomers. We next examined the inhibition difference between these two 
regioisomers in compound b7. To directly separate the two isomers in b7 seemed not 
feasible as the resolution of separation was rather bad. In order to solve this problem, 
intermediate 3-23-1 was firstly reacted with azide 7 to produce two regioisomers 
3-24-1 and 3-24-2 which was successfully separated by prep-TLC. Their 
regioconformations were identified with nosey NMR. As shown in Figure 5, in 
compound 3-24-1, there was no correlation between H9 and H5 so that the distance 
between these two protons was far. But in compound 3-24-2, there was strong 
correlation between H9 and H5, indicating these protons were close. 3-24-1 and 




Figure 3.11 Synthesis and identification of regioisomer b7-b and b7-s. (A) 
Synthetic scheme of b7-b and b7-s. (B) Partial nosey spectrums of b7-b and b7-s, full 




With the two regioisomers in hand, we next measured their inhibition against 
caspase-1. It was found that b7-b 
but the other isomer b7-s had almost no inhibition against caspase-1 within the 
concentration range (4 nM-40 M) (Figure 6). These results indicated that the 



















Figure 3.12 IC50s of compound b7-b/b7-s against caspase-1 measured by probe 
NP. 
 
3.4 Conclusion  
In conclusion, we have firstly designed and synthesized two fret-based probe 
(NPA and NP) for caspase-1. NPA had an AOMK motif that can potentially form a 
covalent bond with targeted proteins. But NPA expressed little reactivity with 
caspase-1, which was out of our expectation. On the contrary, NP showed much 
higher reactivity with caspase-1. NP had a much higher dynamic range and showed 
more sensitive to caspase-1 than the widely used fluorogenic probe Ac-YVAD-AMC. 
This new probe will definitely enrich the chemical tools to detect caspase-1 and 
facilitate the drug development of caspase-1. Secondly, we introduce the 
bioorthoganol reaction between cyclooctyne and azide, for the first time, to serve an 
efficient means to set up small molecule library against caspase-1. This initial try 
leads to find one potent inhibitor against caspase-1. With the development of 
bioorthogonal chemistry, more and more this kind of reaction will be available. Hence, 
we expected this concept that using bioorthogonal chemistry serves the drug 
development of interest targets can be widely used in the field of chemical biology 
and medicinal chemistry. 
Probe NP’s success was built on the specific well known caspase-1 inhibitor, 
Pralnacasan. This inhibitor provided a good starting scaffold to be utilized to 
synthesize excellent probe (NP) which will further promote our understanding of this 
important enzyme. From this case, we can see that a good inhibitor can not only 
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facilitate the drug development, but also serve greatly in the field of chemical biology. 
Encouraged by this example, in the next chaptor, I will present our efforts dedicated to 
developing potent inhibitors for bromodomains playing important roles in epigetics, 














Small molecule Microarray generated through 
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High-throughput screening (HTS), a powerful tool to screen a large compound 
library which discover the potential hits with high efficiency, is now widely used to 
find and identify potent inhibitors for targets of interest in the drug development. 
Among the different means of HTS, small-molecule microarray (SMM) is a 
potentially unprecedented means for massive parallel high-throughput screening of 
compound libraries with a variety of proteins and celleular targets. A critical step for 
SMM screening is to immobilize the compound library onto the surface of solid 
support by virtue of the interaction between tag A attached to each member of a 
compound library and tag B attached onto the surface of a solid support. Currently, 
there are two classical methods to do the immobilization. One is through non-covalent 
interaction between tag A and tag B. The other one is through covalent interaction 
between tag A and tag B. Non-covalent immobilization may be easy to set up, but the 
interaction is weak, thereby affecting the subsequent screening results. A common 
weakness for covalent immobilization methods is that tag A and tag B limited to some 
extent in terms of the compound library’s diversity. In this chapter, a new and covalent 
immobilization method by the bioorthogonal reaction between tetrazine and 
cyclooctene was developed. The results showed that this is, so far, the fastest 
immobilization method. Application of this new method led to find potent inhibitors 
of bromodomains.   
 
4.2 Introduction 
   Epigenetics refers to the study of heritable changes in gene expression or cellular 
phenotype caused by mechanisms other than changes in the underlying DNA 
sequence. -N-acetylation of lysine residues (KAc) is one of the most frequently 
occurring posttranslational modifications (PTMs) in proteins associated with 
epigenetics.
[56,57] 
Lysine acetylation is abundant in large macromolecular complexes 
that function in chromatin remodeling, DNA damage, and cell-cycle control. 
Acetylation affects the physiochemical properties of modified lysine residues by 
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neutralizing their positively charged side-chains. In histones, acetylated lysines have 
reduced electrostatic interactions with the negatively charged DNA phosphates, 
providing a more relaxed chromatin structure that is associated with transcriptionally 
active genes. The cellular histone acetylation levels are stringently controlled by two 
enzyme families: the histone acetyltransferases (HATs, or the so-called epigenetic 
“writers”) and histone deacetylases (HDACs, or the so-called epigenetic “erasers”). In 
addition, acetylated lysine residues affect gene transcription through interaction with 
bromodomain (BRD)-containing proteins (BCPs, the so-called epigenetic “readers”). 
In recent years, epigenetic proteins including HATs and HDACs have been the main 
focus of intense research in medicinal chemistry and drug discovery. These enzymes 
are considered “druggable” because they possess well-known reaction mechanisms 
and compact substrate-binding pockets.
[95,96]
 In fact, two currently FDA approved 
drugs, Vorinostat and Romidepsin, work by the inhibition of HDAC activity in T-cell 
lymphoma, thereby balancing the aberrant lysine acetylation profile in the disease. On 
the other hand, the developments of protein-protein interaction (PPI) inhibitors that 
target the epigenetic “readers” (e.g. BRDs in BCPs) are considered much more 
challenging. It is a generally accepted notion that, small molecules, due to their 
limited sizes and functional groups, are normally insufficient enthalpically to bind to 
the much larger surface present in the protein-protein interface.
[61,62]
 This simplistic 
view, however, has recently been challenged by two ground-breaking studies, 
published independently in 2010 by James Bradner’s group at Harvard Medical 
School and a group of medicinal chemists at GSK.
[63, 64]
 The serendipitous discovery 
of two small molecule inhibitors, JQ-1 and I-BET, both of which are potent, 
nanomolar inhibitors of BET bromodomains (e.g. BRD4), has spurred enormous 
interests in both academia and the pharmaceutical industry in pursuit of other small 




BCPs are protein-binding domains and possess no enzyme activities. For most of 
the 61 human BRDs, there is little definite knowledge about their cognate 
KAc-binding sequences.
[101] 
A recent study that aims to systematically delineate this 
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information using large-scale structural studies and histone-peptide arrays against 
more than 30 representative human BRDs failed to identify any sub-micromolar 
acetylated peptides suitable for use in high- throughput screening (HTS) assays, .e.g. 
FP experiments.
[101]
 Current available assays for screening of BRD-binding molecules, 
including fluorescence polarization (FP), isothermal titration calorimetry (ITC), 
protein stability shift assay and surface plasmon resonance (SPR), are either limited to 
only few well-known BRDs (e.g. BRD2/3/4), or not amenable to large-scale HTS due 
to the large amount of samples required.
[65, 102]
 Protein stability shift assay, though a 
medium-throughput platform, provides only small Tm shifts which are not sufficient 
to delineate small binding differences amongst different protein-ligand interactions. It 
is therefore not surprising that both JQ1 and I-BET were identified serendipitously 
from screening of random, in-house compound libraries using cell-based reporter 
assays without any prior target information.
[58, 63, 64]
 These assays, though useful in 
some instance, have the critical drawback that they are not “target-oriented”, and hits 
identified may not actually act on their intended BRD targets. Therefore, in order for 
any drug development program focusing on the discovery of BRD inhibitors to be 
successful, one must first develop an HTS platform that enables general, systematic 
and large-scale screening of BRD-small molecule interactions en masse. This is 
however currently unavailable. Small-molecule microarrays are well-suited for 
high-throughput (HT) studies of protein–small molecule interactions. Binding results 
of tens and thousands of immobilized compounds to the targeted protein or cellular 
targets can be obtained and analyzed within one single day. Here, in this study, we 
synthesized a small compound library based on JQ-1 and GW841819X (a mimic to 
I-BET).
[68]
 This library where each member contained a trans-cyclooctene (TCO) tag 
was immobilized on tetrazine modified glass slide by the bioorthogonal ligation 
between TCO and tetrazine (Figure 1). The desired SMM was used to screen dozens 








Figure 4.1 Overall strategies. a) Synthesis of small molecules with a trans-cyclooctene (TCO) tag (SM-TCO) followed by immobilization of 
SM-TCO onto tetrazine slide to generate SMM screened with bromodomains; b) Development of new immobilization method by bioorthogonal 
reaction between tetrazine and TCO. 
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4.3 Results and discussion 
4.3.1 Chemical synthesis 
4.3.1.1 synthesis of tetrazine, TITC-TCO and other building blocks 
 Scheme 4.1 Synthesis of FITC-TCO, Tetrazin-Gly-NH2 
 
As shown in scheme 4.1, NH2-tetrazine (4-54) was synthesized according to 
published procedure.
[103]
 Then compound 4-54 reacted with activated Fmoc-Gly-OH 
followed by de-protection of fmoc group to give compound 4-56, which was used to 
prepare the tetrazine slides. Trans-cyclooctene 4-57 was prepared under UV 
irradiation. 4-57 was introduced an acid handle under strong basic condition to give 
TCO-COOH. Then protected FITC was firstly attached an amine handle, which next 
reacted with TCO-COOH, followed by liberation of free FITC to give FITC-TCO. 




Scheme 4.2 Synthetic scheme and structures of building blocks. (A) Synthesis of  
building block 1 used in the library’s synthesis; (B) Structure of building block 2; (3) 
synthesis of TCO linker (4-60) used in the library’s synthesis. 
 
As shown in Scheme 4.2, building blocks (AB) were prepared according to 
published procedure. Acid building blocks are commercial available. TCO was 
equipped with an amine group with a peg linker in between to give compound 4-60 
(Scheme 4.2c).  
 
4.3.1.2 Set-up of small molecule library via solid phase synthesis 
With the building blocks in hand, we firstly tried to use solid phase synthesis to 
generate the small molecule library. The rationale was that solid phase synthesis 
would be much more efficient than solution phase synthesis to set up a library 
containing a large number of compounds. The solid phase synthetic route was shown 







Scheme 4.3 Solid phase synthetic route for small molecule library set up 
 
 
Figure 4.2 LCMS profile of product on resin after first two steps. The mian peak is 
desired product. 
   The first two steps (amino reduction and coupling) proceeded smoothly. The 
reaction were quite clean and the main peak was corresponding to the desired product. 
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De-protection of allyl group with Pd(PPh3)4 and phenylsilane in THF followed by 
coupling with block A1B1 also lead to form the desired product though there are two 




Figure 4.3 LCMS profile of product on resin after first four steps. The peak pointed 
with a arrow was desired product. 
 
The next step to form the 7-member ring underwent the de-protection fmoc group 
and ring formation under acid condition. As shown in Figre 4.4, the reaction appeared 
clean enough and the main peak was the desired product.  
 
 
Figure 4.4 LCMS profile of product on resin after first four steps. The peak pointed 
with a arrow was desired product. 
 
Problems encountered in the next step to convert oxygen of amide bond in the 7 
-member ring to sulfur with lawesson's reagent (Figure 4.5). Not only the desired 
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conversion happened, but also was oxygen of amide bond close to resin converted to 
sulfur. This addition conversion was destructive to the whole scheme. The compounds 
will probably not be cleaved from resin after thiol carbonyl reacted with hydrazine 




Figure 4.5 Conversion oxygen of amide bond in the 7 -member ring to sulfur. Top: 
reaction scheme; middle: LCMS profile of reaction; Bottom: structure of the 
compound corresponding to the main peak in LCMS. 
 
In order to solve the above problem, another different rout was employed (Figure 
4.6). The resin was firstly treated with diethyl chlorophosphate and acetic hydrazide, 
followed by heating in butanol to form 1, 2, 4-triazolyl ring. But the LCMS showed 
the reaction was quite complicated and no desired product was observed. After this 
failure, we give up solid phase approach and turned to solution phase synthesis to set 
up the compound library.   
 











Figure 4.6 Alternative route to form 1, 2, 4-triazolyl ring. Top: reaction scheme; 
bottom: LC profile of the reaction.  
 
4.3.1.3 Set-up of small molecule library via solution phase synthesis 
 
 
Scheme 4.4 Synthesis of whole library (compound 4-25 used as an example) 
 
It appeared difficult to used solid phase to set up the small molecule library. 
Efforts were then shifted to use solution phase to do the job (Scheme 4.4). The good 
point is that the route was shorter than that of solid phase. Briefly, block AB coupled 
with protected aspartic amino acid to give compound 4-49. 4-49 underwent 
de-protection followed by treatment with acid to give compound 4-50. Treatment of 
4-50 with lawesson's reagent in toluene at reflux gave compound 4-51. 4-51 firstly 
reacted with hydrazine hydrate and then reacted with activated acid to give 25T. 25T 
was treated with TFA and then introduced the linker to give compound 4-25. A total 
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of 48 compounds were synthesized with good purity (>95% judging from LCMS). All 
the products were verified with high resolution mass. Representative compounds were 
confirmed by NMR. All the members of library were listed in the Table 4.1.  
 






































































































































































































































































[a] Entries highlighted in yellow are compounds based on know bromodomain 
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inhbitor I-BET and JQ-1. 
 
Table 4.2 Arrangement of library and control compound per sub-grid on the array 
4-46 4-41 4-36 4-31 4-26 4-21 4-16 4-11 4-6 4-1 
4-46 4-41 4-36 4-31 4-26 4-21 4-16 4-11 4-6 4-1 
4-47 4-42 4-37 4-32 4-27 4-22 4-17 4-12 4-7 4-2 
4-47 4-42 4-37 4-32 4-27 4-22 4-17 4-12 4-7 4-2 
4-48 4-43 4-38 4-33 4-28 4-23 4-18 4-13 4-8 4-3 
4-48 4-43 4-38 4-33 4-28 4-23 4-18 4-13 4-8 4-3 
TCO-OH 4-44 4-39 4-34 4-29 4-24 4-19 4-14 4-9 4-4 
TCO-OH 4-44 4-39 4-34 4-29 4-24 4-19 4-14 4-9 4-4 
DMSO 4-45 4-40 4-35 4-30 4-25 4-20 4-15 4-10 4-5 
DMSO 4-45 4-40 4-35 4-30 4-25 4-20 4-15 4-10 4-5 
4.3.2 Evaluation of new immobilization method on glass slide 
A key step for fabrication of SMM is immobilization of compound libraries on the 
functionalized slides. Compounds and surface of slides normally contain two different 
tags whose interaction will attach the library onto the slides.
[69]
 The most commonly 
used interaction are non-covalent binding and covalent chemical ligation. 
Non-covalent examples include biotin and tetra-avidin interaction,
[105]
 C14 
hydrocarbon chain and polystyrene interaction,
[106]
 fluorous-based interaction (C8F17 
and Teflon).
[107] 
Although these methods are frequently used, they have several 
drawbacks. For example, some non-covalent bindings are weak as 71% of the 
immobilized compound by C14 hydrocarbon chain and polystyrene interaction will be 
washed away when using methanol to wash once.
[106]
 Covalent chemical ligation is 
another commonly employed immobilization method. Mild reactions including 
Michael addition,
[108]
 Diels–Alder reaction,[109] Staudinger ligation,[110] thiol-ene 
reactions
[111]
 and photoaffinity reaction
[112]
 were successfully used to perform the 
immobilization. However, these reactions have their intrinsic drawbacks. For example, 






 rendered long time 
incubation (overnight) when doing the immobilization
[110]
. Photoaffinity approach 
seems promising, while the generated highly reactive intermediate which is 
chemically promiscuous may destroy the warhead or pharmacophore of compound 
immobilized. Approaches using Michael addition and thiol-ene reaction overlooked 
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the fact that Michael acceptor and thiol are often used for development of compound 
library’s diversity. Thus, these reactions cause the library’s diversity to be 
intrinsically shrinked. 
To overcome these problems, we developed a new immobilization generated by 
the bioorthogonal reaction between tetrazine and trans-cyclooctene (TCO)
[113] 
which 
is widely used for bio-imaging of protein 
[27]
 and small molecule.
[114]
 Tetrazine was 
selected to be attached onto surface of glass slide. Tetrazine slide was prepared 
according to the procedure (Figure 4.7A). Briefly, the piranha solution-treated glass 
slide was functionalized with (aminopropyl) - triethoxysilane,  succinic anhydride 
and NHS respectively. The resulting activated slides were incubated with tetrazine in 
DMF to give the tetrazine slide. Then Fluorescein-TCO (Figure 4.7B) was used as a 
model compound to assess the efficiency and kinetics of immobilization induced by 
tetrzaine and TCO on tetrazine-coated slides. To evaluate the kinetics of 
TCO-tetrazine reaction on surface, solution  of  Fluorescein-TCO  with three 
different concentration were spotted on tetrazine slides. The first spot was allowed to 
react for 60 min; subsequent spots were spotted at different times, with the last spot 
spotted just 1 min before washing. The immobilization reaction shows so fast that the 
relative fluorescent intensity were almost same, which is dramatically better than the 
very recent reported method by Valentin Wittmann’s group where tetrazine and 
dienophile were used to immobilize carbohydrate onto the slides
[115]
. Moreover, this is 
to our knowledge the fastest immobilization of small molecule onto slides. To 
optimize the concentration of the substrate for immobilization, we spotted a tetrazine 
slide with solution (DMSO:Waater = 1:1) of various concentration of 
Fluorescein-TCO (0 M - 1 mM). After incubation for 10 min and washing, the image 
of the slide was recorded and the integral fluorescent intensity analyzed (Figure 4.7D). 
M 





Figure 4.7 Evaluation of new immobilization method on glass slide. a) Fabrication of 
tetrazine slide. b)Structure of FITC-TCO. c) images of FITC-TCO spotted on 
tetrazine slides versus time, top 9 spots (20 M); middle 9 spots (50 M); bottom 9 
spots (100 M). d) images of FITC-TCO spotted on tetrazine slides versus 
concentration, 4 spots per concentration. 
 
4.3.3 Screening SMM with different proteins 
After successful evaluation of this new immobilization method, we shifted our 
efforts to apply this method to generate a SMM which was then screened by 
bromodomains. This small molecule library was then spotted onto the tetrazine 
modified glass slides. One glass slide was divided into 12 sub-grids, each of which 
was spotted the whole library. Thus, one slide can be used to screen 12 different 
proteins. Totally, 55 proteins (1 M) including 12 bromodomains, 39 SH2 domains 
and 4 14-3-3 proteins were screened against the 48 compounds. The fingerprint of 
their binding affinity were obtained and displayed in the heat maps (Figure 4.8a). 
Generally, the results showed that proteins beyond bromodomains had little or weaker 
affinity towards the immobilized compounds compared to bet family of 
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bromodomains which showed stronger and distinct bindings (Figure 4.8b). 
   We next carried out concentration-dependent assay against all the 12 
bromodomains on the array. Each protein had 8 different concentrations varying from 
10 nM to 5000 nM (Figure 4.8c and Figure S1). To get the Kd value, the fluorescence 
intensity data from the concentration-dependent experiments, representing a total of 
9216 individual data points (48 small molecules × 8 concentrations × 12 proteins, in 
duplicate) were quantified, filtered and fitted (SI). As shown in Figure 2c, Kd of 
compound 4-13 (JQ1) against bet family bromodomains are similar with published Kd 
measured by ITC.
[63]
 This means SMM can provide an accurate and much more 
efficient means for bromodomain screening as all these 9216 assays can be finished 
and analyzed within one work day. Judging from the whole library’s Kd calculated 
from array, within bet family bromodomains, there firstly appeared to be little 
preference for the bulky groups attached to 1,2,4-triazolyl ring suggesting that 
hydrophobic pocket accommodating this position is small. This result was consistent 
with published crystal structure of BRD2(1) bingding with GW841819X.
[68]
 The 
methyl  group  attached to 1,2,4-triazolyl ring bound to a small hydrophobic pocket 
which resided the methyl group of the acetyl headgroup of the acetyl-lysine. Bulky 
groups that cannot be accommodated in this pocket would increase the compound’s 
Kd. Secondly, the aromatic ring fused to the benzodiazepine core bound to lipophilic 
pocket termed ZA channel.
[68]
 Although this channel seemed lipophilic and spacious, 
additional hydrophobic groups attached this aromatic ring decreased the binding. For 
example, Kd of the binding between compound 4-13 and BRD4(2) was 131.5±35.4 
nM, while the Kd was 399.8±110.1 nM  for compound 4-37 which had a six 





Figure 4.8 Microarray profiles of small molecule library with different proteins. a) Color heat map displaying binding of the 48 compounds against 55 fluorescently labelled 
proteins (1 M); b) Representative image of binding profiles; c) Microarray image showing binding profiles of the 48-member library against fluorescently labelled BRD4(2) 
at various concentrations; d) Comparison of JQ1’s Kd for bet family bromodomains measured in SMM and Kd published in the literature, NA, not available, ND, not 
determined; e) SMM screened with mixed proteins containing an equal amount of Cy5 labeled BRD4(2) (500 nM) and one Cy3 labeled bromodomain (500 nM). Bar graph 
representing the selectivity scores, log2 (Cy5 Brd4(2)/Cy3 other bromodomain) fro compound 4-1, 4-13, 4-25, and 4-27.
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Next, we used dual-colour ratiometric approach which can provide ligand binding 
difference among structurally homologous proteins in a mix-manner to compare the 
binding difference between Brd4(2) and other bromodomains.
[105] 
With the dual-color 
approach Brd4(2) selective compounds could be readily and reliably interrogated with 
another bromodomain and visually identified (red spots in Figure 4.8e). A selectivity 
score of log2(Cy5 Brd4(2)/Cy3 other bromodomains) was obtained for compound 4-1, 
4-13, 4-25 and 4-37. All of them showed much weaker binding to non-bet family 
bromodomains (WAR9, TAF1L, PCAF, BRD1). Within bet family bromodomains, 
BRD3(1) showed stronger binding than BRD4(2) to the above four compounds and 
BRDT and BRD2(2) showed weaker binding, which is consistent with published 
results.
[63]
 While BRD4(1) and BRD3(2) showed weaker binding than BRD4(2) to 
compound 4-13 (JQ1), which was not consistent with published results.
[63]
 This was 
maybe because the binding speed of JQ1 with BRD4(1), BRD3(2) was slower than 
BRD4(2) although JQ1 showed strong binding with all these three proteins in the 

















4.3.4 Secondary validation of hits in SMM screening 
According to the SMM screening, we found compound 4-25 which had similar or 
stronger binding with bet family bromodomains compared with JQ1 (Figure 4.8c). To 
further verify this hit, we subsequently separated the two enantiomers (±)-25T which 
was without TCO tag by chiral column to obtain (+)-25T and (-)-25T (Figure 4.9).  
 
 
Figure 4.9 Chiral separation of compound (±)-25T. (±)-25T was separated by HPLC 
using IA column (250 mm, 5 mm id, 10 μm) with Hexane (containing 20% ITA, 0.1% 
DEA, 5% DCM). 
 
Secondary validations were carried out for these two enantiomers. As shown in 
Figure 4.10a, (+)-25T had strong antiproliferative activity in the cell line of MV4-11, 
while (-)-25T did not inhibit its growth at all. THP-1 and MV4-11 cell lines revealed 
an increase in the percentage of cells in G0/G1 upon exposure to (+)-25T (Figure 
4.10b). Moreover, (+)-25T can inhibit c-Myc’s expression on a time and 
concentration dependent manner (Figure 4.10c). Taken together, these results 









Figure 4.10 Secondary validation of (±)25T. a) Dose-response curve of MV4-11 cells 
treated with (+)-JQ1, (+)-25T or (-)-25T for 72 h, NA, not available; b) Cell cycle 
profile of MV4-11 cells after treatment with DMSO, (+)-JQ1, (+)-25T or (-)-25T 
(500 nM) for 24 h, numbers are percentage of cells in G0/G1; c) Western blot analysis 
of different inhibitor treatment on c-Myc experession. Different compounds (500 nM) 
were incubated with MV4-11 cells for 24 h (upper two rows);  Dose-dependent 
(middle two rows) and time-dependent (bottom two rows) effects of (+)-25T 
treatment on c-Myc expression in MV4-11 cells. 
 
 
4.3.5 SMM screening with CREBBP and GCN5L2 
 
 
Figure 4.11 SMM screened with different Cy3 labeled GCN5L2 and CREBBP 
 
To our surprise, GCN5L2 and CREBBP showed almost equal binding with the 
immobilized compounds (Figure 4.8a, 4.8b and Figure 4.11). A reasonable 
explanation for this phenomenon is that there must be a unified structural motif on 
each spot. Our SMM was generated by the bioorthogonal reaction between tetrazine 
and cyclooctene. Thus, the conjugate of tetrazine and cyclooctene was the unified 
motif on each spot and probably had binding to the screened proteins. To test this 
assumption, we synthesized the conjugates of different tetrazines and TCO-OH and 
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further measured binding constants of these conjugates to CREBBP and GCN5L by 
isothermal titration calorimetry (ITC). As shown in Figure 4.12, the conjugates 
showed strong binding with GCN5 and CREBBP. Especially for the latter, Kd is about 
2.6 M for the conjugates TT-2 and TT-3.  Furthermore, we synthesized FTT (1:1 
mixture of compound 4-53 and FITC-TCO) and masured its binding to GCN5L2 and  
CREBBP  by  the fluorescence polarization (FP) assay. FTT had a dissociation 
constant (Kd) of 1.29±0.44 M to GCN5L2 and of  0.51±0.17 M to CREBBP 
(Figure 4.12c). Hence, FTT could be a good FP probe to measure binding between 
these two proteins with other small molecules sharing same binding mode with TT2. 
 
 
Figure 4.12 Structures of conjugates between tetrazine and TCO-OH or FITC-TCO; b) 
Kd measured by ITC for binding between proteins (CREBBP or GCN5L2) and TT-1, 
TT-2 or TT-3; 3) Titration of FTT with CREBBP and GCN5L2. 
 
4.5 Conclusion 
Overall, in this chapter, a pretty efficient immobilization method by tetrazine and 
trans-cyclooctene was developed. The immobilization was so fast that it can be 
finished within several minutes, which is, to our knowledge, the fastest 
immobilization method in SMM. Due to this high speed, ten and thousands screening 
assays can be carried out and data analyzed at the same day. The SMM generated by 
90 
 
this immobilization method was further applied to perform inhibitor screening for 
bromodomains which are lack of high throughput inhibitor screening method. 
Screening the SMM (48 compounds immobilized) against different bromodomains 
lead to discovery potent inhibitors for both bet-family bromodomains and others.  
 
 
Figure 4.13 SMM by tetrazine and TCO identified potent inhibitor for bet family 
bromodomains and beyond. 
 
The same approach can be easily utilized to find potent inhibitors for other 
bromodomians. Beside, TT-2 provided a good starting scaffold for further 
optimization. The exact binding mode of TT-2 with CREBBP and GCN5L2 was 




Chapter 5: Concluding remarks 
 
Proteins perform a vast array of functions within living organisms. In the 
post-genome era, the great challenges become visualization of intracellular proteins 
directly in living cells. Furthermore, to identify a potent inhibitor of interested protein 
is another challenge. This thesis mainly involved development chemical probes to 
address these challenges. 
In chapter 1, by modifying the existing SNAP-tag protein labeling approach, we 
have successfully developed both one-and two-photon quenched probes, BGQFL-9 
and BGQNP-9, respectively, that could covalently label a SNAP-tag mutant protein 
(mSNAP) with moderate efficiency. We showed that, in addition to C-8, the N-9 
position in BG is also suitable for quencher attachment. Our results indicate real-time 
detection of both the labelling reaction and live cell imaging could be achieved using 
this system. This, togeher with other recenlty developed enzyme-detecting TPM 
probes, will open up new opportunities for bioimaging of important enzymes and their 
activities in deep tissues, where conventional fluorescence microscopy has very 
limited utilities. Nevertheless, a potential drawback of this approach is that it is 
difficult to probe the endogenous proteins because of requirement of fused tag.  
In chapter 2, we have designed and synthesized two fret-based probes (NPA and 
NP) targeting caspase-1. NPA had an AOMK motif that can potentially form a 
covalent bond with targeted proteins. But NPA expressed little reactivity with 
caspase-1, which was out of our expectation. On the contrary, NP showed much 
higher reactivity with caspase-1. NP had a much higher dynamic range and showed 
more sensitive to caspase-1 than the widely used fluorogenic probe Ac-YVAD-AMC. 
This new probe will definitely enrich the chemical tools to detect caspase-1 and 
facilitate the drug development of caspase-1. Secondly, we introduce the 
bioorthoganol reaction between cyclooctyne and azide, for the first time, to serve an 
efficient means to set up small molecule library against caspase-1. This initial try 
leads to find one potent inhibitor against caspase-1. With the development of 
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bioorthogonal chemistry, more and more this kind of reaction will be available. Hence, 
we expected this concept that using bioorthogonal chemistry serves the drug 
development of interest targets can be widely used in the field of chemical biology 
and medicinal chemistry. 
Probe NP’s success was built on the specific well known caspase-1 inhibitor, 
Pralnacasan. This inhibitor provided a good starting scaffold to be utilized to 
synthesize excellent probe (NP) which will further promote our understanding of this 
important enzyme. From this case, we can see that a good inhibitor can not only 
facilitate the drug development, but also serve greatly in the field of chemical biology. 
Encouraged by this example, in chapter 4, efforts were dedicated to developing potent 
inhibitors for bromodomains playing important roles in epigetics, using small 
molecule microarray (SMM). 
   To achieve this goal, a pretty efficient immobilization method by tetrazine and 
trans-cyclooctene was firstly developed. The immobilization was so fast that it can be 
finished within several minutes, which is, to our knowledge, the fastest 
immobilization method in SMM. Due to this high speed, ten and thousands screening 
assays can be carried out and data analyzed at the same day. The SMM generated by 
this immobilization method was further applied to perform inhibitor screening for 
bromodomains which are lack of high throughput inhibitor screening method. 
Screening the SMM (48 compounds immobilized) against different bromodomains 











Chapter 6  
 
 





All chemicals were purchased from commercial vendors and used without further 
purification, unless otherwise noted. Tetrahydrofuran (THF) was distilled over sodium 
and used immediately. Dichloromethane (CH2Cl2) was distilled over CaH2. All 
non-aqueous reactions were carried out under nitrogen atmosphere in oven-dried 
glassware. All 
1
H NMR and 
13
C NMR spectra were taken on a Bruker ACF-300/500 
MHz NMR spectrometer, using CDCl3 or (CD3)2SO as the solvent. Chemical shifts 
are reported in parts per million referenced with respect to residual solvent (CDCl3 = 
7.26 ppm and (CD3)2SO = 2.50 ppm) for 
1
H NMR, (CDCl3 = 77.0 ppm and (CD3)2SO 
= 40.0 ppm) for 
13
C NMR. LC-MS spectra were recorded using Shimadzu LC-MS 
(IT-TOF) and Shimadzu LC-MS (ESI). Extent of reaction was monitored by thin layer 
chromatography (TLC) using Merck 60 F254 pre-coated silica gel plates with 
fluorescent indicator UV254. After the plates were subjected to elution in the TLC 
chamber, the spots were visualized under UV light or using the appropriate stain (I2, 
KMnO4, ninhydrin, ceric ammonium molybdate (CAM)). Flash column 
chromatography was carried out using Merck silica gel (0.040-0.063). Chiral 
separation was performed with IA column. In-gel fluorescence scanning was carried 
out with Typhoon 9410 fluorescence gel scanner (GE Amersham).  
 
6.2 Chapter 2 
6.2.1 Chemical synthesis 
(2-1) 
To a solution of DR1 (900 mg, 2.86 mmol) in the mixture of dichloromethane (12 
mL) and acetonitrile (4 mL) cooled in an ice-water bath was added triethylamine 
(0.65 mL, 4.63 mmol) and 4-tolueneulfonyl chloride (900 mg, 4.72 mmol). The 
resulting reaction mixture was stirred at the same temperature for 10 hours. The 
reaction was quenched by addition of water (20 mL). The organic layer was taken, 
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washed with water (20 mL×3) and brine (20 mL×3), dried with sodium sulphate, 
concentrated and purified by chromatography with dichloromethane hexane:ethyl 
acetate (5:1 to 3:1) to give the product (240 mg, 17.2% yield).  
1
H NMR (300 MHz, 
DMSO-d6)δ8.36 (d, J = 9.0 Hz, 2H), 7.94 (d, J = 9.0 Hz, 2H), 7.78 (d, J = 9.0 Hz, 
2H), 7.70 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 6.78 (d, J = 9.0 Hz, 2H), 4.24 
(t, J = 5.4 Hz, 2H), 3.74 (t, J = 5.4 Hz, 2H), 3.44 (q, J = 6.9 Hz, 2H), 2.35 (s, 3H), 
1.11 (t, J = 6.9 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6)δ156.1, 151.0, 146.9, 144.9, 
142.9, 131.7, 130.0, 127.5, 125.8, 124.9, 122.4, 111.6, 67.8, 48.1, 45.1, 21.0, 11.8; 
LC-MS (IT-TOF) calcd for [M+H]
+
:469.15, Found: 469.14. 
 
(2-2) 
To a suspension of (4-(aminomethyl)phenyl)methanol (2.1 g, 15.0 mmol) in the 
mixture of methanol (20 mL) and water (20 mL) was added potassium carbonate (3.1 
g) and copper sulphate (40 mg). To this suspension was added freshly prepared 
trifluoromethanesulfonyl azide (18 mmol) in dichloromethane (20 mL). The resulting 
mixture was stirred at room temperature overnight. The mixture was diluted by 
addition of water (50 mL) and dichloromethane (50 mL). The organic layer was taken, 
washed with water (20 mL×2), brine (20 mL×2), concentrated to give a light yellow 
oil which was purified by chromatography with hexane:ethyl acetate (5:1) to obtain 
the desired product (2 g, 81.8% yield). 
1
H NMR (300 MHz, CDCl3)δ7.41 (d, J = 8.1 
Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 4.72 (s, 2H), 4.36 (s, 2H), 2.11 (brs, 1H); 
13
C NMR 
(75 MHz, CDCl3)δ140.9, 134.6, 128.3, 127.2, 64.7, 54.4. 
 
 (2-3) 
1-(6-(methylamino)naphthalen-2-yl)ethanone (107 mg, 0.54 mmol) was 
suspended in actonitrile (10 mL). To this suspension was added propargyl bromide 
(298 mg, 2.0 mmol), disodium hydrogen phosphate (225 mg, 1.58 mmol), potussium 
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iodide (20 mg, 0.12 mmol). The resulting mixture was stirred at 60 
o
C for 48 hours. 
Then the solvent was removed and the residue was purified by chromatography with 
hexane:ethyl acetate (3:1) and recrystallization to give the product (240 mg, 25.0% 
yield). 
1
H NMR (300 MHz, CDCl3)δ8.37 (d, J = 1.5 Hz, 1H), 7.98 (dd, J1 = 8.7 Hz, 
J2 = 1.5 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.30 (s, 1H), 7.07 
(d, J = 1.8 Hz, 1H), 4.22 (d, J = 2.7 Hz, 2H), 3.16 (s, 3H), 2.70 (s, 3H), 2.26 (t, J = 2.4 
Hz, 3H); 
13
C NMR (75 MHz, CDCl3)δ197.6, 148.7, 137.3, 131.4, 130.6, 130.1, 
126.5, 125.9, 124.5, 117.0, 107.5, 78.7, 72.3, 42.2, 38.5, 26.3; LC-MS (IT-TOF) calcd 
for [M+H]
+
: 238.12, Found: 238.11. 
 
(2-4) 
To a solution of FLAC (92 mg, 0.2 mmol) and prop-2-yn-1-amine (30 mg, 0.54 
mmol) in DMF (5 mL) was added HATU (150 mg, 0.39 mmol). The resulting mixture 
was stirred at room temperature overnight. The reaction was quenched by addition of 
water (20 mL). The aqueous solution was extracted with ethyl acetate (20 mL×2). The 
organic layer washed with water (20 mL×2), brine (20 mL×2), concentrated and 
purified with chromatography with hexane:ethyl acetate (4:1) to give the product (57 
mg, 57% yield). 
1
H NMR (300 MHz, CDCl3)δ8.09 (m, 2H), 7.54 (s, 1H), 7.06 (s, 
2H), 7.05 (m, 1H), 6.80 (m, 4H), 5.32 (s, 1H), 4.12 (m, 2H), 2.21 (s, 6H), 2.20 (s, 1H); 
13
C NMR (75 MHz, CDCl3)δ168.9, 168.0, 165.0, 153.1, 152.1, 151.2, 140.2, 129.6, 
128.8, 128.2, 125.5, 122.2, 117.9, 115.6, 110.4, 81.5, 78.6, 72.0, 29.8, 20.9; LC-MS 
(IT-TOF) calcd for [M+H]
+





To a solution of 2-4 (57 mg, 0.11 mmol) in methanol (6 mL) was added sodium 
methanolate (3M in methanol) (1 mL). The resulting mixture was stirred at room 
temperature for 2 hours. Then the solvent was removed under reduced pressure. To 
the residue was added water (20 mL). The pH of the solution was adjusted to 3. The 
resulting solid was collected by filtration to give the desired product (40 mg, 87.8% 
yield). 
1
H NMR (300 MHz, DMSO-d6) δ 10.14 (brs, 2H), 9.14 ((t, J = 5.4 Hz, 1H), 
8.18 (dd, J1 = 8.1 Hz, J2 = 1.2 Hz, 1H), 8.08 (d, J = 8.1 Hz, 1H), 7.71 (s, 1H), 
6.71-6.54 (m, 7H), 3.99 (dd, J1 = 5.4 Hz, J2 = 2.4 Hz, 2H), 3.08 (d, J = 2.4 Hz, 1H); 
13
C NMR (75 MHz, CDCl3)δ168.3, 164.6, 159.9, 153.0, 152.2, 140.2, 129.8, 129.5, 
128.8, 125.3, 122.7, 113.1, 109.5, 102.6, 81.0, 73.4, 29.0; LC-MS (IT-TOF) calcd for 
[M+H]
+
: 414.09, Found: 414.08. 
 
 (2-6) 
    1.0 g (5.9 mmol) of 6-Chloro-guanine was dissolved in a mixture of DMF (40 
mL) and DMSO (5 mL) at 40 °C. After being cooled to room temperature, 1.4 ml of 
1-methyl-pyrrolidin (13.2 mmol) were added and the resulting mixture was stirred 
further for 18 hours. 2 mL of an acetone/hexane (1:1) mixture were added to complete 
the precipitation. The solid was filtered, washed with ether and dried in vacuo, to give 
the desired product (0.9 g, 66% yield). 
1
H NMR (300 MHz, DMSO-d6) δ13.46 (s, 
1H), 8.34 (s, 1H), 7.10 (s, 2H), 4.60 (m, 2H), 4.01 (m, 2H), 3.65 (s, 3H), 2.24 (m, 2H), 
2.06 (m, 2H); LC-MS (IT-TOF) calcd for [M-Cl]
+





   To a solution of 2-2 (333 mg, 2.04 mmol) in dry DMF (10 mL) cooled in an 
ice-water bath was added NaH (60% dispersed in oil; 256 mg, 6.40 mmol) in small 
portions. Then 570 mg (2.24 mmol) of 2-6 and 20 mg of 4-(dimethylamino) pyridine 
(DMAP; 0.16 mmol) were added. The resulting reaction mixture was stirred at room 
temperature for 4 hours. The reaction was quenched by addition of water (1 mL). The 
solvent was removed under reduced pressure. The resulting residue was purified by 
chromatography with dichloromethane:methanol (30:1) to give the desired product 
(350 mg, 52.7% yield). 
1
H NMR (300 MHz, DMSO-d6)δ12.35 (bs, 1H), 7.81 (s, 1H), 
7.53 (d, J = 8.1 Hz 2H), 7.39 (d, J = 7.8 Hz, 2H), 6.08 (s, 1H), 5.53 (s, 2H), 4.46 (s, 
2H); 13C NMR (75 MHz, DMSO-d6) δ 159.9, 137.2, 135.7, 128.9, 128.7, 66.8, 53.8; 
LC-MS (IT-TOF) calcd for [M+H]
+
: 297.1212, Found: 297.1121. 
 
(BGQ-9)   (BGQ-7) 
 
To a solution of 2-7 (170 mg, 0.57 mmol) in DMF (8 mL) was added 2-1 
(DR1-OTs; 284 mg, 0.60 mmol) and K2CO3 (202 mg, 1.46 mmol). The resulting 
mixture was stirred at room temperature for 48 hours. Then the solvent was removed 
under reduced pressure. The resulting residue was purified by chromatography with 
dichloromethane:ethyl acetate (5:1/1:1) to give the desired products BGQ-9 (150 mg, 
44.5%) and BGQ-7 (92 mg, 15.5%). BGQ-9: 
1
H NMR (300 MHz, DMSO-d6)δ8.37 
(d like, 2H), 8.34 (d like, 2H), 7.94 (m, 3H), 7.92 (d, J=1.8 Hz,2H), 7.50 (d, J = 8.1 
Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 6.94 (d, J = 9.0 Hz, 2H), 6.53 (s, 2H), 5.50 (s, 2H), 
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4.43 (s, 2H), 4.26 (t, J = 6.6 Hz, 2H), 3.83 (t, J = 6.6 Hz, 2H), 3.44 (m, 2H), 1.10 (t, J 
= 6.9 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6)δ160.3, 160.1, 156.5, 154.9, 151.7, 
147.2, 143.3, 140.3, 137.0, 135.7, 129.0, 128.8, 126.5, 125.3, 122.8, 114.0, 111.9, 
66.8, 53.6, 48.9, 45.0, 12.3; LC-MS (ESI) calcd for [M+H]
+
: 593.24, Found: 593.25. 
BGQ-7: 
1
H NMR (300 MHz, DMSO-d6)δ8.36 (d, J = 9.0 Hz, 2H), 8.13 (s, 1H), 7.94 
(d, J = 8.7 Hz, 2H), 7.70 (d, J = 9.0 Hz, 2H), 7.56 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 7.8 
Hz, 2H), 6.78 (d, J = 9.0 Hz, 2H), 6.19 (s, 2H), 5.54 (s, 2H), 4.44 (s, 2H), 4.39 (t, J = 
6.3 Hz, 2H), 3.76 (t, J = 6.3 Hz, 2H), 3.20 (m, 2H), 0.94 (t, J = 6.9 Hz, 3H); 
13
C NMR 
(75 MHz, DMSO-d6)δ164.5, 159.9, 156.6, 156.5, 151.5, 147.3, 146.3, 143.2, 136.6, 
135.9, 129.0, 128.9, 126.3, 125.3, 122.8, 111.8, 106.0, 67.1, 53.6, 50.6, 45.0, 44.3, 
12.1, LC-MS (ESI) calcd for [M+H]
+
: 593.24, Found: 593.25. 
 
General procedure for the synthesis of compounds BGNP, BGFL and BGAF.  
Briefly, 2-7 and the corresponding alkyne-containing dye (1.0 eq) were suspended in 
a mixture of DMSO/water (2:1) (3 mL). To the suspension was added CuI (1.0 eq) 
and DIEA (1.0 eq). The resulting mixture was stirred at room temperature for 48 
hours. Then the product was directly purified by preparative HPLC with elution 
gradients using acetonitrile (containing 0.1% TFA) and water (containing 0.1% TFA). 
 
 (BGNP) 
   59 mg (0.2 mmol) of compuound 2-7 was used and 30 mg of the product was 
obtained (28.3% yield). 
1
H NMR (300 MHz, DMSO-d6)δ8.43 (s, 1H), 8.17 (bs, 1H), 
8.05 (s, 1H), 7.90 (d, J = 9.0 Hz, 2H), 7.80 (dd, J1= 9.0 Hz, J2= 1.5 Hz, 1H), 7.66 (d, J 
= 8.7 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.40 (dd, J1= 9.0 Hz, J2= 2.4 Hz, 1H), 7.27 (d, 
J = 8.1 Hz, 2H), 7.03 (s, 1H), 5.54 (s, 2H), 5.46 (s, 2H), 4.74 (s, 2H), 3.11 (s, 3H), 
2.60 (s, 3H); HRMS (ESI) m/z: 534.2375 (Calcd for [M+H]
+





30 mg (0.1 mmol) of compound 2-7 was used and 5.2 mg of product was obtained 
(7.3% yield). 
1
H NMR (300 MHz, DMSO-d6)δ10.18 (brs, 2H), 9.22 (m, 1H), 
7.99-8.19 (m, 4H), 7.70 (s, 1H), 7.49 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 
6.55-6.69 (m, 8H), 5.53 (s, 2H), 5.48 (s, 2H), 4.43 (d, J = 5.4 Hz, 2H); HRMS (ESI) 
m/z: 710.2101 (Calcd for [M+H]
+
: 710.2106).  
 
(BGAF) 
30 mg (0.1 mmol) of coumpound 2-7 was used and 8.0 mg of product was 
obtained (10.1% yield). 
1
H NMR (300 MHz, DMSO-d6)δ9.22 (t, J = 5.7 Hz, 1H), 
8.13-8.24 (m, 3H), 8.00 (s, 1H), 7.83 (s, 1H), 7.48 (t, J = 8.1 Hz, 2H), 7.29-7.33 (m, 
4H), 6.94 (m, 4H), 5.53 (s, 2H), 5.47 (s, 2H), 4.43 (d, J = 5.4 Hz, 2H), 2.28 (s, 6H); 




General procedure for the synthesis of compounds BGQFL-9, BGQFL-7 and 
BGQAF-9.  
The precursor compound (BGQ-9 or BGQ-7) and the corresponding 
alkyne-containing dye (1.2 eq) was suspended in a mixture of DMSO/DCE (1:2) (3 
mL). To the suspension was added CuI (1 eq) and DIEA (1 eq). The resulting mixture 
was stirred at room temperature for 4 hours. Then the product was directly purified by 
preparative HPLC with elution gradients using acetonitrile (containing 0.1% TFA) 





30 mg (0.1 mmol) of BGQ-9 was used and 3.1 mg of product was obtained (6.2% 
yield). 
1
H NMR (300 MHz, DMSO-d6)δ10.16 (s, 2H), 9.21 (t, J = 5.4 Hz, 1H), 
7.70-8.36 (m, 10H), 7.45 (d, J = 7.8 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 6.94 (d, J = 9.0 
Hz, 2H), 6.68 (d, J = 1.5 Hz, 2H), 6.52-6.56 (m, 6H), 5.51 (s, 2H), 5.45 (s, 2H), 4.42 
(d, J = 5.4 Hz, 2H), 4.26 (m, 2H), 3.83 (m, 2H), 3.44 (m, 2H), 1.10 (t, J = 6.9 Hz, 3H); 
HRMS (ESI
+
) m/z: 1006.3331 (Calcd for [M+H]
+




   30 mg (0.1 mmol) of BGQ-7 was used and 15 mg of product was obtained (31.2% 
yield). 
1
H NMR (300 MHz, DMSO-d6)δ10.15 (brs, 2H), 9.24 (m, 1H), 7.92-8.36 (m, 
5H), 7.69-7.73 (m, 3H), 7.52 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 6.78 (d, J = 
9.0 Hz, 2H), 6.68 (d, J = 1.8 Hz, 2H), 6.53-6.58 (m, 4H), 5.52 (s, 4H), 4.41 (m, 4H), 
3.75 (m, 2H), 3.09 (m, 2H), 0.86 (t, J = 6.9 Hz, 3H); HRMS (ESI
+
) m/z: 1006.3357 
(Calcd for [M+H]
+





30 mg (0.1 mmol) of BGQ-9 was used and 16 mg of product was obtained (29.1% 
yield). 
1
H NMR (300 MHz, DMSO-d6)δ9.06 (m, 1H), 8.32-8.35 (dd, J1= 7.2 Hz, J2= 
2.1 Hz, 2H), 8.04-8.06 (m, 2H), 7.76-7.92 (m, 6H), 7.34 (d, J = 8.1 Hz, 2H), 7.24 (m, 
2H), 6.92 (m, 6H), 6.76 (d, J = 8.1 Hz, 2H), 6.52 (brs, 2H), 5.38 (s, 2H), 4.70 (d, J = 
15.3 Hz, 2H), 4.62 (d, J = 15.3 Hz, 2H), 4.19 (m, 2H), 3.90 (m, 2H), 3.76 (m, 2H), 
2.54 (s, 1H), 2.25 (s, 3H), 2.24 (s, 3H), 1.05 (t, J = 6.9 Hz, 3H); HRMS (ESI
+
) m/z: 





   
        (BGQNP-9)                      (BGQNP-7) 
  
To a solution of BGNP (15 mg, 0.028 mmol) in DMF (4 mL) was added 
DR1-OTs (25 mg, 0.053 mmol) and K2CO3 (20 mg, 0.145 mmol). The resulting 
mixture was stirred at room temperature for 48 hours. Then the solvent was removed 
under reduced pressure. The resulting residue was directly purified by preparative 
HPLC with elution gradients of acetonitrile (containing 0.1% TFA) and water 
(containing 0.1% TFA), giving the desired products BGQNP-9 (6.5 mg, 28.0% yield) 
103 
 
and BGQNP-7 (3.5 mg, 15.0% yield). BGQNP-9: 
1
H NMR (300 MHz, DMSO-d6)δ
8.42 (s, 1H), 8.36 (d, J = 9.0 Hz, 2H), 7.64-8.02 (m, 9 H), 7.37-7.44 (m, 3H), 7.24 (d, 
J = 8.1 Hz, 2H), 7.03 (d, J = 2.1 Hz, 1H), 6.94 (d, J = 9.0 Hz, 2H), 6.51 (brs, 2H), 
5.52 (s, 2H), 5.44 (s, 2H), 4.74 (s, 2H), 4.25 (m, 2H), 3.81 (m, 2H), 3.10 (s, 3H), 2.60 
(s, 3H), 1.10 (t, J = 6.9 Hz, 3H); HRMS (ESI
+





H NMR (300 MHz, DMSO-d6)δ8.34-8.44 (m, 4H), 8.05 (s, 
1H), 7.61-7.94 (m, 7H), 7.50 (d, J = 7.8 Hz, 2H), 7.27-7.39 (m, 4H), 7.01 (d, J = 2.1 
Hz, 1H), 6.76 (m, 2H), 5.54 (s, 2H), 5.52 (s, 2H), 4.73 (s, 2H), 4.40 (m, 2H), 3.75 (m, 
2H), 3.08 (m, 5H), 2.58 (s, 3H), 0.86 (t, J = 6.9 Hz, 3H); HRMS (ESI
+





6.2.2. Cloning and Recombinant Expression of SNAP and Mutant 
Proteins 
His-SNAP for bacterial expression, Flag-SNAP and Flag-H2B-SNAP for 
mammalian expression were generous gifts from Prof. Christopher J. Chang 
(University of California, Berkeley). The wildtype AGT construct was obtained from 
Open Biosystems (USA) in the form of an entry clone. For the bacterial constructs, 
Quick Change
®
 site-directed mutagenesis was conducted to prepare G132-SNAP using 
the His-SNAP construct as a template. The residue Lys132 in His-SNAP was mutated 
to Gly132 using the corresponding primers (G132-F and G132-R). For the GG-SNAP 
mutant in which residues Lys131 and Thr132 in SNAP were mutated to Gly131 and 
Gly132, the wildtype AGT construct was taken as a template, truncated, cloned back 
into the pDEST 17 destination vector (Invitrogen) by Gateway
®
 cloning. Similar 
Quick change
®
 site-directed mutagenesis was conducted to yield the mammalian 
expression plasmids Flag-GG-SNAP and Flag-H2B-GG-SNAP using the 
corresponding primers (m-G131-G132-F and m-G131-G132-R). All the constructs 
were sequence verified by using the Sequenase DNA sequencing kit (BigDye 
Terminator version 3.1; Applied Biosystems) and a set of custom-made internal 









The bacterial expression SNAP plasmids (His-SNAP, G132-SNAP, GG-SNAP) 
were transformed into propagation host BL21(Ai) cells, grown at 37 °C in LB 
medium with appropriate antibiotics for 2-4 hours until OD600 of 0.4-0.6 was reached. 
Upon induction of protein expression, the culture was grown for an additional 3-5 
hours before being harvested by centrifugation at 4000 rpm for 15 minutes at 4 °C. 
Cell lysates were prepared by resuspension of the resulting pellets in PBS buffer 
containing 1 mM PMSF and 1 mg/ml lysozyme, followed by sonication. For protein 
purification, Ni-NTA (Qiagen) was used according to the supplier’s protocol. 
Fractions containing the desired purified protein (His-AGT, G132-SNAP or 
GG-SNAP) were combined and buffer exchanged into PBS buffer using 
Slide-A-Lyzer Dialysis cassettes (Thermo Scientific), concentrated using an Amicon 
Ultra-15 Ultracel-10K centrifugal unit (Millipore). The concentration of the final 
protein stock solutions was determined by the Bradford method. 
 
6.2.3 Labeling of probes with recombinant SNAP mutants 
To detect in vitro protein labeling by SDS-PAGE, different purified SNAP 
proteins (His-SNAP, G132-SNAP, GG-SNAP; 1 M each at final concentration) were 
each added to a solution of either BGFL, BGQFL-9 or BGQFL-7 (1 M each at final 
concentration) in a PBS buffer containing DTT (1 mM) at 25°C . After 4 hours, the 
labeling reaction was added an equal volume of 2 × SDS gel loading buffer, denatured 
at 95 °C for 10 minutes, then resolved on an SDS-PAGE (12% gradient precast gel). 
The gel was visualized by in-gel fluorescence scanning using a Typhoon 9410 
Variable Mode Imager scanner.  
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To detect successful labeling of the GG-SNAP mutant by the two-photon 
quenching probe BGQNP-9, which could not be visualized on the Typhoon 9410 gel 
scanner, an indirect competition assay was used instead. Briefly, 3 L (100 M conc.) 
of the purified GG-SNAP mutant protein was added to a solution of BGQNP-9 (100 
M) in HEPES (100 mM, pH 7.4) containing DTT (1 mM) and DMSO (3%) at 25 °C. 
Aliquots (10 L) of this reaction mixture were taken at 0, 1, 4 and 9 hours, 
respectively, and immediately incubated with BGFL (100 M, 1 L) for 15 minutes. 
Then an equal volume of an 2 × SDS gel loading buffer (11 L) was added, and the 
resulting mixture was denatured at 95 °C for 10 minutes, resolved by an SDS-PAGE 
gel (12% gradient precast gel), visualized by in-gel fluorescence scanning.  
MALDI-TOF MS was used to further confirm the successful labeling GG-SNAP 
by BGQFL-9 (Figure S4). A total of 1 L BGQFL-9 stock solution (1 mM) was added 
to 2 L of GG-SNAP (100 M in PBS) at 25 °C and incubated overnight. Free 
BGQFL-9 probe was removed using a Sephadex G-50 Quick Spin column 
(DNA-grade; GE Amersham), then subsequently prepared, according to vendor’s 
instructions by using α-cyano-4-hydroxycinnamic acid as the matrix, for 
MALDI-TOF MS analysis. 
Microplate-based, time-dependent fluorescence measurement was done with 
SNAP mutants and BGQFL-9 and results are shown in Figure 2c and 2d in the 
maintext. Briefly, to the wells of 384-well plate were added different SNAP mutants 
(2.5 L each; conc.: 100 M), BGQFL-9 (5.0 L; conc.: 100 M), DTT (2.5 L, 10 
M) and PBS (15 L). The intensity of the fluorescence was monitored over time 
using a standard fluorescence microplate reader (Tecan and/or Biotek). 
6.2.4 Labeling with mammalian cell lysates 
Unless otherwise indicated, normally the CHO-9 cell line (AGT-deficient) was 
cultured in growth media (F12) supplemented with 5% fetal bovine serum, and 
maintained in a humidified atmosphere of 5% CO2 at 37 °C. CHO-9 cell lines were 
transiently transfected with the Flag-GG-SNAP plasmid by using the indofectin 
tranfection kit (Genecopoeia, USA). After 40 hours, cells were harvested. Cell lysates 
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were prepared by using RIPA buffer (50 mm Tris, pH 7.5, 150 mm NaCl, 1% NP-40) 
and further labeled with BGQFL-9 for 4 hours. The mixture was resolved by 
SDS-PAGE gels and visualized by florescence scanning, Coomassie blue staining and 
Western blotting. 
6.2.5 Bioimaging  
One-photon imaging was done with an Olympus IX71 inverted microscope, 
equipped with a 60X oil objective (NA 1.4, WD 0.13 mm) and CoolSNAP HQ CCD 
camera (Roper Scientific). Data processing was done with the MetaMorph software 
(Molecular Devices). Two-photon imaging was performed using a Leica TCS SP5X 
optical Microscope System equipped with a Ti:Sappire femtosecond laser and HCX 
PL APO 100×/1.40-0.70 OIL CS objective. Data processing was done using the Leica 
image analysis software.  
For live cell in vivo labeling of Flag-H2B-GG-SNAP with BGQFL-9, BGAF, 
BGQNP-9 and BGNP, CHO-9 (AGT-deficient) cells were transfected with 
Flag-H2B-GG-SNAP plasmid. After three hours, the media was changed to F12 
(containing 5% FBS), and cells were incubated at 37 ºC for 40 hours. Subsequently, 
cells were incubated with the indicated probe for 4 or 6 hours, followed by 





6.3 Chapter 3 
6.3.1 Chemical synthesis 
(3-1) 
To the solution of DR1-OTs (1.55 g, 3.30 mmol) in acetonitrile (50 mL) was added 
sodium bicarbonate (3.32 g, 39.6 mmol) and methyl 2-aminoacetate hydrochloride 
(2.48 g, 19.8 mmol). The reaction mixture was stirred at 60 
o
C for 24 hours. After it 
cooled down to room temperature, the reaction mixture was condensed under reduced 
pressure. The desired residue was purified with chromatography to give the product 
(900 mg, 70.9%). 
1
H NMR (300 MHz, CDCl3) δ 8.31 (dd, J1 = 7.2 Hz, J2 = 2.1 Hz, 
2H), 7.86-7.91 (m, 4H), 6.79 (d, J = 9.0 Hz, 2H), 3.72 (s, 3H), 3.51-3.55 (m, 4H), 3.46 
(s, 2H), 2.90 (t, J = 6.9 Hz, 2H), 1.23 (t, J = 6.9 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) 
δ 172.67, 156.79, 151.4, 147.2, 143.6, 126.2, 124.6, 122.5, 111.3, 51.8, 50.7, 50.6, 
46.9, 45.6, 12.1; LC-MS (ESI) calcd for [M+H]
+
:386.18, found: 386.35. 
 
(3-2) 
To the solution of acetic acid (304 mg, 2.67 mmol) in DCM (20 mL) was added 
EDC.HCl (511 mg, 2.67 mmol), HOBt (120 mg, 0.8 mmol) and DIEA (460 mg, 3.56 
mmol). Then 3-1 (685 mg, 1.78 mmol) was added to the above solution. The resulting 
reaction mixture was stirred at room temperature overnight. To the reaction mixture 
was added DCM (30 mL) and water (20 mL). The organic layer was taken, washed 
with water (20 ml), brine (20 mL), dried with sodium sulfite and purified with 
chromatography to give the product (700 mg, 92.1%). The product contained two 





H NMR (300 MHz, CDCl3) δ 8.30-8.34 (m, 2H), 7.88-7.94 (m, 4H), 
6.73-6.85 (m, 2H), 4.11 (s, 0.87H), 4.03 (s, 1.13H), 3.78 (s, 1.65H), 3.75 (s, 1.18H), 
3.48-3.65 (m, 6H), 2.11 (s, 1.21H), 2.06 (s, 1.68H), 1.24 (m, 3H); 
13
C NMR (75 MHz, 
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CDCl3) δ 171.4, 171.0, 169.7, 169.5, 156.7, 156.5, 151.3, 150.5, 147.6, 147.3, 144.0, 
143.7, 126.4, 126.3, 124.6, 1227, 122.6, 111.3, 111.2, 52.6, 52.2, 52.0, 48.9, 48.1, 
47.6, 47.4, 46.2, 45.5, 21.5, 20.9, 12.3, 12.2; LC-MS (IT-TOF) calcd for 
[M+H]
+
:428.19, found: 428.16. 
 
(3-3) 
To the suspension of 3-2 (680 mg, 1.6 mmol) in the mixed solvent (ethyl alcohol, 
5mL; THF, 5 mL; water, 5 mL) was added lithium hydroxide monohydrate (350 mg, 
8.3 mmol). The resulting reaction mixture was stirred at room temperature for 5 hours. 
Then the solvent was removed under reduce pressure. To the residue was added water 
(30 mL). The pH was adjusted to 4. The solid was collected by filtration, dried to give 
the product (630 mg, 95.4 %). 
1
H NMR (300 MHz, DMSO-d6) δ 8.38 (dd, J1 = 9.0Hz, 
J2 = 1.5 Hz, 2H), 7.94 (d, J = 8.7 Hz, 2H), 7.86 (m, 1H), 7.00 (d, J = 9.0 Hz, 1H), 6.90 
(d, J = 9.0 Hz, 1H), 4.35 (s, 1.04H), 4.12 (s, 0.97H), 3.47-3.64 (m, 9H), 1.99 (s, 
1.47H), 1.94 (s, 1.56H), 1.14 (t, J = 6.9 Hz, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
δ171.0, 170.4, 170.2, 169.9, 156.2, 151.6, 151.3, 146.9, 146.7, 142.8, 142.7, 126.2, 
126.1, 124.9, 122.4, 111.4, 52.1, 51.6, 50.7, 47.8, 47.6, 47.0, 44.9, 44.6, 21.2, 20.6, 
12.2, 12.0. 
1
H NMR (300 MHz, DMSO-d6, at 80 
o
C) δ 8.32 (d, J = 8.1 Hz, 2H), 7.91 
(d, J = 8.4 Hz, 2H), 7.86 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 4.18 (s, 2H), 
3.53-3.72 (m, 9H), 2.01 (s, 3H), 1.23 (t, J = 6.9 Hz, 3H); LC-MS (IT-TOF) calcd for 
[M+H]
+
:414.17, found: 414.15. 
 
(3-4) 




g, 2.9 mmol) and potassium fluoride (841 mg, 14.5 mmol). The reaction mixture was 
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stirred at room temperature for 5 hours. Then ethyl acetate (100 mL) and water (50 
mL) was added to the reaction mixture. The organic phase was taken, washed with 
water (50 mL×3), brine (50 mL), dried with sodium sulfite and purified with 
chromatography to gieve the product (1.2 g, 92.3 %). 
1
H NMR (500 MHz, CDCl3) δ 
8.28-8.31 (m, 2H), 7.88-7.92 (m, 4H), 7.74 (d, J = 7.5 Hz, 2H), 7.56 (d, J = 7.0 Hz, 
2H), 7.40 (dd, J1 = 7.5 Hz, J2 = 15.5, 1H), 7.29-7.31 (m, 1H), 6.86 (d, J = 9.5 Hz, 
0.64H), 6.75 (d, J = 9.5 Hz, 0.39H), 5.90 (m, 1H), 4.88-5.02 (m, 2H), 4.53-4.57 (m, 
2H), 4.43 (m, 1H), 4.10-4.26 (m, 3H), 3.57-3.63 (m, 4H), 3.48 (m, 2H), 2.84 (m, 1H), 
2.68 (m, 1H), 2.10 (m, 3H), 1.41 (s, 9H), 1.25 (m, 3H); 
13
C NMR (125 MHz, CDCl3) 
δ 201.3, 200.9, 171.6, 171.1, 170.4, 168.6, 156.8, 156.6, 156.1, 156.0, 151.4, 150.6, 
147.5, 147.3, 144.0, 143.7, 143.6, 143.5, 143.5, 141.3, 127.9, 127.8, 127.1, 127.0, 
126.4, 124.9, 124.8, 124.7, 124.6, 122.7, 122.6, 120.1, 120.0, 111.4, 111.3, 82.4, 82.2, 
67.5, 67.1, 67.0, 54.4, 54.3, 51.7, 48.7, 47.4, 47.1, 46.0, 45.3, 36.3, 21.4, 20.8, 12.3, 
12.2; LC-MS (ESI) calcd for [M+H]
+
:821.35, found: 821.55. 
 
(3-6) 
To the solution of 6-amino-2-naphthoic acid (1.0 g, 5.34 mmol) in methanol (50 mL) 
was added thionyl chloride (1.0 mL) under ice-water bath. Then the reaction mixture 
refluxed for 4 hours. After reaction mixture cooled down, the reaction was quenched 
by addition of NaHCO3 (saturated) and pH value was adjusted to 8. The mixture ws 
extracted with ethyl acetate (100 mL). The organic layer was washed with brine (50 
mL), dried with sodium sulfate and concentrated to give the title compound (1.0 g, 
93.4 %). 
1
H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 7.95 (dd, J1 = 9.0 Hz, J2 = 1.5 
Hz, 1H), 7.76 (d, J = 9.0Hz, 1H), 7.59 (d, J = 9.0Hz, 1H), 6.98 (m, 2H), 4.03 (brs, 2H), 
3.94 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 167.6, 146.4, 137.4, 131.0, 130.9, 126.6, 





To the solution of 3-6 (1.0 g, 4.98 mmol) in acetonitrile (30 mL) was added K2CO3 
(1.0 g, 7.24 mmol) and methyl iodine (0.4 mL, 6.4 mmol). The reaction was refluxed 
overnight. Then reaction mixture was condensed under reduced pressure the desired 
residue was purified with chromatography to give the title compound (300 mg, 
27.9 %). 
1
H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 7.95 (dd, J1 = 9.0 Hz, J2 = 1.5 
Hz, 1H), 7.70 (d, J = 9.0Hz, 1H), 7.63 (d, J = 9.0Hz, 1H), 6.89 (dd, J1 = 9.0 Hz, J2 = 
1.5 Hz, 1H), 6.76 (d, J = 1.5Hz, 1H), 4.13 (brs, 1H), 3.94 (s, 3H), 2.95 (s, 3H); 
13
C 
NMR (125 MHz, CDCl3) δ 167.6, 148.9, 137.9, 131.0, 130.4, 126.1, 125.9, 125.7, 





To the solution of 3-7 (230 mg, 1.06 mmol) in acetonitrile (10 mL) was added cesium 
carbonate (700 mg, 2.15 mmol) and 3-bromoprop-1-yne (80 % in toluene, 0.3 mL, 
2.67 mmol). Then reaction mixture was condensed under reduced pressure the desired 
residue was purified with chromatography to give the title compound (204 mg, 
76.1 %). 
1
H NMR (500 MHz, CDCl3) δ 8.46 (s, 1H), 7.97 (d, J = 9.0Hz, 1H), 7.83 (d, 
J = 9.0Hz, 1H), 7.69 (d, J = 9.0Hz, 1H), 7.24 (dd, J1 = 9.0 Hz, J2 = 1.5 Hz, 1H), 7.04 
(s, 1H), 4.18 (s, 2H), 3.95 (s, 3H), 3.11 (s, 3H), 2.21 (s, 1H); 
13
C NMR (125 MHz, 
CDCl3) δ 167.5, 148.5, 137.2, 130.8, 130.4, 126.3, 126.1, 125.8, 123.9, 117.1, 107.6, 






To the suspension of 3-8 (200 mg, 0.79 mmol) in THF (10 mL) and water (10 mL) 
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was added lithium hydroxide (140 mg, 5.83 mmol). The reaction mixture was stirred 
at 50 
o
C for 8 hours. Then the reaction mixture was condensed under reduced pressure. 
To the residue was added water (20 mL). The pH value of aqueous solution was 
adjusted to 6. The desired solid was extracted with ethyl acetate (30 mL×3). The 
combined organic phase was washed with brine (30 mL), dried and concentrated to 






To the suspension of (S)-2-((S)-4-carboxy-2-(1,3-dioxoisoindolin-2-yl) 
butanoyl)hexahydropyridazine-3-carboxylic acid prepared according to the published 
procedure
[103]
 (6.0 g, 15.4 mmol) in methyl isobutyl ketone (65 mL) was added 
p-Toluenesulfonic acid (100 mg, 0.58 mmol). The resulting mixture was refluxed for 
8 hours. Then the mixture was cooled down to room temperature. The solid was 
collected by filtration and then this solid was suspended in ethanol (50 mL) and 
filtered again to give the desired product (3.16 g, 61.4%). 
1
H NMR (500 MHz, 
DMSO-d6) δ 13.3 (brs, 1H), 7.87-7.92 (m, 4H), 5.21 (dd, J1 = 3.0 Hz, J2 = 6.0 Hz), 
5.16 (dd, J1 = 9.0 Hz, J2 = 11.5 Hz), 4.47 (m, 1H), 3.43-3.50 (m, 1H), 3.17-3.24 (m, 
1H), 2.91 (dt, J1 = 3.5 Hz, J2 = 12.5 Hz), 2.29-2.39 (m, 2H), 2.08-2.12 (m, 1H), 
1.78-1.84 (m, 1H), 1.67-1.71 (m, 1H), 1.49-1.54 (m, 1H); 
13
C NMR (125 MHz, 






To the suspension of 3-10 (200 mg, 0.54 mmol) in t-BuOH (10 mL) was added 
(Boc)2O (400 mg, 1.83 mmol) and DMAP (50 mg, 0.41 mmol). The resulting mixture 
was stirred overnight. Then the solvent was reduced under reduced pressure. The 
desired residue was purified with chromatography to give the product (166 mg, 
72.2%). 
1
H NMR (300 MHz, CDCl3) δ 7.82-7.86 (m, 2H), 7.84 (m, 2H), 7.72 (m, 2H), 
5.28 (m, 2H), 4.69 (m, 1H), 3.64 (m, 1H), 3.41 (m, 1H), 2.21-2.42 (m, 3H), 1.75 (m, 
2H), 1.46 (s. 9H); 
13
C NMR (75 MHz, CDCl3) δ 172.3, 168.2, 167.9, 167.6, 134.2, 
123.5, 83.0, 52.9, 49.8, 41.3, 30.4, 27.9, 26.2, 25.7, 20.1. LC-MS (IT-TOF) calcd for 
[M+H]
+




To the solution of compound 3-11 (166 mg, 0.39 mmol) in ethanol (10 mL) was added 
hydrazine hydrate (0.1 mmol, 2.0 mmol). The resulting mixture was stirred at 60
o
C 
for 3 hours. Then all the solvent was removed under reduced pressure. The desired 
residue was dissolved in DMF (5 mL), which was then added to the solution of 
compound 18 (150 mg, 0.62 mmol), HBTU (400 mg, 1.06 mmol) and HoBt (14 mg, 
0.1 mmol) in DMF (5 mL). The resulting mixture was stirred at room temperature for 
8 hours. To the reaction mixture was added ethyl acetate (100 mL) and water (100 
mL). The organic phase was taken, washed by water (30 mL×3), brine (30 mL), 
dried over sodium sulfite, concentrated and purified with chromatography to give the 
product (100 mg, 49.7%). 
1
H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 7.75 (d, J = 9.0 
Hz, 2H), 7.64 (d, J = 9.0 Hz, 1H), 7.24 (d, J = 6.0 Hz, 1H), 7.21 (d, J = 9.0 Hz, 1H), 
6.99 (s, 1H), 5.26-5.29 (m, 2H), 5.12-5.17 (dd, J1 = 8.0 Hz, J2 = 18.5 Hz, 1H), 4.64 (d, 
J = 13.0 Hz, 1H), 4.15 (s, 2H), 3.49-3.56 (m, 1H), 3.07 (s, 3H), 2.84-2.90 (m, 4H), 
2.77 (s, 1H), 2.35-2.38 (m, 1H), 2.23 (m, 2H), 1.85-1.97 (m, 3H), 1.46 (s, 9H), 1.23 
(m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 171.8, 170.6, 168.2, 166.8, 162.4, 148.1, 
136.4, 130.0, 127.5, 127.2, 126.5, 126.1, 123.9, 117.3, 107.6, 83.0, 78.8, 72.2, 53.3, 
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48.7, 42.2, 41.2, 38.5, 36.3, 31.3, 30.1, 27.9, 25.5, 20.0. 
 
 (NPA) 
To the solution of 3-4 (98 mg, 0.12 mmol) in DMF (4 mL) was added diethyl amine 
(0.5 mL). The resulting mixture was stirred at room temperature for 1 h, then the 
diethyl amine was removed under reduced pressure. At the same time, compound 3-12 
(90 mg, 0.17 mmol) was dissovled in DCM (5 mL) and TFA (2 mL). The resulting 
mixture was stirred at room temperature for 8 hs, then all the solvent was removed 
under reduced pressure. The desired residue was dissolved in DMF (5 mL). To this 
solution was added HBTU (70 mg, 0.2 mmol), HOBt (5 mg, 0.04 mmol). The 
resulting mixture was stirred at room temperature for 20 mins. Then 3-5 in DMF 
prepared above was added to reaction mixture, which was then stirred at room 
temperature for 4 hs. Then EA (50 mL) and water (50 mL) were added to reaction 
mixture. The organics were taken, washed with water (20 mL×3), brine (20 mL), 
dried over Na2SO4, purified with prep-TLC to give the product (6.3 mg, 5.3%). 
1
H 
NMR (500 MHz, DMSO-d6) δ 12.49 (brs, 1H), 8.61-8.68 (m, 1.68 H), 8.54 (d, J = 8.0 
Hz, 0.46 H), 8.34-8.37 (m, 3H), 7.92 (d, J = 9.0 Hz, 2H), 7.83-7.86 (m, 4H), 7.74 (d, J 
= 9.0 Hz, 1H), 7.35-7.38 (dd, J1 = 2.5 Hz, J2 = 9.0 Hz, 1H), 7.11 (d, J = 2.5 Hz, 1H), 
6.99 (d, J = 9.0 Hz, 1.45H), 6.92 (d, J = 9.0 Hz, 0.87H), 5.45 (m, 1H), 4.88-5.18 (m, 
3H), 4.61-4.75 (m, 1H), 4.43-4.46 (m, 1H), 4.29 (d, J = 1.5 Hz, 2H), 4.14 (s, 1.4H), 
4.01 (s, 0.79H), 3.44-3.68 (m, 6H), 3.19-3.23 (m, 2H), 3.10 (t, J = 2.5 Hz, 1H), 3.02 (s, 
3H), 2.88-2.93 (m, 1H), 2.57-2.77 (m, 3H), 2.16-2.36 (m, 5H), 1.90-1.99 (m, 4H), 
1.64-1.70 (m, 2H), 1.23 (s, 2H), 1.49 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, 
DMSO-d6) δ 172.1, 171.6, 171.5, 170.4, 166.8, 156.7, 152.1, 148.6, 147.2, 143.2, 
136.4, 130.2, 128.1, 125.9, 125.0, 123.0, 122.9, 118.0, 111.9, 107.6, 104.9, 80.3, 75.0, 
52.2, 49.0, 47.4, 45.1, 41.9, 41.2, 40.5, 40.4, 40.2, 40.1, 38.5, 30.0, 29.3, 21.8, 21.3, 
20.1, 12.7, 12.5; LC-MS (IT-TOF) calcd for [M+H]
+




To the solution of DR1-OTs (2.0 g, 4.26 mmol) in DMF (30 mL) was added sodium 
azide (415 mg, 6.39 mmol). The reaction mixture was stirred at 50 
o
C for 5 hours. 
Then reaction mixture was cooled down to room temperature. Ethyl acetate (100 mL) 
and water (50 mL) was added. The organic layer was taken. The aqueous layer was 
further extracted with ethyl acetate (50 mL×2). The combined organic layer was 
washed with water (50 mL×2), brine (50 mL), dried with sodium sulfite and purified 
with chromatography to give the product (1.35 g, 93.8 %). 
1
H NMR (300 MHz, 
CDCl3) δ 8.31 (dd, J1 = 9.0Hz, J2 = 2.4 Hz, 2H), 7.87-7.91 (m, 4H), 6.78 (d, J = 8.1 
Hz, 2H), 3.51-3.61 (m, 6H), 1.25 (t, J = 6.9 Hz, 1H); 
13
C NMR (75 MHz, CDCl3) δ 
156.6, 150.7, 147.3, 143.8, 126.1, 124.5, 122.6, 111.4, 49.4, 48.8, 45.8, 12.2; LC-MS 
(IT-TOF) calcd for [M+H]
+
:340.15, found: 340.13. 
 
(3-14) 
To the solution of 3-13 (900 mg, 2.65 mmol) in THF (30 mL) and water (58 mg) was 
added triphenylphosphine (1.04 g, 3.97 mmol). The reaction mixture was stirred at 
room temperature for 2 hours. Then more water (58 mg) was added. The resulting 
mixture was stirred at room temperature for 24 hours. Then all the solvent was 
removed under reduced pressure. The desired residue was purified with 
chromatography to give the title product (463 mg, 53.8 %). 
1
H NMR (500 MHz, 
DMSO-d6) δ 8.36 (d, J = 8.5 Hz, 2H), 7.93 (d, J = 9.0 Hz, 2H), 7.83 (d, J = 9.0 Hz, 
2H), 6.89 (d, J = 9.0 Hz, 2H), 3.51 (m, 2H), 3.43 (t, J = 7.5 Hz, 2H), 2.76 (t, J = 7.5 
Hz, 2H), 1.15 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 156.2, 151.7, 
146.6, 142.4, 126.1, 124.9, 122.3, 111.4, 52.8, 45.0, 12.1; LC-MS (IT-TOF) calcd for 
[M+H]
+





To the solution of Fmoc-ASP(tBu)-OH (1.6 g, 3.9 mmol) in the solvent of DCM (20 
mL) and DMF (10 mL) was added EDC.HCl (1.01 g, 5.26 mmol), HOBt (240 mg, 
1.78 mmol) and DIEA (512 mg, 3.96 mmol). Then 3-14 (1.1 g, 3.5 mmol) was added 
to the above solution. The mixture was stirred at room temperature for 4 hours. To the 
mixture was added DCM (80 mL) and water (30 mL). The organic layer was taken, 
washed with water (30 mL×3), brine (30 mL), dried with sodium sulfite and purified 
with chromatography to give the product (1.2 g, 48.4 %). 
1
H NMR (500 MHz, CDCl3) 
δ  8.29 (d, J = 9.0Hz, 2H), 7.89 (d, J = 9.0Hz, 2H), 7.87 (d, J = 9.0Hz, 2H), 7.74 (m, 
2H), 7.54 (d, J = 7.5Hz, 2H), 7.40 (m, 2H), 6.82 (d, J = 9.0Hz, 2H), 6.71 (brs, 1H), 
5.91 (d, J = 6.0Hz, 1H), 4.48 (brs, 1H), 4.42 (d, J = 6.0Hz, 2H), 4.42 (t, J = 6.0Hz, 
1H), 3.49-3.53 (m, 6H), 2.95 (m, 1H), 2.61 (m, 1H), 1.45 (s, 9H), 1.22 (t, J = 7.0Hz, 
1H); 
13
C NMR (125 MHz, CDCl3) δ 171.0, 156.7, 151.2, 147.3, 143.8, 143.6, 143.5, 
141.4, 141.3, 127.8, 127.7, 127.0, 126.3, 124.6, 122.5, 120.1, 120.0, 111.4, 82.0, 67.1, 





To the solution of 3-15 (1.0 g, 1.41 mmol) in DCM (15 mL) was added piperidine (3 
mL). The resulting mixture was stirred at room temperature for 8 hours. Then all the 
solvent was evaporated under reduced pressure. The residue containing free amine 
product was re-dissolve in DMF (10 mL). To a separated RBF was added DMF (20 
mL), 3-10 (548 mg, 1.47 mmol), HBTU (834 mg, 2.2 mmol), HOBt (108 mg, 0.8 
mmol), DIEA (170 mg, 1.31 mmol). The resulting mixture was stirred at room 
temperature for 10 minutes. Then the above amine solution was added and the 
resulting mixture was stirred at room temperature overnight. Then most of the solvent 
was removed under reduced pressure. To the residue was added water (100 mL) and 
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EA (150 mL). The organics were taken, washed with water (50 mL×3), brine (50 mL), 
dried over sodium sulfite, filtered and concentrated, the residue was purified with 
chromatography (hex/EA=10/1:1/1) to give the product (400 mg, 32.3%). 
1
H NMR 
(500 MHz, CDCl3) δ 8.24 (d, J = 9.0 Hz, 2H), 7.77-7.83 (m, 6H), 7.69 (m, 2H), 7.40 
(d, J = 7.5 Hz, 1H), 6.97 (m, 1H), 6.79 (m, 2H), 5.29 (dd, J1 = 9.0 Hz, J2 = 11.5 Hz, 
1H), 5.14 (m, 1H), 4.65-4.69 (m, 1H), 4.57-4.60 (m, 1H), 3.33-3.41 (m, 1H), 
2.97-3.01 (m, 1H), 2.84 (dd, J1 = 4.5 Hz, J2 = 17.0 Hz, 1H), 2.64 (dd, J1 = 7.0 Hz, J2 = 
17.0 Hz, 1H), 2.33-2.46 (m, 3H), 1.97-2.01 (m, 1H), 1.78-1.85 (m, 2H), 1.58-1.62 (m, 
1H), 1.42 (s, 9H), 1.19 (t, J = 7.0 Hz, 3H), 0.79-0.86 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3) δ 172.3, 170.6, 169.0, 168.2, 167.7, 156.6, 151.2, 147.1, 143.6, 134.2, 126.2, 
124.5, 123.4, 122.4, 111.3, 82.0, 53.3, 49.8, 49.5, 48.9, 45.3, 41.5, 37.4, 36.4, 30.3, 
27.9, 26.0, 24.8, 19.2, 12.1; LC-MS (ESI) calcd for [M+H]
+
: 838.35, found: 838.35. 
 
(NP) 
To the solution of 3-16 (97 mg, 0.12 mmol) in ethanol (10 mL) was added hydrazine 
hydrate (60 mg, 1.2 mmol). The resulting mixture was stirred at 60
o
C for 2 hours. 
Then all the solvent was removed under reduced pressure. The residue containing the 
desired free amine was re-dissolve in DMF (2 mL). To a separated RBF was added 
DMF (3 mL), 6-(dimethylamino)-2-naphthoic acid (40 mg, 0.18 mmol) and PyBOP 
(125 mg, 0.24 mmol). The resulting mixture was stirred at room temperature for 10 
minutes. Then the above amine solution was added. The resulting mixture was stirred 
at room temperature overnight. Then most of the solvent was removed under reduced 
pressure. To the residue was added water (20 mL) and EA (50 mL). The organics 
were taken, washed with water (20 mL×3), brine (20 mL), dried over sodium sulfite, 
filtered and concentrated, the residue was purified with chromatography 
(hex/EA=10/1:1/1) to give the coupling product which was dissolved in the mixture 
of DCM (5 mL) and TFA (5 mL). The mixture was stirred at room temperature for 8 
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hours. Then all the solvent was removed under reduced pressure. The residue was 
purified with prep-TLC (DCM/MeOH=20:1) to give the final product (11.4 mg, 
11.2%). 
1
H NMR (300 MHz, DMSO-d6) δ 8.50 (d, J = 7.5 Hz, 1H), 8.44 (d, J = 7.5 
Hz, 1H), 8.36 (m, 2H), 8.31 (brs, 1H), 8.15 (m, 1H), 7.93 (m, 2H), 7.79-7.85 (m, 4H), 
7.69 (d, J = 8.5 Hz, 1H), 7.28 (dd, J1 = 2.5 Hz, J2 = 9.0 Hz, 1H), 6.95 (d, J = 2.0 Hz, 
1H), 6.93 (d, J = 9.5 Hz, 2H), 5.13 (t, J = 5.0 Hz, 1H), 4.87-4.92 (m, 1H), 4.53 (q, J = 
7.0 Hz, 1H), 4.41 (m, 1H), 3.40-3.50 (m, 4H), 3.04 (m, 6H), 2.94 (m, 1H), 2.62 (dd, J1 
= 6.0 Hz, J2 = 16.0 Hz, 1H), 2.34 (m, 1H), 2.17-2.24 (m, 2H), 2.04 (m, 1H), 1.90 (m, 
1H), 1.68 (m, 1H), 1.60 (m, 1H), 1.14 (t, J = 7.0 Hz, 1H); 
13
C NMR (125 MHz, 
DMSO-d6) δ 172.3, 169.8, 166.9, 156.7, 152.0, 150.0, 147.2, 143.2, 136.7, 130.2, 
128.1, 126.8, 126.6,  126.0, 125.4, 125.1, 124.9, 122.9, 117.1, 111.9, 105.4, 52.8, 
50.3, 49.2, 49.1, 45.4, 41.4, 37.1, 30.4, 29.2, 25.9, 19.5, 12.5.  
 
 (3-17) 
To the solution of cyclooctane-1,3-dione (590 mg, 4.2 mmol) in acetonitrile (30 mL) 
was added caesium carbonate (2.73 g, 8.4 mmol) at room temperature. The resulting 
mixture was stirred for 30 minutes. Then the reaction mixture was cooled down at 
ice-water bath. Selectfluor (4.1g, 11.6 mmol) was added the above reaction mixture 
which was stirred at ice-water bath for additional 30 minutes. Then the reaction 
mixture was stirred at room temperature for one hour. The solvent was removed under 
reduced pressure. The residue was diluted with 1N HCl (20 mL), which was then 
extracted with ether (50 mL×3). The combined organics was washed with brine (100 
mL), dried with sodium sulfite, filtered and concentrated. The desired residue was 
purified with chromatography to give the product (230 mg, 31.1%). 
1
H NMR (500 
MHz, CDCl3) δ 2.65-2.69 (m, 4H), 1.79-1.84 (m, 4H), 1.63-1.65 (m, 2H); 
13
C NMR 





To the solution of 3-methyl-3-oxetanemethanol (1.6 mL, 16.2 mmol), DCC (3.7 g, 
17.9 mmol) and DMAP (98.6 mg, 0.82 mmol) in DCM (20 mL) was added iodoacetic 
acid (3.08 g, 16.6 mmol) in DCM (30 mL) drop-wise under ice-water bath. The 
resulting mixture was stirred at ice-water bath for 1 hour. Then the reaction mixture 
was warmed up to room temperature over 1.5 hours. The reaction was then quenched 
by addition of acetic acid (1 mL). The mixture was stirred for 30 more minutes and 
then diluted with DCM (100 mL). The mixture was filtered off. The filtrate was taken, 
washed with water (100 mL×3), NaHCO3 sat. aqueous solution (100 mL×2), brine 
(100 mL), dried over sodium sulfite, filtered and concentrated. The residue was 
diluted with DCM (50 mL). The unsoluable precipitate was removed by filtration. The 
filtrate was concentrated to give an yellow oil. This oil was then dissolved in THF 
(100 mL). To the above solution was added triphenylphosphine (4.69 g, 17.8 mmol). 
The resulting mixture was stirred room temperature for 40 hours. The ether (100 mL) 
was added to reaction mixture. The precipitate was collected by filtration, dried, to 
give the product (6.0 g, 69.2%). 
1
H NMR (500 MHz, CDCl3) δ 7.77-7.87 (m, 9H), 
7.65-7.69 (m, 6H), 5.44 (d, J = 13.5 Hz, 2H), 4.25 (s, 4H), 4.11 (s, 2H), 1.18 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 164.4 (d, J = 3.4 Hz), 135.3 (d, J = 3.0 Hz), 133.9 (d, J 
= 10.8 Hz), 130.3 (d, J = 13.1 Hz), 117.8 (d, J = 88.5 Hz), 79.1, 71.0, 38.8, 33.8 (d, J 
= 56.6 Hz), 20.9. 
 
(3-18) 
To the solution of 3-25 (543 mg, 1.02 mmol) in DCM (8 mL) was added DBU (160 
mg, 1.05 mmol) at ice-water bath. The resulting mixture was stirred at ice-water bath 
for 20 minutes. Then 3-17 (180 mg, 1.02 mmol) was added to reaction mixture. The 
reaction mixture was allowed to stirred at room temperature for 48 hours. Then all the 
solvent was removed and the desired residue was purified with chromatography to 
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give the product (100 mg, 32.4%). 
1
H NMR (500 MHz, CDCl3) δ 6.47 (s, 1H), 4.50 (d, 
J = 6.5 Hz, 2H), 4.38 (d, J = 6.5 Hz, 2H), 4.23 (s, 2H), 2.78 (t, J = 6.5 Hz, 2H), 2.64 
(m, 3H), 1.77-1.82 (m, 2H), 1.69 (m, 2H), 1.49-1.53 (m, 2H), 1.33 (s, 3H); 
13
C NMR 
(125 MHz, CDCl3) δ 199.9 (t, J = 27.5Hz), 164.8, 150.1 (t, J = 20.0Hz), 120.9 (t, J = 
8.8Hz), 113.9 (t, J = 253.8Hz), 79.4, 69.0, 38.9, 37.2, 26.5, 26.4, 25.2, 21.0.  
 
(3-19) 
To the solution of 3-18 (2.3 g, 7.6 mmol) in methanol (80 mL) was added Pd/C (200 
mg). Then the mixture was charged with hydrogen and stirred for 24 hours. The Pd/C 
was removed by filtration. The filtrate was concentrated under reduced pressure. The 
desired residue was dissolved in dried DCM (80 mL). To the solution was added 
freshly distilled BF3.Et2O (100 L) at ice-water bath. Then the reaction mixture was 
warmed up to room temperature and stirred for an additionl 20 huors. The reaction 
was then quenched by addition of TEA (1.5 mL) followed by addition of deactivated 
silica gel (10 g). All the solvent was removed under reduced pressure. The desired 
mixture was purified with chromatography (Hex/EA=50/1:20:1) to give the product 
(2.2 g, 95.2%).  
1
H NMR (300 MHz, CDCl3) δ 3.85 (s, 6H), 2.43-2.58 (m, 3H), 2.18 
(dd, J1 = 14.4 Hz, J2 = 1.5 Hz, 1H), 1.84-2.03 (m, 3H), 1.29-1.59 (m, 6H), 0.76 (s, 
3H); 
13
C NMR (75 MHz, CDCl3) δ 205.7 (dd, J1 = 25.7 Hz, J2 = 29.2 Hz), 122.3 (dd, 
J1 = 248.4 Hz, J2 = 255.9 Hz), 108.7, 72.4, 39.0 (t, J = 21.0 Hz), 38.5, 34.3 (t, J = 4.8 
Hz), 30.1, 26.6, 26.0 (d, J = 7.2 Hz), 24.6 (d, J = 2.8 Hz), 23.0, 14.3. 
 
(3-20) 
To the solution of KHMDS (2.5 mL) in THF (30 mL) was added 3-19 (300 mg) in 
THF (15 mL) dropwise under -78
o
C. The resulting mixture was stirred at -78
o
C for 
three hours. Then Tf2NPh (400 mg) in THF (15 mL) was added to reaction mixture. 
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The reaction mixture was allowed to warm up to room temperature slowly. Then the 
reaction mixture was stirred at room temperature overnight. Then deactivated silica 
gel (10 g) was added to reaction mixture. All the solvent was removed under reduced 
pressure. The desired residue was further purified with chromatography 
(Hex:EA=50:1/25:1) to give the product (330 mg, 75.6%). 
1
H NMR (300 MHz, 
CDCl3) δ 6.03 (t, J = 9.6 Hz, 1H), 3.87 (s, 6H), 2.59-2.70 (m, 1H), 2.42 (m, 2H), 2.22 
(dd, J1 = 14.7 Hz, J2 = 1.8 Hz, 1H), 1.90-1.92 (m, 1H), 1.61-1.69 (m, 6H), 0.92 (s, 
3H); 
13
C NMR (75 MHz, CDCl3) δ 142.9 (t, J = 30 Hz), 126.6, 120.5 (t, J = 121.8 Hz), 




3-20 (902 mg, 2.1 mmol) was dissolved in THF (30 mL). The solution was cooled 
down to -20
o
C. 0.2 M solution of LDA was made by adding n-butyllithium (2.8 mL of 
2M solution in cyclohexane, 5.6 mmol) dropwise to a solution of diisopropylamine 
(950 L, 6.72 mml) in THF at -78oC. Then 11 mL of this freshly prepared LDA was 
added to the above solution at -20
o
C over half an hour. The mixture was then brought 
to room temperature over 30 minutes. Then the deactivated silica gel was added to the 
reaction mixture, which was then concentrated and purified with chromatography to 
give the product (120 mg, 20.0%). 
1
H NMR (500 MHz, CDCl3) δ 3.88 (s, 6H), 
2.48-2.55 (m, 1H), 2.27-2.33 (m, 2H), 2.01-2.22 (m, 4H), 1.71-1.78 (m, 1H), 1.65 (dd, 
J1 = 4.0 Hz, J2 = 14.0 Hz, 1H), 1.50 (m, 1H), 1.24-1.44 (m, 1H), 0.78 (s, 3H); 
13
C 
NMR (125 MHz, CDCl3) δ 119.7 (t, J = 236.8 Hz), 109.7 (t, J = 11.1 Hz), 85.4 (dd, J1 
= 41.5 Hz, J2 = 46.5 Hz), 72.5, 51.8 (t J = 23.6 Hz), 34.9 (dd, J1 = 41.5 Hz, J2 = 46.5 





To 3-21 (130 mg, 0.45 mmol) in mixture of methanol (7 mL) and water (0.7 mL) was 
adde PPTS (240 mg, 0.96 mmol), after which the mixture was stirred at room 
temperature for 24 hours. Then the reaction was quenched by addition of saturated 
NaHCO3 (4 mL) and the mixture was condensed under reduced pressure. The crude 
product was diluted with brine (10 mL) and extracted with EA (15 mL×3). The 
combined organics was washed with brine (15 mL) and a HCl/brine solution (1:1 1 M 
HCl/brine, 10 mL×2), dried over sodium sulfate, filtered and concentrated. The 
desired residue was dissolved in dioxane (2 mL) and water (0.4 mL). To this mixture 
was added LiOH (141 mg, 5.8 mmol). The resulting mixture was stirred at room 
temperature for 2.5 hours. The mixture was acidified with 1 M HCl (6 mL), and 
further diluted with brine (8 mL) and extracted with EA (15 mL×4). The combined 
organics was washed with (1:1 1 M HCl/brine, 10 mL), dried over sodium sulfate, 
filtered and concentrated, purified with chromatography (Hex/EA/AcOH=10/1/0.01) 
to give the desired product (60 mg, 65.9%). 
1
H NMR (500 MHz, CDCl3) δ 2.73-2.78 
(m, 2H), 2.32-2.40 (m, 3H), 2.06-2.16 (m, 2H), 1.75-1.86 (m, 2H), 1.63-1.69 (m, 1H), 
1.37-1.43 (m, 1H); 
13
C NMR (125 MHz, CDCl3) δ 178.1, 120.7 (t, J = 238.0 Hz), 
110.5 (t, J = 11.1 Hz), 84.7 (dd, J1 = 41.4 Hz, J2 = 46.6 Hz), 52.5 (t, J = 24.2 Hz), 33.5 
(d, J = 3.2 Hz), 32.6 (d, J = 34.5 Hz), 32.4 (d, J = 1.8 Hz), 27.6, 20.2. 
 
 
To the solution of 3-22 (29 mg, 0.14 mmol) in THF (2 mL) was added NMP (32 mg, 
0.3 mmol) and isobutyl chloroformate (27 mg, 0.2 mmol) at 0 
o
C. The resulting 
mixture was stirred at same temperature for 10 minutes. Then (S)-tert-butyl 
3-amino-4,4-dimethoxybutanoate (55 mg, 0.25 mmol) was added to the reaction 
mixture. The mixture was stirred at 0 
o
C for half an hour and then stirred at room 
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temperature for 4 hours. Then silica gel was added to the reaction mixture. The 
solvent was evaporated under reduced pressure. The residue was purified with 
chromatography (Hex/EA=30:1/5:1) to give the first isomer (3-23-1) 28 mg, Rf = 0.38 
(Hex/EA = 3/1); 
1
H NMR (500 MHz, CDCl3) δ 6.14 (d, J = 9.0 Hz, 1H), 4.40-4.44 (m, 
1H), 4.31 (d, J = 9.0 Hz, 1H), 3.38 (s, 3H), 3.37 (s, 3H), 2.74-2.81 (m, 1H), 2.58 (dd, 
J1 = 4.0 Hz, J2 = 15.0 Hz, 1H), 2.49 (dd, J1 = 6.0 Hz, J2 = 15.5 Hz, 1H), 2.43 (dd, J1 = 
7.0 Hz, J2 = 15.5 Hz, 1H), 2.27-2.34 (m, 2H), 2.04-2.12 (m, 3H), 1.71-1.77 (m, 2H), 
1.50-1.56 (m, 1H), 1.42 (s, 9H), 1.24-1.38 (m, 1H); 
13
C NMR (125 MHz, CDCl3) δ 
170.8, 170.3, 121.1 (t, J = 236.8), 110.2 (t, J = 10.8), 104.6, 85.0 (dd, J1 = 41.5 Hz, J2 
= 46.6 Hz), 80.0, 55.9, 55.2, 53.0 (t, J = 24.0), 47.7, 35.5 (d, J = 2.75), 35.1, 32.4 (d, J 
= 1.88), 32.4, 32.3, 27.9, 27.3, 20.1; LC-MS (IT-TOF) calcd for [M+H]
+
:426.2068, 
found: 426.1770, the second isomer (3-23-2) 24 mg, Rf = 0.30 (Hex/EA = 3/1); 
1
H 
NMR (500 MHz, CDCl3) δ 6.16 (d, J = 8.5 Hz, 1H), 4.40-4.45 (m, 1H), 4.35 (d, J = 
4.5 Hz, 1H), 3.38 (s, 3H), 3.37 (s, 3H), 2.76-2.82 (m, 1H), 2.55 (dd, J1 = 3.5 Hz, J2 = 
15.0 Hz, 1H), 2.46 (d, J = 6.0 Hz, 1H), 2.26-2.35 (m, 2H), 2.04-2.13 (m, 3H), 1.86 (m, 
1H), 1.70-1.76 (m, 1H), 1.52-1.58 (m, 1H), 1.42 (s, 9H), 1.34-1.38 (m, 1H); 
13
C NMR 
(125 MHz, CDCl3) δ 170.8, 170.4, 121.1 (t, J = 236.8), 110.2 (t, J = 11.0), 104.4, 85.0 
(dd, J1 = 41.4 Hz, J2 = 46.6 Hz), 80.9, 55.6, 54.9, 53.2 (t, J = 24.0), 47.4, 35.5 (d, J = 
2.75), 35.3, 32.4 (d, J = 1.75), 32.3, 32.2, 27.9, 27.7, 20.1; LC-MS (IT-TOF) calcd for 
[M+H]
+
: 426.2068, found: 426.1777.  
 
   
To the solution of SM in TFA (1 mL) and DCM (1 mL) was added water (0.5 mL). 
The resulting mixture was stirred at room temperature overnight. Then all the solvent 
was removed under reduced pressure to give the desired product.  
 
Typical procedure for the synthesis of azido building block 




Preparation of triflyl azide: Sodium azide (1 g, 15.4 mmol) was dissolved in a 
distilled water (5 mL) and then dichloromethane (DCM, 8 mL) was added. This 
mixture was cooled on an ice bath for 20 min. Triflyl anhydride (1 mL, 5.97 mmol) 
was added slowly over 5 min and the mixture was stirred for 2 h. The mixture was 
transferred to a separatory funnel and then DCM phase removed. The aqueous phase 
was extracted with DCM (2×4 mL). The organic portions, containing the triflyl azide, 
were pooled and washed once with saturated NaHCO3 and used without further 
purification. 
Preparation of azido acid: The corresponding amine (3 mmol) was combined with 
K2CO3 (594.5 mg, 4.5 mmol) and CuSO4 5.H2O (7.53 mg, 30 mol) in a distilled 
water (10 mL) and methanol (MeOH, 20 mL). The triflyl azide in DCM (16 mL) was 
added and the mixture was stirred at ambient temperature and pressure overnight. 
Subsequently, water (20 mL) and DCM (30 mL) were added to reaction mixture. The 
organic phase was taken, washed with ammonium chloride (saturated aqueous 
solution) (30 mL) and brine (30 mL), dried over sodium sulfite and purified with 




H NMR (300 MHz, CDCl3) δ 7.19-7.33 (m, 5H), 3.41-3.47 (m, 1H), 
2.62-2.79 (m, 2H), 1.74-1.85 (m, 2H), 1.28 (d, J = 6.6 Hz, 3H); 
13
C NMR (75 MHz, 





H NMR (300 MHz, CDCl3) δ 7.28-7.41 (m, 5H), 3.39-3.57 (m, 2H), 
3.03-3.11 (m, 1H), 1.42 (d, J = 2.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 143.3, 







H NMR (300 MHz, CDCl3) δ 3.67-3.71 (m, 4H), 3.29-3.34 (m, 2H), 
2.54-2.58 (m, 2H), 2.46-2.49 (m, 4H); 
13





H NMR (300 MHz, CDCl3) δ 7.27-7.30 (m, 3H), 7.13-7.17 (m, 1H), 
3.55 (t, J = 7.2 Hz, 2H), 2.90 (t, J = 7.2 Hz, 2H); 
13
C NMR (75 MHz, CDCl3) δ 140.0, 





H NMR (300 MHz, CDCl3) δ 7.28 (m, 2H), 6.97 (m, 2H), 4.31 (s, 2H), 
3.86 (s, 3H); 
13





H NMR (500 MHz, CDCl3) δ 4.03-4.08 (m, 1H), 3.87-3.91 (m, 1H), 
3.75-3.80 (m, 1H), 3.35 (dd, J1 = 4.0 Hz, J2 = 13.0 Hz, 1H), 3.20 (dd, J1 = 6.0 Hz, J2 = 
13.0 Hz, 1H), 1.86-2.00 (m, 3H), 1.61-1.68 (m, 1H); 
13
C NMR (125 MHz, CDCl3) δ 





H NMR (500 MHz, CDCl3) δ 6.76-6.81 (m, 3H), 5.96 (s, 2H), 4.22 (s, 
2H); 
13








H NMR (500 MHz, CDCl3) δ 7.32-7.41 (m, 5H), 4.64 (q, J = 7.0 Hz, 
1H), 1.56 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 140.8, 128.7, 128.0, 





H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 
Hz, 2H), 4.34 (s, 2H); 
13






H NMR (500 MHz, CDCl3) δ 7.28-7.31 (m, 2H), 7.05-7.09 (m, 2H), 
4.31 (s, 2H); 
13





H NMR (300 MHz, CDCl3) δ 7.61-7.65 (m, 4H), 7.36-7.50 (m, 5H), 
4.40 (s, 2H); 
13
C NMR (75 MHz, CDCl3) δ 141.21, 140.46, 134.31, 128.7, 128.6, 





H NMR (300 MHz, CDCl3) δ 4.26 (m, 1H), 4.04 (dd, J1 = 6.3 Hz, J2 = 
8.4 Hz 1H), 3.76 (dd, J1 = 5.7 Hz, J2 = 8.4 Hz, 1H), 3.37 (dd, J1 = 4.8 Hz, J2 = 12.9 
Hz, 1H), 3.27 (dd, J1 = 5.4 Hz, J2 = 12.9 Hz, 1H), 1.45 (s, 3H), 1.35 (s, 3H); 
13
C NMR 





To the solution of 3-23-1 (24 mg, 0.059 mmol) in acetonitrile (2 mL) was added azide 
7 (20 mg, 0.083 mmol). The mixture was stirred at room temperature for 24 hours. 
Then all the solvent was removed under reduced pressure. The desired residue was 
redissolved in DCM (1 mL) and then seperated by prep-TLC (DCM/MeOH = 20:1) to 
give 3-24-1 (10 mg, 26.3%), Rf = 0.23 (DCM/MeOH = 15:1); 
1
H NMR (500 MHz, 
CDCl3) δ 7.90 (d, J = 8.0 Hz, 1H), 7.82 (m, 1H), 7.75 (dd, J1 = 2.5 Hz, J2 = 8.0 Hz, 
1H), 7.44-7.50 (m, 2H), 7.33-7.37 (m, 2H), 6.37 (t, J = 5.5 Hz, 1H), 6.31 (d, J = 9.0 
Hz, 1H), 5.30 (d, J = 16.5 Hz, 1H), 5.24 (d, J = 16.5 Hz, 1H), 5.01 (dd, J1 = 6.0 Hz, J2 
= 14.5 Hz, 1H), 4.76 (dd, J1 = 5.0 Hz, J2 = 14.5 Hz, 1H), 4.41-4.43 (m, 1H), 4.31 (d, J 
= 4.0 Hz, 1H), 3,36 (s, 6H), 3.18-3.26 (m, 1H), 3.09-3.14 (m, 1H), 2.85-2.91 (m, 1H), 
2.73 (dd, J1 = 5.0 Hz, J2 = 15.0 Hz, 1H), 2.50 (dd, J1 = 6.0 Hz, J2 = 15.5 Hz, 1H), 2.45 
(dd, J1 = 6.5 Hz, J2 = 16.0 Hz, 1H), 2.07 (dd, J1 = 8.0 Hz, J2 = 15.0 Hz, 1H), 
1.66-1.70 (m, 1H), 1.47-1.60 (m, 2H), 1.42 (s, 9H), 0.98-1.05 (m, 1H); 
13
C NMR (125 
MHz, CDCl3) δ 170.8, 169.8, 166.0, 133.7, 132.6, 131.1, 128.6 (d, J = 7.5 Hz), 126.5, 
126.4, 125.8, 125.2, 123.2, 104.5, 80.8, 55.8, 55.1, 47.7, 41.6, 35.1, 27.9, 25.5, 24.2, 
22.2; HRMS (ESI
+
) m/z: 666.3094 (Calcd for [M+Na]
+
: 666.3079); and 3-24-2 (15 
mg, 39.4%), Rf = 0.20 (DCM/MeOH = 15:1); 
1
H NMR (500 MHz, CDCl3) δ  7.91 
(m, 1H), 7.86 (m, 1H), 7.79 (d, J = 8.0 Hz) 7.49-7.51 (m, 2H), 7.34-7.40 (m, 2H), 
6.42 (m, 1H), 6.20 (d, J = 9.0 Hz, 1H), 5.00 (d, J = 16.5 Hz, 1H), 4.94 (d, J = 16.5 Hz, 
1H),  4.91 (dd, J1 = 5.5 Hz, J2 = 14.5 Hz, 1H), 4.86 (dd, J1 = 5.5 Hz, J2 = 14.5 Hz, 
1H), 4.41-4.45 (m, 1H), 4.32 (d, J = 4.0 Hz, 1H), 3.40 (s, 3H), 3.39 (s, 3H), 2.77-2.97 
(m, 3H), 2.68 (dd, J1 = 5.0 Hz, J2 = 15.0 Hz, 1H), 2.51 (dd, J1 = 5.5 Hz, J2 = 15.5 Hz, 
1H), 2.44 (dd, J1 = 6.5 Hz, J2 = 15.5 Hz, 1H), 2.02 (dd, J1 = 8.5 Hz, J2 = 15.0 Hz, 1H), 
1.55-1.63 (m, 2H), 1.44-1.48 (m, 1H), 1.43 (s, 9H), 1.37-1.40 (m, 1H), 1.22 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 170.9, 170.3, 164.4, 133.8, 132.3, 131.1, 128.8 (d, J = 
127 
 
Hz), 126.8, 126.7, 126.0, 125.3, 123.0, 104.7, 80.8, 56.1, 55.4, 50.8, 47.9, 41.7, 35.0, 
28.0, 26.1, 21.7, 20.4; HRMS (ESI
+





To the solution of 3-24-1 (10 mg) or 3-24-2 (15 mg) in TFA (1 mL) and DCM (1 mL) 
was added water (0.5 mL). The resulting mixture was stirred at room temperature 
overnight. Then all the solvent was removed under reduced pressure to give the 
desired product respectively in quantitative yield. b7-b, redissolved in DMSO (0.6 mL, 
25.9 mM) and then used directly in the biological experiment. HRMS (ESI
+
) m/z: 
542.2198 (Calcd for [M+H]
+
: 542.2215); b7-s, redissolved in DMSO (0.6 mL, 38.9 
mM) and then used directly in the biological experiment. HRMS (ESI
+
) m/z: 




6.4 Chapter 4 
6.4.1 Chemical synthesis 
(4-52) 
To the solution of protected fluoresein acid (1.0 g, 2.17 mmol) in DMF (20 mL) 
was added HATU (1.1 g, 3.0 mmol) and tert-butyl (2-aminoethyl)carbamate (500 mg, 
3.10 mmol). The resulting mixture was stirred at room temperature for 4 hours. Then 
reaction was quenched by addition of water (100 mL) and EA (100 ml). The organic 
phase was taken, washed with water, brine, dried with sodium sulfate, condensed and 
purified with chromatography (hexane/EA=5:1/3:1) to give the product (1.0 g, 76.9%). 
1
H NMR (500 MHz, CDCl3) δ 8.47 (s, 0.66H), 8.22 (d, J = 8.0 Hz, 0.66H), 8.13 (d, J 
= 8.5Hz, 0.33H), 8.09 (d, J = 8.5 Hz, 0.33H), 7.79 (s, 0.66H), 7.73 (s, 0.33H), 7.62 (s, 
0.33H), 7.28 (m, 0.66H), 7.12 (m, 1H), 7.10 (s, 0.66H), 6.79-6.85 (m, 4H), 5.51 (m, 
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0.66H), 5.06 (m, 0.33H), 3.58-3.61 (m, 1.32H), 3.48-3.50 (m, 0.66H), 3.44 (m, 
1.32H), 3.35 (m, 0.66H), 2.33 (s, 6H), 1.45 (s, 6H), 1.32 (s, 3H); 
13
C NMR (125 MHz, 
CDCl3) δ 168.8, 168.2, 165.8, 155.0, 153.1, 152.3, 152.2, 151.5, 151.4, 141.1, 136.7, 
134.4, 129.0, 128.8, 128.2, 126.6, 125.4, 123.8, 122.7, 117.8, 115.8, 110.6, 110.5, 80.3, 
80.2, 47.4, 40.7, 28.3, 28.1; LC-MS (ESI) calcd for [M+H]
+
:603.19, found: 603.30. 
 
(FITC-TCO) 
To the solution of 4-52 (54 mg, 0.09 mmol) in DCM (5 mL) was added 
trifluoroacetic acid (1 mL). The resulting solution was stirred at room temperature for 
3 hours. Then the mixture was condensed under reduced pressure. The desired residue 
was dissolved in THF and pH was adjusted to 8 by N-methyl morpholine (NMP). 
Then this solution was added to the activated TCO-COOH (29 mg, 0.16 mmol) which 
is activated by N-methyl morpholine (NMP) (21 mg, 0.20 mmol) and isobutyl 
chlorformate (22 mg, 0.16 mmol) in THF (5 mL) under ice water bath. The resulting 
mixture was stirred for 30 minutes under ice water bath and then stirred at room 
temperature for 2 hours. Then the mixture was condensed under reduced pressure and 
purified over chromatography to give the coupling product which was further treated 
with methoxide in methanol (1M, 5 mL) for 30 minutes. Then the reaction was 
quenched by addition of water (20 mL) and pH was adjusted to 6 by HCl (7% in 
water). The solid was collected by filtration and dried to give the title compound (45 
mg, 86.5%). 
1
H NMR (500 MHz, CDCl3) δ 10.19 (brs, 2H), 8.88 (t, J = 5.5 Hz, 
0.66H), 8.75 (t, J = 5.5 Hz, 0.33H), 8.47 (s, 0.66H), 8.25 (d, J = 8.0 Hz, 0.66H), 8.16 
(d, J = 8.0 Hz, 0.33H), 8.10 (d, J = 8.0 Hz, 0.33H), 7.74 (m, 0.66H), 7.65 (m, 0.66H), 
7.40 (d, J = 8.0 Hz, 0.66H), 6.69 (m, 2H), 6.53-6.60 (m, 4H), 5.46-5.55 (m, 1H), 
5.27-5.34 (m, 1H), 3.59-3.81 (m, 2H), 3.43 (m, 1H), 3.20 (m, 1H), 3.04 (m, 0.66H), 
2.95 (m, 0.33H), 1.97-2.22 (m, 4H), 1.64-1.85 (m, 4H), 1.30-1.45 (m, 2H); 
13
C NMR 
(125 MHz, CDCl3) δ 170.3, 170.1, 168.9, 168.9, 165.4, 165.3, 162.0, 152.3, 136.6, 
136.4, 135.5, 132.5, 129.7, 129.5, 124.5, 123.7, 113.3, 109.5, 102.7, 86.1, 67.9, 38.5, 
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37.6, 37.5, 34.5, 34.4, 32.8, 32.7, 31.6, 31.5; HRMS(ESI) calcd for [M+Na]
+
: 
607.2056, found: 607.2044. 
 
(4-53) 
To the solution of (1Z,N'Z)-N'-(chloro(4-(trifluoromethyl)phenyl)methylene)- 
3-nitrobenzohydrazonoyl chloride prepared according to the published procedure
[103]
 
(1.0 g, 2.56 mmol) in acetonitrile (20 mL) was added hydrazine hydrate (128 mg, 2.56 
mmol). The reaction mixture was stirred at reflux for one hour behind a blast shield. 
Then potassium carbonate (706 mg, 5.12 mmol) was added to reaction mixture, which 
was then refluxed for 8 hours. Then hydrazine hydrate (800 mg, 16.0 mmol) was 
added. The reaction mixture was refluxed for one more hour. After reaction mixture 
was cooled down to room temperature, DCM (100 mL) was added to reaction mixture. 
The organics was washed with brine (30 mL×3), dried with sodium sulfite, filtered 
and concentrated. The desired residue was suspended in acetic acid (8 mL) at 0
o
C. 
Then NaNO2 (1.4 g, 20 mmol) in water (2 mL) was added to above suspension. The 
reaction mixture was stirred at 0
o
C for 3 hours and then diluted with DCM (100 mL). 
The organics was washed with sat. aq. NaHCO3 (30 mL×3), dried over sodium 
sulfite, filtered and concentrated to give the residue which was further purified with 
chromatography (Hex:DCM= 10:1-1:1) to give the product (240 mg, 27.0%). 
1
H 
NMR (500 MHz, CDCl3) δ 9.55 (t, J = 1.5 Hz, 1H), 9.03 (d, J = 8.0 Hz, 1H), 8.83 (d, 
J = 8.5 Hz, 2H), 8.54 (m, 1H), 7.92 (d, J = 8.5 Hz, 2H), 7.86 (t, J = 8.0 Hz, 1H).  
 
(4-54) 
To the solution of 4-53 in ethanol (10 mL) was added Pd/C (80 mg) at argon 
atmosphere. Then the reaction mixture was charged with hydrogen. The mixture was 
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stirred at room temperature for 12 hours. Then the Pd/C was filtered off and the 
filtrated was stirred at room temperature overnight. All the solvent was removed 
under reduced pressure. The desired residue was purified with chromatography 
(DCM/EA=50:1-10:1) to the product (100 mg, 69.0%). 
1
H NMR (500 MHz, 
DMSO-d6) δ 8.71 (d, J = 8.0 Hz, 2H), 8.06 (d, J = 8.0 Hz, 2H), 7.81 (t, J = 1.5 Hz, 
2H), 7.71 (m, 1H), 7.33 (t, J = 7.5 Hz, 1H), 6.89 (m, 1H), 5.57 (s, 2H); 
13
C NMR (125 
MHz, DMSO-d6) δ 164.2, 162.9, 150.2, 136.4, 132.4, 132.2, 130.5, 128.6, 126.8 (q, J 
= 3.75 Hz), 125.5, 123.3, 118.7, 115.6, 112.8.  
 
(4-55) 
To the solution of Fmoc-Gly-OH (61 mg, 0.2 mmol) in THF (5 mL) was added 
NMP (40 mg, 0.4 mmol) and isobutyl chloroformate (30 mg, 0.22 mmol) at 0
o
C. The 
mixture was stirred at 0
o
C for 20 mins. Then 4-54 (48 mg, 0.15 mmol) was added to 
reaction mixture, which was stirred at room temperature for 4 hours. Then silica gel (1 
g) was added to reaction mixture. All the solvent was removed under reduced pressure. 
The desired residue was purified with chromatography to give the product (66 mg, 
74.1%). 
1
H NMR (500 MHz, DMSO-d6) δ 10.38 (s, 1H), 8.90 (s, 1H), 8.74 (d, J = 8.5 
Hz, 2H), 8.26 (d, J = 7.5 Hz, 1H), 8.08 (d, J = 8.5 Hz, 2H), 7.89 (m, 3H), 7.74 (m, 
3H), 7.66 (t, J = 8.0 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.36 (t, J = 7.5 Hz, 2H), 4.34 (d, 
J = 7.0 Hz, 2H), 4.27 (m, 1H), 3.88 (d, J = 6.5 Hz, 2H); 
13
C NMR (125 MHz, 
DMSO-d6) δ 163.8, 163.1, 157.1, 144.3, 141.2, 140.5, 136.3, 132.6, 130.6, 128.8, 






To the solution of tetrazine-Gly-NH-Fmoc (55) (37 mg, 0.06 mmol) in DMF (5 mL) 
was added piperidine (1 mL). The reaction mixture was stirred at room temperature 
for 4 hours. 20 mL of water was added to the reaction mixture, followed by filtration. 
The desired solid was dried and purified by chromatography (DCM/MeOH=30:1) to 
give the titled compound 6 mg, 27.2%. 
1
H NMR (500 MHz, DMSO-d6) δ 8.97 (s, 1H), 
8.76 (d, J = 7.5 Hz, 2H), 8.27 (d, J = 7.5 Hz, 1H), 8.10 (d, J = 7.5 Hz, 2H), 7.97 (d, J 
= 7.5 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 3.36 (s, 2H), 3.17 (s, 1H); 
13
C NMR (125 
MHz, DMSO-d6) δ 172.9, 163.9, 163.1, 132.6, 132.4, 130.5 128.8, 126.8, 125.5, 
123.6, 122.9, 118.5, 46.0; HRMS(ESI) calcd for [M+Na]
+






Cyclooctenol (500 mg) and methyl benzoate (500 mg) was added to 250 mL solvent 
(Ether:Hexanes=9:1) in a 500 mL quartz reaction vessel. No attempt to degas the 
solution was made. The vessel was irradiated with 254 nm light in a UV reactor 
(CL-1000 Ultraviolet Crosslinker, UVP) under constant stirring. At 30 minute 
intervals, the irradiation was stopped and the entire solution was passed through a 
column packed with silver nitrate (10%) impregnated silica. The solution that passes 
through was then transferred back into the quartz flask and irradiation was continued. 
After ten rounds, the irradiation was stopped and the silica was added to a solution of 
ammonium hydroxide and stirred for 5 minutes after which dichloromethane was 
added and stirring continued for 5 more minutes. Then the mixture was filtrated and 
the organic phase was separated out, washed with brine and purified with 
chromatography (hexane/EA=30:1/10:1) to give trans-cyclooctenol (50 %) as a 
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mixture of isomers, major one (200 mg), minor one (50 mg).  
Trans-cyclooctenol (major one) 
1
H NMR (500 MHz, CDCl3) δ 5.51-5.57 (m, 1H), 
5.32-5.38 (m, 1H), 3.39-3.43 (m, 1H), 2.21-2.33 (m, 3H), 1.86-1.94 (m, 4H), 
1.52-1.65 (m, 3H). Trans-cyclooctenol (minor one) 
1
H NMR (500 MHz, CDCl3) δ 
5.50-5.55 (m, 2H), 3.99-4.02 (m, 1H), 2.31-2.38 (m, 1H), 2.16-2.23 (m, 2H), 




To the suspension of sodium hydride (60% in mineral oil) in THF (3 mL) was 
added 4-57 (230 mg, 1.8 mmol). The resulting mixture was stirred at room 
temperature for 30 minutes. Then bromoacetic acid (300 mg) in THF (2 mL) and 
potassium iodide (30 mg, 0.18 mmol) was added to the above mixture. The resulted 
mixture was refluxed for 6 hours and then cooled down to room temperature. Most of 
the solvent was evaporated under reduced pressure. To the residue was added water 
(20 mL) in ice-water bath. The pH value was adjusted to 6 using 7% (HCl in water). 
Then DCM (100 mL) was added. The organic phase was taken and washed with brine, 
dried with sodium sulfate, purified with chromatography (hexane/EA=5:1/1:1) to give 
the product (200 mg, 82.6%). 
1
H NMR (300 MHz, CDCl3) δ 9.86 (brs, 1H), 5.57-5.72 
(m, 2H), 4.05-4.17 (m, 2H), 3.46-3.53 (m, 1H), 2.32-2.41 (m, 1H), 1.97-2.17 (m, 4H), 
1.40-1.84 (m, 5H); 
13
C NMR (75 MHz, CDCl3) δ 175.2, 129.6, 129.4, 82.0, 65.4, 33.6, 
33.1, 25.6, 25.3, 22.3. 
 
  (4-61) 
To a stirring solution of 4-57 (0.80 g, 6.35 mmol) in anhydrous methylene chloride 
(50 mL) was added pyridine (1.50 mL, 18.1 mmol). A solution of 
4-nitrophenylchloroformate (1.4 g, 7.0 mmol) in methylene chloride (20 mL) was 
added at room temperature and the resulting solution allowed to stir for 30 minutes. 
133 
 
To the reaction was quenched by addition of NH4Cl (aq), and the layers were 
separated. The aqueous layer was extracted with methylene chloride (20 mL×2). The 
organic phase was combined, dried with sodium sulfate and purified with 
chromatography (hexane/EA=10:1/3:1) to give the product (1.10 g, 61.1%). 
1
H NMR 
(300 MHz, CDCl3) δ 8.32 (m, 2H), 7.41 (m, 2H), 7.49-7.65 (m, 2H), 7.46-7.51 (m, 
1H), 2.35-2.48 (m, 3H), 1.73-2.20 (m, 7H); 
13
C NMR (75 MHz, CDCl3) δ 155.7, 
151.9, 134.8, 133.0, 125.2, 121.7, 86.4, 40.6, 38.1, 34.1, 32.4, 31.0. 
 
To a solution of 2,20-(ethylenedioxy)-bis-ethylamine (2.5 g, 16.8 mmol) in CHCl3 
(20.0 mL), a solution of di-tertbutyldicarbonate (300 mg, 1.38 mmol) in CHCl3 (20.0 
mL) was added dropwise at 0 
o
C under inert atmosphere. At the end of the addition, 
the reaction mixture was allowed to warm up to room temperature and was stirred for 
overnight. Then the reaction mixture was washed with water (30 mL×3) and brine 
(30 mL×1), dried with sodium sulfate and concentrated to give the title product(240 
mg, 70.6%). 
1
H NMR (500 MHz, CDCl3) δ 3.53-3.55 (m, 4H), 3.44-3.46 (m, 4H), 
3.24 (m, 2H), 2.81 (m, 2H), 1.37 (m, 9H); 
13
C NMR (125 MHz, CDCl3) δ 155.9, 78.9, 
73.0, 70.0, 41.4, 40.1, 28.2.  
(4-58) 
To a solution of Gly-Fmoc-OH (160 mg, 0.54 mmol) in DCM (10 mL) was added 
EDC.HCl (130 mg, 0.68 mmol) and DIEA (60 mg, 0.46 mmol) at room temperature. 
Then tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (120 mg, 0.48 mmol) 
was added. The reaction mixture was stirred overnight. The reaction was quenched by 
addition of water (20 mL) and DCM (20 mL). The organic phase was taken, washed 
with saturated NH4Cl (aq) and brine, dried with sodium sulfate and purified with 
chromatography(DCM/MeOH=30:1/15:1) to give the product (150 mg, 59.5 %). 
1
H 
NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.0 Hz, 2H), 7.40 (t, 
J = 7.5 Hz, 2H), 7.30 (t, J = 7.5 Hz, 2H), 6.72 (brs, 1H), 5.84 (brs, 1H), 5.06 (brs, 1H), 
4.40 (m, 2H), 4.21 (t, J = 7.0 Hz, 1H ), 3.88 (m, 2H), 3.46-3.56 (m, 10H), 3.27 (m, 
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2H), 1.42 (m, 9H); 
13
C NMR (125 MHz, CDCl3) δ 169.9, 156.6, 143.8, 141.3, 127.7, 
127.1, 125.1, 119.9, 70.3, 70.1, 67.1, 47.1, 40.3, 39.2, 28.4; LC-MS (ESI) calcd for 
[M+H]
+
:528.27, found: 528.35. 
 
 (4-59) 
To the solution of 4-58 (2.4 g, 4.54 mmol) in dioxane (10 mL) was added HCl 
solution (4 M in dioxane, 20 mL). The resulting mixture was stirred at room 
temperature for 6 hour. Then all the solvent was evaporated under reduced pressure. 
Then the solid was suspended in THF (30 mL). To this suspension was added DIEA 
(1.26 g, 10.0 mmol) and compound-12 (1.1 g, 3.78 mmol). The resulting mixture was 
stirred at room temperature overnight. The solvent was removed under reduced 
pressure and the desired residue was dissolved in EA (100 mL). Then the organic 
layer was washed with water (30 mL) and brine (30 mL), dried with sodium sulfate 
and purified with chromatography (DCM/MeOH=30:1/15:1) to give the title product 
(1.9 g, 86.4%). 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.5 Hz, 2H), 7.41 (d, J = 
7.0 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.32-7.35 (m, 2H), 6.50 (brs, 1H), 5.68 (brs, 1H), 
5.51 (m, 2H), 5.12 (brs, 1H), 4.35-4.45 (m, 3H), 4.25 (t, J = 6.5 Hz, 1H), 3.91 (m, 2H), 
3.50-3.60 (m, 10H), 3.34 (m, 2H), 2.32-2.38 (m, 3H), 1.90-2.00 (m, 4H), 1.70-1.74 (m, 
3H); 
13
C NMR (125 MHz, CDCl3) δ 143.7, 141.3, 134.8, 132.9, 127.7, 127.1, 125.0, 
120.1, 70.3, 70.1, 67.1, 53.4, 47.1, 41.1, 38.6, 34.2, 32.5, 30.9; LC-MS (IT-TOF) 
calcd for [M+H]
+
: 580.30, found: 580.28.  
 
 (4-60) 
To the solution of 4-59 (1.9 g, 3.28 mmol) in chloroform (20 mL) was added 
piperidine (4 mL). The resulting mixture was stirred at room temperature for 6 hours. 
Then all the solvent was removed under reduced pressure. The desired free amine was 






Sulfur (1.1 g, 34.5 mmol) was added as a solid to a solution of 4- chlorobenzoyl 
acetonitrile (6.2 g, 34.5 mmol), 2-butanone (3.1 ml, 34.5 mmol), and morpholine (3.0 
ml, 6.9 mmol) in ethanol (80 ml) at room temperature. The mixture was then heated to 
70 ºC. After 12 h, the reaction mixture was cooled to room temperature and poured 
into brine (200 ml). The aqueous layer was extracted with ethyl acetate (100 mL×3). 
The combined organic layers were washed with brine (150 ml), dried over sodium 
sulphate, concentrated and purified with chromatography (hexane/EA=10:1/3:1) to 
give the product (3.5 g, 38.5%). 
1
H NMR (300 MHz, CDCl3) δ 7.48-7.54 (m, 2H), 
7.40-7.43 (m, 2H), 6.51 (brs, 2H), 2.16 (m, 3H), 1.59 (m, 3H); 
13
C NMR (75 MHz, 
CDCl3) δ 191.5, 163.0, 140.1, 136.6, 129.4, 128.4, 128.3, 117.1, 102.9, 115.3, 15.4, 
12.4; LC-MS (IT-TOF) calcd for [M+H]
+









H NMR (300 MHz, CDCl3) δ 7.35-7.44 (m, 4H), 6.75 (brs, 2H), 
2.48-2.52 (m, 2H), 1.69-1.80 (m, 4H), 1.47-1.50 (m, 2H); 
13
C NMR (75 MHz, CDCl3) 
δ 191.1, 164.9, 140.4, 136.1, 130.8, 128.9, 128.2, 118.5, 115.4, 28.0, 24.5, 22.9, 22.7; 
LC-MS (ESI) calcd for [M+H]
+





H NMR (500 MHz, CDCl3) δ 7.56 (m, 2H), 6.90 (m, 2H), 5.97 (brs, 
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2H), 3.85 (s, 3H), 2.14 (s, 3H), 1.64 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 192.2, 
162.0, 160.5, 133.9, 130.6, 130.5, 129.1, 118.2, 115.4, 113.4, 113.3, 55.3, 15.2, 12.4; 
LC-MS (IT-TOF) calcd for [M+H]
+
:262.09, found: 262.08. 
 
7-3 General procedure for the library synthesis 
(4-49-2) 
To the solution of Fmoc-Asp-OtBu (4.0 g, 9.72 mmol) in chloroform (40 mL) was 
added EDC.HCl (2.2 g, 11.5 mmol) and HOBt (540 mg, 4.0 mmol). Then 
(2-aminophenyl)(phenyl)methanone (1.74 g, 8.8 mmol) was added to above solution. 
The resulting mixture was stirred at 40
o
C for 24 hours. The reaction was quenched by 
addition of water (80 mL). The organic phase was taken, washed with saturated 
ammonium chloride solution, brine and dried with sodium sulfate, purified with 
chromatography (hexane/EA=10:1/5:1) to give the compound A1-1 (3.7 g, 71.2%). 
1
H 
NMR (300 MHz, CDCl3) δ 11.80 (s, 1H), 8.73 (d, J = 8.4 Hz, 1H), 7.68-7.81 (m, 4H), 
7.52-7.61 (m, 5H), 7.42 (m, 4H), 7.30 (m, 2H), 7.13 (m, 1H), 6.31 (d, J = 9.0 Hz, 1H), 
4.84 (m, 1H), 4.70 (m, 1H), 4.31 (m, 2H), 3.24 (dd, J1 = 4.8 Hz, J2 = 16.8 Hz, 1H), 
2.87 (dd, J1 = 4.5 Hz, J2 = 16.8 Hz, 1H), 1.48 (s, 9H); 
13
C NMR (75 MHz, CDCl3) δ 
199.0, 170.7, 169.7, 156.2, 128.0, 127.6, 127.5, 127.0, 126.9, 125.4, 125.2, 123.5, 
122.4, 121.2, 119.8, 81.8, 67.7, 60.3, 52.6, 47.1, 36.9, 27.9, 20.9, 14.1. 
 




H NMR (500 MHz, CDCl3) δ 11.76 (s, 1H), 7.78 (d, J = 7.5 Hz, 2H), 
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7.63-7.67 (m, 2H), 7.34-7.49 (m, 7H), 7.24-7.29 (m, 2H), 6.14 (d, J = 8.0 Hz, 1H), 
4.81 (m, 1H), 4.64 (m, 1H), 4.33 (m, 2H), 3.17 (m, 1H), 2.78 (m, 1H), 2.28 (s, 3H), 
1.70 (s, 3H); 1.45 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 193.1, 168.4, 141.3, 141.2, 
138.4, 138.1, 130.0, 128.5, 127.7, 127.6, 127.1, 127.0, 125.3, 125.1, 119.9, 82.1, 67.8, 





H NMR (500 MHz, CDCl3) δ 11.39 (s, 1H), 7.78 (d, J = 7.5 Hz, 2H), 
7.56-7.64 (m, 4H), 7.40 (t, J = 7.5 Hz, 2H), 7.26-7.29 (m, 2H), 6.08 (m, 1H), 4.77 (m, 
1H), 4.61 (m, 1H), 4.31 (m, 2H), 3.85 (s, 3H), 3.13 (m, 1H), 2.76 (m, 1H), 2.29 (s, 
3H), 1.78 (s, 3H); 1.44 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 193.1, 168.0, 162.9, 
141.3, 141.2, 132.3, 131.3, 128.1, 127.7, 127.6, 127.1, 127.0, 125.4, 125.2, 125.1, 





H NMR (500 MHz, CDCl3) δ 12.01 (s, 1H), 7.75 (m, 2H), 7.66 (m, 1H), 
7.31-7.42 (m, 6H), 7.20-7.26 (m, 2H), 6.13 (d, J = 8.5 Hz, 1H), 4.70 (brs, 1H), 4.61 
(m, 1H), 4.29 (m, 2H), 3.16 (m, 1H), 2.67-2.75 (m, 3H), 1.94 (m, 2H), 1.77 (m, 2H), 
1.61 (m, 3H), 1.54 (m, 2H), 1.43 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 193.0, 168.5, 
156.2, 147.4, 143.5, 141.2, 141.1, 138.8, 137.7, 129.9, 129.6, 128.4. 128.2, 127.7, 
127.6, 127.0, 126.9, 125.4, 125.1, 121.6, 119.8, 82.1, 67.8, 51.7, 47.1, 28.0, 27.4, 24.3, 





The synthesis was according to the published procedure
[3]
. Briefly, to the solution of 
compound A1-1 (600 mg, 1.02 mmol) in DMF (10 mL) was added piperidine (2 mL). 
The resulting solution was stirred for 30 mins at room temperature. Then water (100 
mL) and EA (100 mL) were added to the reaction mixture. The organic phase was 
taken, washed with water and brine, concentrated to a pale yellow liquid. This liquid 
was dissolved in ethanol (20 mL). The acetic acid (5 mL) was added. The resulting 
solution was stirred at 80
o
C for 2 hours. Then the solvent was evaporated under 
reduced pressure and the desired residue was purified with chromatography 
(hexane/EA=10:1/2:1) to give the compound A1-2 (300 mg, 84.3%). 
1
H NMR (500 
MHz, CDCl3) δ 10.00 (s, 1H), 7.52 (m, 3H), 7.44 (t, J = 7.5 Hz, 1H), 7.30-7.38 (m, 
3H), 7.24 (d, J = 8.0 Hz), 7.18 (t, J = 7.5 Hz, 1H), 4.15 (t, J = 7.0 Hz, 1H), 3.41 (dd, 
J1 = 7.0 Hz, J2 = 16.5 Hz, 1H), 3.19 (dd, J1 = 7.0 Hz, J2 = 16.5 Hz, 1H), 1.51 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 172.2, 171.2, 169.8, 139.1, 138.3, 130.3, 127.5, 123.4, 
121.4, 80.6, 60.2, 37.5, 28.1; LC-MS (ESI) calcd for [M+H]
+
:351.17, found: 351.05.  
 




H NMR (500 MHz, DMSO-d6) δ 11.20 (s, 1H), 7.48 (m, 2H), 7.40 (m, 
2H), 3.95 (t, J = 8.0 Hz, 1H), 3.08 (dd, J1 = 8.0 Hz, J2 = 16.5 Hz, 1H), 2.90 (dd, J1 = 
8.0 Hz, J2 = 16.5 Hz, 1H), 2.27 (s, 3H), 1.55 (s, 3H), 1.38 (s, 9H); 
13
C NMR (125 
MHz, DMSO-d6) δ 170.2, 167.9, 163.4, 142.2, 136.7, 134.9, 130.1, 128.5, 128.4, 
125.9, 125.6, 79.7, 61.4, 37.1, 27.7, 14.1, 12.4; LC-MS (IT-TOF) calcd for 
[M+H]
+






H NMR (500 MHz, CDCl3) δ 10.04 (s, 1H), 7.41 (m, 2H), 7.33 (m, 2H), 
4.18 (t, J = 7.0 Hz, 1H), 3.35 (dd, J1 = 7.0 Hz, J2 = 16.5 Hz, 1H), 3.12 (dd, J1 = 7.0 Hz, 
J2 = 16.5 Hz, 1H), 2.65 (t, J = 5.5 Hz, 2H), 1.83 (t, J = 5.5 Hz, 2H), 1.64-1.68 (m, 2H), 
1.42-1.48 (m, 11H); 
13
C NMR (125 MHz, CDCl3) δ 171.1, 169.3, 164.8, 142.4, 136.8, 
136.1, 131.7, 129.5, 128.4, 126.2, 80.5, 61.1, 37.4, 28.1, 28.0, 26.4, 24.5, 22.9, 
22.2;LC-MS (IT-TOF) calcd for [M+H]
+





H NMR (500 MHz, CDCl3) δ 9.25 (s, 1H), 7.42 (d, J = 11.5Hz, 2H), 
6.85 (d, J = 11.5Hz, 2H), 4.19 (t, J = 7.0 Hz, 1H), 3.80 (s, 3H), 3.35 (dd, J1 = 7.0 Hz, 
J2 = 17.0 Hz, 1H), 3.11 (dd, J1 = 7.0 Hz, J2 = 17.0 Hz, 1H), 2.26 (s, 3H), 1.60 (s, 3H), 
1.47 (s, 9H) 1.51 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 171.2, 169.7, 165.4, 161.2, 
140.7, 131.2, 130.3, 128.2, 126.0, 113.6, 80.4, 60.9, 55.2, 37.5, 28.1, 14.3, 12.8; 
LC-MS (IT-TOF) calcd for [M+H]
+




To the solution of compound A1-2 (800 mg, 2.28 mmol) in toluene (30 mL) was 
added Lawesson's reagent (736 mg, 1.82 mmol). The resulting mixture was refluxed 
for 4 hours. The solvent was removed under reduced pressure and the desired residue 
was purified with chromatography (hexane/EA=10:1/2:1) to give the compound A1-3 
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(520 mg, 61.2%). 
1
H NMR (500 MHz, CDCl3) δ 9.87 (s, 1H), 7.57 (m, 3H), 7.47 (m, 
1H), 7.40 (m, 3H), 7.25 (m, 2H), 4.39 (t, J = 7.0 Hz, 1H), 3.60 (dd, J1 = 7.0 Hz, J2 = 
16.5 Hz, 1H), 3.37 (dd, J1 = 7.0 Hz, J2 = 16.5 Hz, 1H), 1.49 (s, 9H); 
13
C NMR (125 
MHz, CDCl3) δ 202.1, 171.0, 169.1, 138.7, 131.5, 130.5, 129.8, 128.9, 128.2, 124.8, 
120.7, 80.6, 63.9, 55.5, 40.8, 28.1. 
 




H NMR (500 MHz, CDCl3) δ 10.68 (brs, 1H), 7.39 (d, J = 8.0 Hz, 2H), 
7.31 (d, J = 8.0 Hz, 2H), 4.41 (t, J = 7.0 Hz, 1H), 3.54 (dd, J1 = 7.0 Hz, J2 = 17.0 Hz, 
1H), 3.27 (dd, J1 = 7.0 Hz, J2 = 17.0 Hz, 1H), 2.28 (s, 3H), 1.60 (s, 3H), 1.47 (s 9H); 
13
C NMR (125 MHz, CDCl3) δ 198.4, 170.9, 164.7, 136.5, 130.3, 130.2, 128.6, 127.9, 





H NMR (500 MHz, CDCl3) δ 10.37 (brs, 1H), 7.41 (d, J = 8.5 Hz, 2H), 
6.86 (d, J = 8.5 Hz, 2H), 4.39 (t, J = 7.0 Hz, 1 H), 3.81 (s, 3H), 3.58 (dd, J1 = 7.0 Hz, 
J2 = 17.0 Hz, 1H), 3.30 (dd, J1 = 7.0 Hz, J2 = 17.0 Hz, 1H), 2.28 (s, 3H), 1.62 (s, 3H), 
1.47 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 199.1, 171.1, 164.9, 161.3, 130.7, 130.4, 
127.4, 113.6, 80.4, 64.9, 55.3, 40.8, 29.6, 28.1, 14.3, 12.8; LC-MS (IT-TOF) calcd for 
[M+H]
+







To the solution of compound 51-2 (500 mg, 1.36 mmol) in THF (30 mL) was added 
hydrazine hydrate (0.2 mL, 4.0 mmol) dropwise under ice-water bath. Then the 
reaction mixture was stirred at room temperature for 5 hours. The solvent was 
evaporated under reduced pressure. The resulted residue was suspended in THF (20 
mL). Then this solution (1 mL) was added to the activated acetic acid (12 mg, 0.20 
mmol) which is activated by N-methyl morpholine (NMP) (31 mg, 0.30 mmol) and 
isobutyl chlorformate (26 mg, 0.20 mmol) in THF (5 mL) under ice water bath. The 
resulting mixture was stirred for 5 hours. Then 1-butanol (8 mL) was added to the 
reaction mixture. The resulting mixture was heated at 90
o
C for 12 hours. All the 
solvent was evaporated under reduced pressure. The desired residue was purified with 
chromatography (DCM/MeOH=50:1) to get the desired product (18 mg, 69.2%). 
1
H 
NMR (500 MHz, CDCl3) δ 7.68 (m, 1H), 7.40-7.50 (m, 6H), 7.30 (m, 2H), 4.57 (dd, 
J1 = 6.0 Hz, J2 = 8.5 Hz, 1H), 3.54 (m, 2H), 2.63 (s, 3H), 1.49 (s, 9H); 
13
C NMR (125 
MHz, CDCl3) δ 170.9, 167.4, 156.6, 150.4, 138.9, 130.5, 127.3, 123.3, 80.8, 53.2, 
37.8, 28.1, 12.2; LC-MS (IT-TOF) calcd for [M+H]
+
:389.19, found: 389.15. 
 
1H NMR, 13C NMR and/or LC-MS data of other representative products 




H NMR (500 MHz, CDCl3) δ7.64-7.67 (m, 1H), 7.41-7.47 (m, 6H), 7.32-7.36 (m, 
2H), 4.54 (dd, J1 = 5.5 Hz, J2 = 8.5 Hz, 1H), 3.48-3.59 (m, 2H), 3.01-3.07 (m, 1H), 





(125 MHz, CDCl3) δ 170.9, 167.3, 156.7, 154.0, 138.9, 133.7, 131.4, 130.5, 129.4, 
129.3, 128.2, 127.2, 123.3, 80.8, 53.1, 37.8, 28.1, 27.7, 20.6, 13.6. LC-MS (IT-TOF) 
calcd for [M+H]
+
:417.2, found: 417.1. 
(4T) 
1
H NMR (500 MHz, CDCl3) δ7.63-7.66 (m, 1H), 7.40-7.45 (m, 6H), 7.33-7.36 (m, 
2H), 4.54 (dd, J1 = 5.5 Hz, J2 = 8.5 Hz, 1H), 3.48-3.59 (m, 2H), 3.36-3.39 (m, 1H), 
1.60 (d, J = 7.0 Hz, 3H), 1.49 (s, 9H), 1.08 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, 
CDCl3) δ 171.0, 167.2, 158.7, 157.0, 139.0, 133.9, 131.6, 131.4, 130.4, 129.5, 129.2, 
128.2, 127.2, 123.3, 80.7, 53.1, 37.8, 28.1, 25.5, 21.5, 20.3, 19.2; LC-MS (IT-TOF) 
calcd for [M+H]
+
:417.2, found: 417.2. 
(5T) 
1
H NMR (500 MHz, CDCl3) δ 7.65-7.68 (m, 1H), 7.40-7.49 (m, 6H), 7.32-7.35 (m, 
2H), 4.54 (dd, J1 = 5.5 Hz, J2 = 8.5 Hz, 1H), 3.49-3.59 (m, 2H), 2.99 (s, 2H), 1.49 (s, 
9H), 0.76 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 171.0, 167.3, 157.3, 152.6, 138.8, 
134.6, 131.6, 131.4, 130.5, 130.0, 129.2, 128.2, 127.2, 124.2, 80.8, 53.3, 47.6, 38.2, 
37.8, 33.0, 29.7, 29.3, 28.1.  
(9T) 
1
H NMR (500 MHz, CDCl3) δ 7.64-7.67 (m, 1H), 7.40-7.48 (m, 6H), 7.32-7.36 (m, 
2H), 4.54 (m, 1H), 3.47-3.59 (m, 2H), 2.74-3.02 (m, 2H), 2.08-2.19 (m, 2H), 1.76 (m, 
1H), 1.48 (s, 9H), 1.18-1.38 (m, 5H), 0.91-1.07 (m, 7H); 
13
C NMR (125 MHz, CDCl3) 
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δ 171.0, 169.1, 167.3, 156.8, 153.8, 153.5, 138.9, 133.8, 131.6, 131.5, 131.4, 130.5, 
129.2, 128.2, 128.1, 127.2, 123.5, 123.4, 80.7, 53.2, 40.8, 40.3, 37.9, 37.3, 36.5, 35.1, 
34.8, 32,3, 31.9, 29.6, 28.4, 28.1;  
(10T) 
1
H NMR (500 MHz, CDCl3) δ 7.64-7.67 (m, 1H), 7.40-7.48 (m, 6H), 7.32-7.36 (m, 
2H), 4.54 (dd, J1 = 5.5 Hz, J2 = 8.5 Hz), 3.48-3.59 (m, 2H), 3.06-3.10 (m, 1H), 
2.88-2.94 (m, 1H), 1.61-1.75 (m, 6H), 1.51-1.56 (m, 2H), 1.48 (s, 9H), 1.37-1.45 (m, 
2H); 
13
C NMR (125 MHz, CDCl3) δ 170.9, 167.3, 156.7, 154.3, 138.9, 133.7, 131.7, 
130.5, 129.4, 129.2, 128.1, 127.2, 123.3, 80.8, 53.1, 39.6, 39.3, 37.8, 33.3, 32.4, 32.3, 
32.2, 28.1, 25.1, 25.0, 24.9; LC-MS (IT-TOF) calcd for [M+H]
+




H NMR (500 MHz, CDCl3) δ 7.61-7.64 (m, 1H), 7.41-7.47 (m, 5H), 7.32-7.37 (m, 
3H), 7.03 (d, J = 8.5 Hz, 2H), 6.74 (d, J = 8.5 Hz, 2H), 4.54 (dd, J1 = 5.5 Hz, J2 = 8.5 
Hz, 1H), 3.69 (s, 3H), 3.50-3.60 (m, 2H), 3.29-3.34 (m, 1H), 3.09-3.13 (m, 1H), 
2.89-2.98 (m, 2H), 1.49 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 170.9, 167.3, 158.1, 
156.6, 153.3, 138.8, 133.4, 131.7, 130.4, 129.3, 129.1, 128.1, 127.2, 123.3, 113.9, 







H NMR (500 MHz, CDCl3) δ 7.38 (m, 2H), 7.33 (m, 2H), 4.55 (t, J = 7.0 Hz, 1H), 
3.54 (d, J = 7.0 Hz, 2H), 2.95-3.06 (m, 2H), 2.39 (s, 3H), 1.68 (s, 3H), 1.49 (s, 9H), 
1.38 (t, J = 7.5 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 170.8, 163.5, 155.6, 154.2, 
136.7, 136.6, 132.3, 130.6, 130.5, 130.4, 129.7, 128.6, 80.8, 53.9, 37.8, 28.1, 19.3, 
14.3, 11.4; LC-MS (ESI) calcd for [M+H]
+




H NMR (500 MHz, CDCl3) δ 7.38 (m, 2H), 7.31 (m, 2H), 4.54 (t, J = 7.0 Hz, 1H), 
3.54 (d, J = 7.0 Hz, 2H), 3.42 (m, 1H), 2.39 (s, 3H), 1.68 (s, 3H), 1.49 (s, 9H), 1.23 (d, 
J = 7.0 Hz, 3H), 1.20 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 170.9, 163.5, 
157.8, 155.8, 136.7, 136.6, 132.3, 130.7, 130.6, 130.5, 129.6, 128.7, 80.8, 53.8, 37.8, 






H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.5 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 4.88 
(d, J = 13.0 Hz, 1H), 4.69 (d, J = 13.0 Hz, 1H), 4.59 (t, J = 7.0 Hz, 1H), 3.54-3.61 (m, 
4H), 2.39 (s, 3H), 1.67 (s, 3H), 1.49 (s, 9H), 1.20 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 
MHz, CDCl3) δ 170.7, 163.8, 156.1, 150.0, 136.6, 132.1, 131.9, 130.6, 130.5 , 129.7, 
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128.6, 80.9, 65.9, 61.7, 53.8, 37.8, 28.1, 14.9, 14.3, 13.0; LC-MS (IT-TOF) calcd for 
[M+H]
+
:501.17, found: 501.17. 
(20T) 
1
H NMR (500 MHz, CDCl3) δ 7.31-7.37 (m, 4H), 4.54 (d, J = 7.0 Hz, 1H), 3.54 (m, 
2H), 2.92 (m, 2H), 2.40 (s, 3H), 1.60-1.75 (m, 11H), 1.49 (s, 9H), 1.12 (m, 3H), 0.96 
(m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 170.8, 163.5, 155.7, 152.7, 136.7, 136.6, 
132.4, 130.8, 130.7, 130.5, 129.5, 128.7, 80.8, 53.9, 37.8, 37.1, 32.8, 32.6, 32.5, 28.1, 







H NMR (500 MHz, CDCl3) δ 7.39 (m, 2H), 7.31 (m, 2H), 4.54 (t, J = 7.0 Hz, 1H), 
3.53 (d, J = 7.0 Hz, 2H), 2.96-3.04 (m, 1H), 2.40 (s, 3H), 2.26-3.34 (m, 1H), 1.77 (m, 
5H), 1.68 (m, 4H), 1.49-1.57 (m, 15H), 1.03-1.10 (m, 3H); 
13
C NMR (125 MHz, 
CDCl3) δ 170.8, 163.5, 155.6, 153.5, 136.7, 136.6, 132.2, 130.7, 130.6, 130.5, 128.6, 
80.8, 53.8, 39.6, 37.8, 33.2, 32.38, 32.36, 32.34, 28.1, 25.1, 25.0, 24.8, 14.2, 13.0; 
LC-MS (IT-TOF) calcd for [M+H]
+






H NMR (500 MHz, CDCl3) δ 7.37 (m, 2H), 7.31 (m, 2H), 7.08-7.31 (m, 4H), 4.55 (t, 
J = 7.0 Hz, 1H), 3.73 (s, 3H), 3.55 (d, J = 7.0 Hz, 2H), 3.20-3.30 (m, 2H), 3.04-3.09 
(m, 2H), 2.39 (s, 3H), 1.67 (s, 3H), 1.50 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 176.8, 
170.8, 163.5, 158.2, 158.0, 155.6, 152.6, 136.6, 132.5, 132.0, 130.8, 129.7, 129.2, 
128.7, 113.9, 80.8, 55.2, 53.8, 37.7, 35.8, 32.3, 29.8, 28.1, 27.9, 14.3, 13.0; LC-MS 
(IT-TOF) calcd for [M+H]
+




H NMR (500 MHz, DMSO-d6) δ 7.36 (m, 2H), 6.97 (m, 2H), 4.36 (m, 1H), 3.77 (s, 
3H), 3.29 (m, 2H), 2.59 (s, 3H), 2.41 (s, 3H), 1.65 (s, 3H), 1.42 (s, 9H); 
13
C NMR 
(125 MHz, DMSO-d6) δ 170.2, 163.7, 161.5, 155.6, 150.1, 132.1, 131.0, 130.7, 130.5, 
130.3, 114.2, 80.5, 79.6, 55.7, 53.8, 38.0, 28.2, 14.4, 13.1, 11.6; LC-MS (IT-TOF) 
calcd for [M+H]
+




H NMR (500 MHz, CDCl3) δ 7.40 (m, 2H), 6.84 (m, 2H), 4.52 (t, J = 7.0 Hz, 1H), 
3.81 (s, 3H), 3.52 (d, J = 7.0 Hz, 2H), 2.91-3.04 (m, 2H), 2.39 (s, 3H), 1.71-1.81 (m, 
2H), 1.70 (s, 3H), 1.49 (s, 9H), 0.99 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) 
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δ 171.0, 163.9, 161.5, 156.0, 153.2, 131.9, 131.2, 131.1, 131.0, 130.2, 129.9, 113.7, 
80.7, 55.3, 53.6, 37.9, 28.1, 27.4, 20.7, 14.2, 13.7, 13.0; LC-MS (IT-TOF) calcd for 
[M+H]
+




H NMR (500 MHz, CDCl3) δ 7.37 (m, 2H), 6.85 (m, 2H), 4.52 (t, J = 7.0 Hz, 1H), 
3.81 (s, 3H), 3.54 (d, J = 7.0 Hz, 2H), 2.94-3.16 (m, 2H), 2.40 (s, 3H), 1.69 (s, 3H), 
1.49 (s, 9H), 0.86 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 176.3, 171.0, 163.9, 161.4, 
156.5, 151.9, 131.7, 130.9, 130.3, 129.7, 113.8, 80.7, 55.3, 53.7, 47.6, 47.4, 37.9, 33.0, 







H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 4.56 
(t, J = 7.0 Hz, 1H), 3.54 (d, J = 7.0 Hz, 2H), 2.96-3.05 (m, 2H), 2.79 (m, 2H), 
1.90-1.97 (m, 3H), 1.72-1.74 (m, 2H), 1.49 (s, 9H), 1.37 (t, J = 7.5 Hz, 3H); 
13
C NMR 
(125 MHz, CDCl3) δ 170.9, 163.4, 155.6, 154.2, 136.7, 136.5, 133.6, 133.2, 132.8, 
129.7, 129.2, 128.6, 80.8, 53.8, 37.8, 28.1, 26.4, 24.7, 22.1, 19.3, 11.4; LC-MS (ESI) 
calcd for [M+H]
+






H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 4.56 
(t, J = 7.0 Hz, 1H), 3.54 (d, J = 7.0 Hz, 2H), 2.87-2.97 (m, 2H), 2.80 (m, 2H), 
1.88-2.01 (m, 3H), 1.61-1.76 (m, 11H), 1.49 (s, 9H), 1.08-1.24 (m, 7H), 0.80-1.00 (m, 
6H); 
13
C NMR (125 MHz, CDCl3) δ 170.9, 163.5, 155.7, 152.7, 136.7, 136.6, 133.8, 
133.4, 132.7, 129.6, 129.5, 128.6, 80.8, 53.8, 37.7, 37.1, 32.9, 32.8, 32.6, 32.4, 28.1, 





General procedure for synthesis of SM-TCO (4-1/4-49) 
To the solution of compound 2T (10 mg) in DCM (2 mL) was added trifluoroacetic 
acid (0.5 mL). The resulting mixture was stirred at room temperature overnight. Then 
all the solvent was removed under reduced pressure. The desired residue was 
dissolved in THF (1.5 mL). To this solution was added N-methyl morpholine (NMP) 
(20 mg, 0.20 mmol) and isobutyl chlorformate (6 mg, 0.044 mmol) under ice water 
bath. The reaction mixture was stirred at ice-water bath for 20 minutes. Then 
compound 60 (0.4 mL, 0.066 M in THF) was added. Then reaction mixture was 
stirred at room temperature for 4 hours. All the solvent was reduced under reduced 
pressure. The desired residue was purified with chromatography 
(DCM/MeOH=20:1/10:1) to give the product (5 mg~8 mg, 29.4%~47.0%). 
 





H NMR (500 MHz, DMSO-d6) δ 8.57 (t, J = 6.0 Hz, 1H), 7.79-7.87 (m, 3H), 7.58 
(m, 1H), 7.39-7.50 (m, 6H), 6.94 (m, 1H), 5.52-5.58 (m, 1H), 5.38-5.45 (m, 1H), 4.47 
(t, J = 7.0 Hz, 1H), 4.18 (m, 1H), 3.78 (dd, J1 = 6.0 Hz, J2 = 16.5 Hz, 1H), 3.66 (dd, 
J1 = 6.0 Hz, J2 = 16.5 Hz, 1H), 3.28-3.48 (m, 16H), 3.19-3.25 (m, 2H), 3.05-3.31 (m, 
3H), 2.85-2.89 (m, 1H), 2.17-2.27 (m, 3H), 1.81-1.90 (m, 4H), 1.47-1.63 (m, 4H), 
1.20 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, DMSO-d6) δ 170.5, 169.4, 167.5, 157.0, 
156.2, 155.4, 139.1, 135.3, 133.5, 132.9, 132.4, 131.4, 131.0, 129.7, 128.6, 128.0, 
124.3, 79.5, 70.0, 69.9, 69.6, 69.3, 53.5, 42.5, 41.1, 38.9, 38.6, 38.1, 34.2, 32.6, 31.0, 
19.2, 11.4; HRMS (ESI) calcd for [M+H]
+




H NMR (500 MHz, DMSO-d6) δ 8.58 (t, J = 6.0 Hz, 1H), 7.81-7.90 (m, 3H), 7.59 (t, 
J = 7.5 Hz, 1H), 7.47-7.49 (m, 1H), 7.39-7.43 (m, 6H), 6.95 (m, 1H), 5.52-5.58 (m, 
1H), 5.38-5.44 (m, 1H), 4.47 (t, J = 7.0 Hz, 1H), 4.19 (m, 1H), 3.75 (dd, J1 = 6.0 Hz, 
J2 = 16.5 Hz, 1H), 3.64 (dd, J1 = 6.0 Hz, J2 = 16.5 Hz, 1H), 3.31-3.41 (m, 8H), 
3.19-3.27 (m, 2H), 2.99-3.09 (m, 4H), 2.89 (d, J = 14.5 Hz, 1H), 2.17-2.25 (m, 3H), 
1.80-1.90 (m, 4H), 1.50-1.63 (m, 4H), 0.69 (m, 9H); 
13
C NMR (125 MHz, DMSO-d6) 
δ 170.5, 169.4, 167.1, 158.4, 158.1, 157.4, 156.2, 152.8, 138.7, 135.3, 134.3, 132.9, 
132.6, 131.3, 131.1, 129.4, 128.8, 128.2, 79.5, 70.0, 69.9, 69.6, 69.3, 53.7, 42.5, 41.1, 
38.9, 38.6, 38.0, 37.8, 34.2, 32.8, 32.6, 31.0, 29.5; HRMS (ESI) calcd for [M+H]
+
: 




6.4.2 Protein expression, purification and on-bead protein labelling 
Histidine (6x)-tagged pNIC28-Bsa447 bromodomain expression constructs were 
obtained from Prof. Bradner’s group at Harvard Medical School. All constructs were 
transformed into competent E. coli BL21(DE3)-R3-pRARE2 cells. Start-up cultures 
were grown overnight at 37 ºC with 50 μg/ml kanamycin and 34 μg/ml 
chloramphenicol. Expression cultures were prepared by diluting start-up cultures 
1:1000 in fresh medium, growth was allowed at 37 ºC to an optical density (OD) of 
about 0.5 (OD600) before the temperature was decreased to 18 ºC. Protein expression 
was induced overnight at 18 ºC with 0.1 mM isopropyl-β-Dthiogalactopyranoside 
(IPTG) at OD 0.8. Cells were harvested and lysed in lysis buffer (50 mM NaH2PO4, 
300 mM NaCl, 10 mM imidazole) by sonication (10 X pulses of 10 s each at half 
maximal power, on ice). The cell lysate was clarified by centrifugation at 10 000 g, 20 
min, 4 ºC before incubation with Nickel-NTA agarose beads (Qiagen). Beads were 
washed in 5x volume wash buffer (50 mM NaH2PO4, 300 mM NaCl, 25 mM 
imidazole) followed by 3x volume of PBS before labelling the pure bromodomains on 
beads. 
Proteins were minimally labeled with either Cy3 or Cy5 N-hydroxysuccinimide 
ester (Amersham, G.E. Healthcare, USA) for 1 h on ice, following the manufacturer’s 
protocols. Unreacted dye was quenched with a 10-fold molar excess of 
hydroxylamine for a further 30 mins. After which, beads were washed in 3x volume 
PBS before eluting with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM 
imidazole) 
Desalting and removal of excess dye was done by buffer exchange using 3 kDa 
MWCO centrifugal devices (Millipore) at 4 ºC according to manufacturer’s protocols. 
Protein concentration was determined using the Bradford protein assay (Bio-Rad). 







Figure 6.1 Fluorescence scanning (left) and Coomassie Brilliant Blue (right) staining 
of on-bead fluorescently labeled proteins (Cy3). Lane1: Marker, Lane 2: BRD4(1) 
elution-1. Lane 3: BRD4(1) elution-2, Lane 4: BRD4(2) elution-1, Lane 5: BRD4(2) 
elution-2, Lane 6: BRD3(1) elution-1, Lane 7: BRD3(1) elution-2, Lane 8: BRD1, 
Lane 9: BRD3(2).  
 
 
Figure 6.2 Cy5 labeled SH2 domains and 14-3-3 proteins. F3: PTPN11 (tandem); G3: 
PTPN6(C); H3: SHB; I3: SHCA/shc1; J3: BLK; K3: BLNK; A4: BMX; B4: 
BRK/PTK6; C4: socs1-2; D4: SRC1; E4: tns4/cten; F4: SH2D1A; D1: NCK1; E1: 
CHN2; F1: FRK; G1: PIK3R2/PI3K P85B (N), H1: PIK3R2/PI3K P55G (C), I1: 
PIK3R2/PI3K P55G (N); J1: PLCG1 (C); K1: PLCG1 (N); A3: PLCG2(C); B3: 
PLCG2(N); C3: PLCG2 (tandem), D3: PTPN11(C); E3: PTPN11(N); G2: GRB10; 
H2: GRB2; I2: GRB7; J2: HCK; K2: HSH2; A1:ITK; B1: LCK; C1: LYN; A2: ABL1; 
B2: APS; C2: BCAR3; D2: BRDG1/stap1; E2: CRK; F2: GRAP2/gads; H4: 14-3-3(β), 
J4: 14-3-3(τ), K4: 14-3-3(ζ). 
 
6.4.3 Microarray preparation  
6.4.3.1 Preparation of tetrazine slides 
25 × 75 mm glass slides (GOLD SEAL) were soaked in piranha solution (H2SO4: 
H2O2 = 7:3) overnight. Slides salinization was done using a solution of 3% 
(aminopropyl)triethoxysilane in 2% water and 95% ethanol with continuous stirring. 
After 2 hourr-incubation, the slides were washed in 95% ethanol and cured at 150 °C 
overnight. The resulting amine slides were then functionalized with COOH in a 
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solution of 180 mM succinic anhydride in DMF for 20 min before soaking in boiling 
water for 2 min. The slides were rinsed with 95% ethanol and dried under argon. To 
functionalize the slides with NHS, the COOH-derivatized slide surface was activated 
with a solution of 100 mM HBTU, 200 mM DIEA, and 100 mM 
N-hydroxysuccinimide in DMF. These surfaces were then incubated with a solution of 
1 mg/mL tetrazine, 20mM DIEA in DMF under coverslips for 1.5 h. Slides were 
washed in DMF followed by 95% ethanol, dried and stored at 4˚C. 
 
6.4.3.2 Library Immobilization 
All small molecule stocks were diluted to spotting solutions of 300 µM in  
DMSO:H2O (3:1) and were distributed in 384-well plates (Genetix). Tetrazine slides 
were spotted using an OmniGrid® Accent (DigiLab, USA) microarray spotter loaded 
with Stealth SMP8B micro-spotting pins (TeleChem, USA). Spots generated were of 
an approximate 350 μm diameter and were printed with a spacing of 450 μm in 
duplicates. The pins were rinsed using two cycles of: 10 s sonication in 100% ethanol, 
10 s wash in 70% ethanol followed by drying under reduced pressure for 10 s. The 
slides were allowed to stand for 5 min on the printer platform before sonication in 
DMF to remove excess small molecules and stored at 4 ºC until use. The slides were 
rinsed with PBS for 30 min and blocked in 1 % BSA PBS for 1 h before incubation 
with labeled proteins. 
 
 
6.4.3.3 Microarray screening 
    In a standard microarray experiment, the labeled protein (1 μM, 80 μL) in 1% 
BSA PBS was applied on to the immobilized sub-arrays using ProPlate Slide 
Chamber system (Grace Biolab) on tetrazine slides. In a microarray Kd experiment, 
various concentrations of the protein (10 – 5000 nM) were applied to different 
sub-arrays and incubated for 90 mins with shaking. For dual colour selective 
screening experiments, an equal amount of a Cy5-labeled protein and another 
Cy3-labeled protein were mixed and applied together to each sub-array. Slides were 
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then washed in PBS for 5 mins before scanning using an ArrayWoRx microarray 
scanner installed with the relevant filters (Cy3: λ ex/em = 548/595 nm; Cy5: λ ex/em 
= 633/685 nm). 
All data were extracted and analyzed using Array-Pro analyzer (Media 
Cybernetics). For Kd measurements, data were fit into an equation (see the supporting 
information) assuming equilibrium have been achieved. Selectivity score data from 
dual-colour ratiometric experiments were obtained from log2(Cy5 BRD4(2)/Cy3 other 
Brds. A positive log2(ratio) indicates a higher binding preference for BRD4(2). 
 
6.4.3.4 Kd analysis 
Binding data of bromodomains against the small molecule library in 
dose-dependent experiments were extracted using Array-Pro analyzer (Media 
Cybernetics). The corresponding Kd was generated by fitting the data to the following 
equation (under the assumption that equilibrium is achieved during the incubation 
period: 
 
                           
 
                                                  
                        
 
 
Saturation dynamics observed when plotting Observed fluorescence against the 
applied Protein concentration were then fitted to the above equation using the Graph 
pad Prism software v.5 (GraphPad, San Diego, USA) revealing the binding 
dissociation constant, Kd. 
 
6.4. 4 Cell anti-proliferation assays 
Cell viability was determined using the XTT colorimetric cell proliferation kit 
(Roche) following manufacturer’s guidelines. Briefly, cells were cultured at 30,000 
cells per well in 96-well dishes. Compounds were added at various concentrations 
(0-5000 nM) in duplicates from stocks where the %DMSO never exceeded 1% in the 
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final solution. The same volume of DMSO was used as a negative control. Upon 72 h 
incubation, appropriate amounts of XTT were added according to manufacturer’s 
instructions and were left to incubate for another 4h before reading at 450 nm. 
 
6.4.5 FACS- Cell cycle analysis 
Cells were seeded at  ~5 × 10
5
 cells per well of 6-well plates and synchronized 
by single thymidine treatment with 2.5 mM thymidine (from 100 mM stock in 1× 
PBS buffer) for 20-24 h. The cells were washed and released in fresh medium before 
adding compounds at 500 nM for 24h. After incubation, the cells were harvested by 
centrifugation at 0.5 RCF, 3 min, 4 ºC and washed in PBS. Cells were then fixed with 
ice cold 70% ethanol for 3h at 4 ºC. The cells were pelleted and washed in PBS before 
staining with 300uL staining solution (20 ug/ml Propidium Iodide, 25 ug/ml RNase A, 
0.1% Triton X-100 in PBS) for 15min at room temperature. Cell cycle stage and cell 
count were obtained by BD Biosciences FACSAria II flow cytometer. All data 
including DNA content histograms were analysed using the BD FACSDiva software 
6.0.  
 
6.4.6 Western blot 
MV4-11 cells were plated at ~2 × 10
5
 cells per well of 12-well plate. After 
incubation with inhibitors, the cells were harvested, washed with PBS once and lysed 
by directly adding one volume of SDS loading buffer with bromophenol blue 
followed by boiling for 10 min. Samples were then resolved on 10% SDS/PAGE gels 
and transferred to PVDF membranes. The membranes were subsequently blocked 
with 4% BSA in TBST (0.1% Tween-20) for 1 h at room temperature. The primary 
antibody (c-Myc, Cell Singaling, #9402) was incubated for 1 h at room temperature 
followed by five times washing with TBST. Then HRP-conjugated anti-rabbit was 
applied for 1 h at room temperature. The blot was developed using Dura Extended 
Duration Substrate (Thermo Scientific). HRP-conjugated anti-GAPDH (sc-25778, 




6.4.7 FP binding assay for CREBBP and GCN5L2 
FP binding assays for the CREBBP and GCN5L2 bromodomains with compound 
FTT were carried out in black 384-well microplates in a total volume of 20 µL in each 
well.
 
For each assay, three basic solutions were prepared. The reaction buffer used in 
the FP assay throughout this study contains 16 mM Na2HPO4, 4 mM NaH2PO4, 150 
mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.02% NaN3 at pH 7.3. Solution A 
contained a fluorescently labeled small molecule FTT, in the reaction buffer (solution 
with 20 nM of the peptide probe). Solution B contained the bromo domain protein in 
the reaction buffer (solution with 10 nM to 200 µM of bromo domain protein). Briefly, 
10 µL of solution A and 10 µL of solution B were mixed and pre-incubated for 30 min 
at room temperature. The polarization values were measured using an Infinite F200 
microplate reader (Tecan, Austria) installed with 2 pairs of polarizers (λEx: 480 nm; 
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Chapter 4_Figure S1 Microarray image showing binding profiles of the 48-member 










Chapter 4_Figure S2 SMM screened with different Cy5 labeled SH2, 14-3-3 and 
Brd4(2) (1 M each). A1: ITK; B1: LCK; C1: LYN; D1: NCK1; E1: CHN2; F1: FRK; 
G1: PIK3R2/PI3K P85B (N), H1: PIK3R2/PI3K P55G (C), I1: PIK3R2/PI3K P55G 
(N), J1: PLCG1 (C), K1: PLCG1 (N), A2: ABL1; B2: APS; C2: BCAR3; D2: 
BRDG1/stap1; E2: CRK; F2: GRAP2/gads; G2: GRB10; H2: GRB2; I2: GRB7; J2: 
HCK; K2: HSH2; A3: PLCG2(C); B3: PLCG2(N); C3: PLCG2 (tandem), D3: 
PTPN11(C); E3: PTPN11(N); F3: PTPN11 (tandem), G3: PTPN6(C); H3: SHB; I3: 
SHCA/shc1; J3: BLK, K3: BLNK; A4: BMX; B4: BRK/PTK6; C4: socs1-2, D4: 






Chapter_4 Figure S3 Colour heat map displaying binding of the 48 compounds 
against 55 fluorescently labelled proteins (1 µM). A1: ITK; B1: LCK; C1: LYN; D1: 
NCK1; E1: CHN2; F1: FRK; G1: PIK3R2/PI3K P85B (N), H1: PIK3R2/PI3K P55G 
(C), I1: PIK3R2/PI3K P55G (N), J1: PLCG1 (C), K1: PLCG1 (N), A2: ABL1; B2: 
APS; C2: BCAR3; D2: BRDG1/stap1; E2: CRK; F2: GRAP2/gads; G2: GRB10; H2: 
GRB2; I2: GRB7; J2: HCK; K2: HSH2; A3: PLCG2(C); B3: PLCG2(N); C3: PLCG2 
(tandem), D3: PTPN11(C); E3: PTPN11(N); F3: PTPN11 (tandem), G3: PTPN6(C); 
H3: SHB; I3: SHCA/shc1; J3: BLK, K3: BLNK; A4: BMX; B4: BRK/PTK6; C4: 
socs1-2, D4: SRC1; E4: tns4/cten; F4: SH2D1A; H4: 14-3-3(β), I4: 14-3-3(γ), J4: 












Chapter_4 Figure S4 GI50 values of MV4-11 (upper) and THP-1 (bottom) cell lines 




Chapter_4 Figure S5 Kd measured by ITC for binding between BRD4(2) and 

































Selected NMR spectrums of compounded used in this thesis are listed in this appendix. 
More spectrm and LCMS profiles of compounds in the two small molecule libraries 








































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             63
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        171.076 degree





























































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             65
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        200.208 degree


































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             56
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        162.584 degree









































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             65
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        201.031 degree






















































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             55
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        196.042 degree

































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             63
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        206.186 degree



































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             76
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        192.292 degree








































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             68
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        183.126 degree
PHC1 :         27.591 degree
BGQNP-7
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